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ABSTRACT 
 
Expanding Beta-Turn Analogs for Mimicking Protein-Protein Hot Spots. 
(August 2006) 
Samuel Onofre J. Reyes, B.S., University of the Philippines Los Baños 
Chair of Advisory Committee: Dr. Kevin Burgess 
 
 Solid-phase syntheses of two 14-membered ring peptidomimetics were done to 
determine whether or not a beta-turn structure can facilitate macrocyclization.  NMR 
methods, together with CD and QMD calculations, do not fully support this assumption.  
However, cyclizations of more ordered structures like those of compounds 2 were more 
efficient than those for highly strained ring systems like 1. 
 A small library of 18-membered ring peptidomimetics that accommodate an extra 
amino acid residue was synthesized on resin.  Their syntheses were not complicated by 
head-to-tail dimer impurity, unlike those for previously synthesized 14-membered 
systems.  These larger macrocycles exhibit beta-turn structures as verified by NMR, CD 
and QMD techniques.  Moreover, two compounds in this series (3a and 3g) were shown 
to have agonistic properties for TrkC in cell survival assays. 
 Dimerization of monovalent mimics was achieved first by modifying the organic 
template so that monovalent mimics with requisite functional groups can be synthesized.  
Second, the monovalent units were dimerized using sequential nucleophilic substitutions 
on fluorescently labeled dichlorotriazine.  Our rationale to make bivalent compounds out 
of monovalent ones was justified when compound 4 was shown to bind TrkA with a 20 
nM affinity. 
 Reactions of amino acids with NH4SCN under acylating conditions produced 2-
thiohydantoins in which the nitrogen of the amino acid (N1) was acylated.  This was 
proven by 2-D NMR which showed no cross-peak between the NH signal observed and 
the Cα-H of the amino acid.  When the compound was deacylated, a new NH signal 
appeared and the corresponding cross-peak with the Cα-H was observed. 
 iv
 Solution-phase syntheses of non-peptidic mimics were achieved by doing a 
double substitution on a dihalogenated nitrobenzene scaffold.  Sonogashira and SNAr 
reactions were done to install the required side-chains to give the desired compounds.  
These non-peptidic compounds can be easily adapted to our DTAF-Inp dimerization 
protocol since the nitro groups can be easily reduced. 
 Attempts to make a spirotetracyclic peptidomimetic with three side chain mimics 
were done by synthesizing the spirocyclic diketopiperazine precursor.  The synthesis of 
the DKP was achieved by making the cyclic quaternary amino acid that was coupled to 
another amino acid via the HOAt-EDC method.  This protocol gave dipeptides in high 
yields.  These dipeptides were deprotected and cyclized to the DKP under mildly acidic 
conditions in toluene. 
 v
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CHAPTER I 
INTRODUCTION 
 
1.1 The Nerve Growth Factor and the Neurotrophin Family 
 Neurotrophins (NTs) are dimeric polypeptide growth hormones that regulate the 
development, differentiation and survival of nerve cells.1  Members of the neurotrophin 
family include nerve growth factor (NGF), brain-derived neurotrophin factor (BDNF), 
neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5) and neurotrophin-6 (NT-6).2,3  They 
have approximately 50% sequence homology and dimerize non-covalently in parallel 
fashion where each monomer is about 13 kDa. 
 
NGF
NT-4/5
BDNF NT-3
NGF
NT-3
NT-4/5
BDNF
Trk-A Trk-B Trk-C p-75  
 
Figure 1.1.  The neurotrophins and their receptors. 
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 These NTs mediate signaling by binding to two types of cell surface receptors: 
p75 and tyrosine kinases, Trks.  p75 binds to all neurotrophins with similar affinities 
(Figure 1.1).  It contains a cytoplasmic ‘death’ domain which has been shown to be 
involved in apoptosis.4  Thus, in most cases, binding to p75 initiates events leading to cell 
death.5  However, it can also promote neuronal survival by activating the transcription 
factor NF-κB in the presence of Trk activation.6 
 Tyrosine kinases, on the other hand, are more specific in binding to NTs and they 
do so with very high affinities (pM range).  Tyrosine kinase A (TrkA) is the receptor for 
NGF,7 tyrosine kinase B (Trk B) was shown to bind to BDNF8 and NT-4/59, and tyrosine 
kinase C (TrkC) was found to bind NT-3.10  Although these receptors bind at high 
affinities, TrkA and TrkB also bind NT-3 albeit at lower degrees.11,12  Binding of NTs to 
Trk receptors results in dimerization of the latter.  This event occurs with concomitant 
phosphorylation of tyrosine residues in the receptor cytoplasmic domain, triggering 
intracellular signaling cascades.  Adapter proteins are then recruited and pathways 
leading to neuronal survival and neurite outgrowth are activated.13 
 NTs bind to the extracellular portion of Trk receptors which is comprised of five 
domains: two cysteine-rich clusters (domains 1 and 3), three leucine-rich motifs (domain 
2) and two immunoglobin (Ig)-like regions (domains 4 and 5).14  This extracellular part 
of Trk is not as homologous as its intracellular kinase domain. However, in domain 5, 
there is a stretch of 9 amino acid residues that are conserved in all Trk receptors.15  This 
high degree of similarity has paramount importance as most experiments reveal the 
necessity and sufficiency of domain 5 in binding to neurotrophins.2,4  In fact, the only 
crystal structure of a neurotrophin-Trk complex that has been solved to date contains only 
domain 5.16,17  NGF and domain 5 of TrkA were shown to crystallize to form a bat-
shaped complex (Figure 1.2).  Two binding patches can be seen from the ligand-receptor 
interface: a specificity patch and a conserved patch.  The specificity patch involves the N-
terminal residues (6-9) of the NGF that form a short helix which packed itself to the 
ABED sheet of TrkA.  This interaction is facilitated by hydrophobic residues at both 
regions of the pocket.  It is important to point out that in crystal structures of NTs, this N-
terminus region is disordered.  Also, there is a very low degree of homology between 
residues at this pocket for other neurotrophins and Trks, implying that this interaction 
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might be unique for NGF-TrkA complex.  The second patch is called a conserved patch 
and is formed by the central beta-sheet of NGF in contact with loops AB, C’D, and EF of 
TrkA.  Most of the residues involved in this patch are highly conserved among the 
neurotrophins and Trks, hence, this patch is believed to be also present in other NT-Trk 
complexes. 
 
A'
BED
A
F
G
C
C' L1
L4
L2
L3
 
Figure 1.2.  Crystal structure of dimeric nerve growth factor complexed with domain 5 of 
Trk A. 
 
 
 In contrast to NGF-TrkA complex, the crystal structure of NGF binding to p75 
reveals a 2:1 NGF:p75 stoichiometry (Figure 1.3).18  This is unexpected considering the 
mode of binding of NTs to Trk receptors.  Another surprise is that while other tumor 
necrosis factor (TNF) receptors, to which p75 belongs, bind trimeric TNF ligands, p75 
engage dimeric NTs.  The three-dimensional structure shows that p75 positions itself in 
between the groove formed by two NGF monomers.  There are two binding sites in the 
complex and most contacts involve charge complementarity between the highly negative 
surface of p75 and the positively charged residues of NGF.  Mapping these two sites on 
the alignment of residues in other NTs reveal highly conserved sequences.  This explains 
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the observed affinity of p75 to all members of NT family.  Because of the way p75 binds, 
there is a pseudo binding site on the other side of the NGF dimer.  However, this site is 
not accessible to another p75 because of an allosteric effect caused by the first binding.  
The structure also reveals an opening for Trk binding which could support experimental 
evidence that both TrkA and p75 are required for high affinity NGF binding sites.6 
 
 
Figure 1.3.  NGF-p75 crystal structure. 
 
1.2 Neurotrophins and Neurodegenerative Diseases 
 Neurotrophins (NTs) vary in population through the peripheral and central 
nervous systems, but have a higher density in the hippocampus region of the brain.  In 
recent years, it has been established that a decrease in trophic support plays a major role 
in the pathogenesis of neurodegenerative diseases.4  Neurotrophins such as NGF and 
BDNF have been implicated in Alzheimer’s and Huntington’s disease, respectively.  
Although NTs have been used clinically, they have poor pharmacological properties 
which make them unsuitable for therapeutic use.19  To circumvent this, more researchers 
have been employing small-molecule mimics, not only of NTs but of other proteins as 
well.  In this approach, the structural and/or functional properties of a protein are being 
copied by a molecule much smaller in size.20 
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 In the case of NTs, ‘hot-spot’ regions are identified as those that interact or bind 
to Trk receptors.  These ‘hot-spots’ are then translated into a small molecule that could 
potentially possess NT activity.  Ligand binding regions or sequences that interact with 
the receptor are determined by chimeric recombination or site-directed mutagenesis 
studies.  For NTs and some growth factors, a lot of the ‘hot-spots’ involve beta-turn 
regions.19  Beta-turn is one of the three common secondary structures that peptides and 
proteins adopt.21  It also plays a major role in recognition events in many protein-protein 
interactions.  Beta-turn regions in NGF are highlighted in Figure 1.2.  The amino acid 
residues in these positions are listed in Table 1.1.  By mapping similar turn regions in 
other neurotrophins, beta-turn residues were identified.  The sequences in the loops are 
highly conserved among different sources of NGF.  This high fidelity can also be seen for 
NT-3. 
 
Table 1.1.  Amino acid sequences of beta-turn residues in neurotrophins. 
β-turn sequence Protein source 
30-33 44-47 93-96 
     
NGF murine DIKG INNS DEKQ 
 human DIKG INNS DGKQ 
 bovine DIKG INNS DNKQ 
 guinea pig DIKG VNNN DGKQ 
     
  30-33 44-47 93-96 
     
BDNF pig DMSG VSKG DSKK 
     
  29-32 42-45 92-95 
     
NT-3 mouse DIRG KTGN ENNK 
 human DIRG KTGN ENNK 
 
1.3 Beta-turn Peptidomimetics 
 While proteins or peptides mediate a lot of biological processes, they have 
undesirable pharmacological properties, like proteolytic stability, that limit their 
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therapeutic use.  To circumvent this, researchers have turned to peptidomimetics - 
compounds that are not related structurally to a particular protein or peptide, but have the 
essential functional groups displayed in a characteristic three-dimensional pattern that 
will serve as the recognizing feature in binding.22,23  Those interactions in which the 
spatial arrangement of side chains is critical often involve beta-turns.24  Thus, making 
beta-turn mimetics is a rational approach to make small-molecule analogs of the parent 
protein or peptide.  However, incorporating beta-turn conformations in small organic 
molecules to produce beta-turn peptidomimetics is a formidable challenge considering 
the diversity of beta-turns (Table 1.2).21 
 
Table 1.2.  Different types of beta-turns with corresponding dihedral angles. 
φ1
ψ1
φ2
ψ2
HN
NH HN
O
R2
R1
O
R3
O
R
O
a generic β-turn  
 
Angles/Degrees Turn 
type φ2 ψ2 φ3 ψ3
     
   I -60  -30 -90    0 
   I´  60   30  90    0 
   II -60 120  80    0 
   II´  60          -120 -80    0 
   III -60  -30 -60 -30 
   III´  60   30  60  30 
   IV has 2 or more angles that differ by at least 40° from types I – III´ 
   V -80   80  80 -80 
   V´  80 -80 -80  80 
   VI has cis-Pro at position 3 
   VII has a kink in the chain created by ψ2 ∼180° & | φ3|<60° or | ψ2|<60° and φ3 ∼180°
  
 
Despite of this, a lot of groups have devoted extensive efforts to generate beta-turn 
mimics.23,25  Turn mimics can be classified as internal or external.26  In both cases, 
 7
cyclization is used as a means to enforce constraint.27  Internal turn mimics have the 
pseudo C10 skeleton motif that incorporates side chains of interest.  Examples include 
structures A and B which were developed by Kahn and Olson, respectively.28,29  External 
turn mimics, on the other hand, are dipeptide-derived cyclic analogs that do not highlight 
i+1 and i+2 positions.  Structures C and D, developed by Friedinger and Nagai, 
respectively, are prime examples.30,31 
 
N N
H
NH
NH
O
R1 O
O
R
H2N O HN R3
O
R4
NH2
NHPh
CO2Et NHAc
O
N NH2
O
R
HO2C
N
S
H
NH2
HO2C
A B C D
 
 
 
 These early works on beta-turn peptidomimetics, although promising, have gained 
partial success mainly because there is simply limited information available regarding 
which turns are involved in the interaction.  Ellman showed that this structural biology 
problem can be circumvented by making libraries of beta-turn mimics efficiently.  By 
employing solid-phase chemistry and using readily available starting materials, expedient 
synthesis of beta-turn mimics E was achieved.32 
 While a library of beta-turn mimics may be useful, especially if the interaction 
between the ligand and the receptor is not fully understood, the hit rate for an active 
compound may be not very high compared to a focus library of mimics.  However to 
have a focus library, information regarding the structural biology of the target must be 
available.  With recent advances in crystallography and spectroscopy this information is 
more accessible now.  Notable examples wherein a smaller, but a focus set of mimics was 
made based on known interactions include DeGrado’s RGD mimics F and Kessler’s 
sugar amino acid mimics G.33,34  Compounds F were designed based on the known 
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affinity of the RGD tripeptide to glycoprotein IIb/IIIa.  Mimics G, on the other hand, are 
based on the sequence of somatostatin. 
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 Our initial approach in this context is to use amino acids in the turn regions of the 
neurotrophin and constrain them through cyclization using an organic template.  This 
design is based on ring-fused C10 backbone motif which resembles back-to-back beta-
turns of cyclic hexapeptides H.  The extended turn of H can be represented by a non-
peptidic moiety which will be the organic template portion of the peptidomimetic as 
shown in I.35  The synthesis is done on solid phase for increased productivity and 
minimized purification procedures.  Y is used as the anchoring region for resin 
attachment. 
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Figure 1.4.  Rationale of peptidomimetic design.  Half of the cyclic hexapeptides was 
replaced by a nonpeptidic moiety.  Our first peptidomimetic design. 
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1.4 Conformational Studies on Beta-Turn Peptidomimetics 
 It is important once the synthesis of a supposed beta-turn mimetic is accomplished 
to determine whether or not the compound has characteristics typical of such a turn 
conformation.  This applies strongly to cyclic peptides since their structures resemble a 
beta loop more than other peptidomimetics.  The techniques most commonly used to 
elucidate peptidomimetics conformation are: NMR and CD spectroscopies, X-ray 
crystallography and molecular modeling.  Of these, NMR, CD and molecular modeling 
are the ones that are routinely used in our laboratories. 
 
1.4.1 Conformational Studies Using NMR 
1.4.1.1 Coupling Constants 
 The dihedral angles, φ1, ψ1, φ2 and ψ2 around the backbone of the four amino 
acids of a beta-turn give the turn its corresponding type (i.e. Type I, II, etc.). The vicinal 
coupling constant 3J is dependent on the dihedral angle36 and their relationship is 
expressed in the Karplus equation:37 
3J = 6.7 cos2 (φ - 60) -1.3 (φ - 60) + 1.5 
In the case of the homonuclear coupling between amide NH and CαH, the torsion angle 
can be easily calculated using this equation. 38  For Types I and II beta-turn, there have 
been generally accepted values of 3J (4 and 9 Hz for i + 1 and i + 2 residues, respectively 
for Type I; while 4 and 5 Hz for the same residues for Type 2).  However the coupling 
constants alone do not give an unambiguous type assignment for a particular compound 
especially for linear peptides because of conformational averaging under the NMR time 
scale.39 
 
1.4.1.2 Dipolar Through Space Couplings 
 Nuclei which are in close proximity develop nuclear Overhauser Effect (NOE) 
when the saturation energy of one nucleus is transferred to a neighboring one, resulting to 
an enhanced NMR signal of the latter.  In NOESY experiments, cross peaks between 
protons have proved to be useful in determining inter -hydrogen distance and orientation 
within a molecule.36  One of the disadvantages of NOE is that the time it takes for the 
signal to build up depends on the correlation time of the distance between the two nuclei.  
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Correlation times in medium-sized peptides often give rise to very small NOE’s.  To 
circumvent this, the rotating frame NOE (ROESY) experiment was developed.  However, 
in a ROESY experiment all the signals are positive that may give rise to artifacts (like 
TOCSY signals).38  In general, medium to strong NOE indicates a distance of at most 5.0 
Å.  In case of Type I and Type II beta-turns, because of the opposite orientation of the 
amido group formed by i + 2 and i + 3 residues, cross peaks made by protons in these 
residues indicate what secondary structure the peptide might have. For instance, a Type I 
turn has a characteristic cross-peak between NH protons at the i + 2 and i + 3 positions; 
this is absent in Type II, which instead has a signal between CαH at i + 2 and NH at i + 
3.40 
 
1.4.1.3 Temperature Coefficients 
 Most studies on cyclic peptides indicate higher negative gradients (∆δNH/∆T) on 
amide protons suggest these maybe solvent exposed.  A less negative gradient would 
imply hydrogen bonding or the proton maybe oriented within the turn, shielding it from 
the solvent.  It is widely accepted that for turn structures, values less negative than -4 
ppb/°C indicate that the proton is sequestered from the solvent and is probably hydrogen-
bonded.36  While the magnitude of amide NH has been useful in locating reverse turns, 
one disadvantage is ‘false positive’ observations due to side chain participation.38  
Another drawback that could result to ambiguous interpretation is the change in the 
conformation of the molecule is not taken into account even as the temperature is 
increased.41 
 
1.4.2 CD Spectroscopy 
 The difference in absorption of left and right circularly polarized lights by a chiral 
molecule gives the characteristic ellipticity of the compound seen on a CD spectrum.  CD 
spectroscopy offers a fast and convenient way in analyzing alpha helical and beta sheet 
conformations.  These secondary structures have been studied extensively and their 
signature CD patterns have been well established.42,43  In the case of cyclic peptides, the 
p-p* and n-p* transitions of the amide chromophore give the characteristic CD spectrum 
for a particular type of turn.42  Type I and type III beta-turn have a strong positive band 
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between 180-190 nm and a negative band centered around 205 nm.  Type II on the other 
hand exhibits a maximum between 200 and 205 nm and a minimum at 225 nm.44  While 
CD spectroscopy offers a fast and convenient way of analyzing peptide and protein 
secondary structure, the analysis might be complicated by other chromophores that 
absorb in the UV region of interest (180 – 230 nm). 
 
1.4.3 Molecular Modeling 
 Computer-aided modeling is now being used almost routinely to complement the 
results obtained from the methods described above.  Data from NMR are being applied as 
modeling constraints and this type of semi-empirical technique has been extensively used 
in molecular simulations.45,46  One of the most common calculation techniques used as a 
conformational searching tool is molecular dynamics.47  Our laboratories have been using 
Quenched Molecular Dynamics (QMD) to determine preferred conformations in solution 
but without adding any constraint from NMR data.  This provides an unbiased result in 
assigning a secondary structure for a particular molecule that may support or contradict 
empirical results. 
 In QMD, heat is used to overcome potential energy barriers in dynamics 
simulations.  Structures in this stage are being extracted periodically and then minimized 
(quenched).  This step produces a collection of conformations that are grouped according 
to homogeneity which can be used to judge the molecule’s preferred conformation. 
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CHAPTER II 
BETA-TURN STRUCTURE AS A POSSIBLE DRIVING FORCE FOR 
MACROCYCLIZATION 
 
2.1 Introduction 
 In medicinal chemistry, it is difficult to study relationships between conformation 
and biological activity if flexibility is not controlled.  One way of imposing 
conformational constraint to linear peptides or their derivatives (like peptidomimetics) is 
through cyclization.48  This process can render the cyclic compound to have several 
desirable biological properties over its linear counterpart.  Such properties include 
increase in: biological activity,49 resistance to proteolytic degradation50,51 and specificity 
to a particular target.  There are several ways to cyclize a linear peptide or 
peptidomimetic and reviews regarding this subject have been published.52,53  A lot of 
these methods, although different in the approaches give an amide bond at the end of the 
cyclization.  The examples that will be given in the next paragraphs feature synthesis of 
cyclic peptides/peptidomimetics that do not create amide bonds in the cyclization step. 
 One of the earliest techniques in making cyclic peptides is through a disulfide 
bond (S-S).  Thiol-containing amino acids such as cysteine and penicillamine are 
incorporated at both ends of the linear peptide and then subjected under oxidizing 
conditions to form the S-S bond.  An elegant example of this mode of cyclization was 
demonstrated by Barany and co-workers by using a solid supported oxidant.54  In this 
case, a synthetic route to anchor the oxidant, Ellman’s reagent (5,5´-dithiobis-2-
nitrobenzoic acid, DNTB) onto a solid support was developed.  After removal of the thiol 
protection, the linear peptide was reacted with an excess of the solid-supported reagent 
and was “captured” via thiol exchange reaction.  A second thiol exchange created the 
disulfide bond within the peptide with concomitant cleavage from the resin-bound 
reagent (Figure 2.1).  This methodology was applied to well-known disulfide-linked 
cyclic peptides such as oxytocin and somatostatin.54 
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Figure 2.1.  Disulfide bond formation using a solid-supported Ellman’s reagent. 
 
 
 Another reaction that proceeds with high efficiency like disulfide bond formation 
is oxime bond formation.  While this is not a very popular technique to make cyclic 
peptide analogs, Tam and co-workers have shown that linear, unprotected peptides 
bearing a hydroxylamine and aldehyde functionalities can be cyclized in an 
intramolecular fashion.55  This methodology was applied to make a V3 loop mimic of 
gp120 which contains a peptide sequence being targeted as a neutralizing determinant for 
developing vaccines.  The linear precursor was made on Wang resin; after TFA cleavage, 
the serine end of the molecule was oxidized and converted to an aldehyde, which 
underwent facile attack by the hydroxylamine group creating the oxime bond which 
cyclizes the molecule (Figure2.2).  The cyclization was complete in two minutes as 
monitored by reverse-phase HPLC. 
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Figure 2.2.  Tam’s mode of cyclization via oxime bond formation. 
 
 
 One of the ‘hottest’ reactions of the last decade is ring-closing metathesis (RCM) 
and it is not surprising that it has found utility in the field of peptide chemistry.  Several 
groups have employed this reaction to make cyclic peptides and they have appeared in a 
review elsewhere.56  However, one example worth mentioning is the one reported by 
Liskamp.57  In this work, N-alkylation with hydroxyalkenes was employed to yield the 
metathesis precursors.  This method of installing the alkene group does not compromise 
the amino acid side chains which can be important for biological activity.  Once the linear 
alkene precursors are made, RCM was achieved using Grubbs’ first generation catalyst.  
One attractive feature of this work is that the site where the RCM occurs can be verified 
via mass spectrometry as shown in Figure 2.3. 
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Figure 2.3.  Examples of Leu enkephalin derivatives synthesized via 
application of ring closing metathesis. 
 
 
 Our group has also been involved in the synthesis of cyclic peptidomimetics and 
initial works in this area had involved the application of nucleophilic aromatic 
substitution (SNAr) reactions to create the macrocyclic compound. 
2.2 Solid Phase SNAr Macrocyclization 
 Solid phase synthesis has its roots on Merrifield’s invention of doing peptide 
synthesis on polystyrene-based support.58  The idea of tethering an organic molecule on a 
solid matrix has revolutionized the field of organic synthesis and reactions other than 
amide bond formation were also found to be suitable on-resin.59,60  This proved to be 
crucial not only in the development of combinatorial chemistry but also in the 
advancement of medicinal chemistry as wide range of molecules including heterocycles, 
peptides and carbohydrates are prepared at a faster rate. 
 The displacement of a leaving group in an aromatic ring by a nucleophile, 
otherwise known as SNAr (substitution nucleophilic aromatic) reaction is one the most 
common reactions in organic chemistry.  This reaction has been known since the 1900’s, 
however, its application as a tool for macrocyclization was demonstrated only 15 years 
ago.  In an attempt to find an alternative to synthesize the C-O-D ring of vancomycin, 
Buegelmanns showed that SNAr macrocyclizations can be employed using a phenol 
group (Figure 2.4).61  Interestingly, the researchers found that concentration was not a 
factor in the macrocyclization step.  Three years after, this type of synthesis for 
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heterodectic compounds was applied on a solid support in a collaborative effort by 
Burgess and Zhu in their work on OF4949 derivatives (Figure 2.5).62  They also found 
that removal of the silylether protection on the phenol functionality by TBAF was 
sufficient for nucleophilic attack.  Thus, a milder condition for cyclization is possible 
which reduced epimerization that was observed under basic conditions. 
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Figure 2.4.  Demonstration of SNAr macrocyclization toward the synthesis  
of C-O-D ring of vancomycin. 
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Figure 2.5.  Solid-phase SNAr macrocyclization to synthesize an OF4949 III derivative. 
 
 
 Our group has focused on similar type of macrocyclization to make beta-turn 
peptidomimetics.  Early studies on beta turn peptidomimetics in our group involved a C10 
motif in which a peptide fragment is locked by an organic moiety through the cyclization 
process.35  These mimics resemble turn-extended-turn conformations of cyclic 
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hexapeptides.63,64  Thirteen to 16-membered ring compounds were made with a variety of 
nucleophiles like alcohol (-OH), amine (-NH2) and thiol (-SH), all of which came from 
amino acid side-chains.35  The syntheses of these compounds were done on a solid 
support.  Conventional peptide synthesis strategy based on the Fmoc protecting group 
was employed to make linear precursors for the macrocyclization event.  In this case, 
intramolecular SNAr reactions were used to give the final products I-NH2 shown 
below.65,66  While the cyclization reactions appear to be facile, and some of the products 
exhibit beta-turn characteristics, it is not known whether or not an anticipated secondary 
structure is responsible for the efficiency of the macrocyclization process. 
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 To investigate on this issue, we have set out to compare SNAr cyclizations of two 
model compounds.  Their structures are given in Figure 2.6 and their syntheses are 
depicted in Schemes 2.1 and 2.2.  Both compounds have the same ring size (14-
membered ring) but from molecular stick models, it seemed that compounds 1 are more 
strained and are not capable of adopting a beta-turn structure.  On the other hand, 
compounds 2 have some flexibility but still possess rigidity and can possibly adopt a turn 
structure. 
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Figure 2.6.  Structures of SNAr products 1 and 2. 
 
2.3 Syntheses of Compounds 1 and 2 
 The syntheses of compounds 1 and 2 followed conventional solid-phase Fmoc (9-
fluorenylmethoxy carbonyl) peptide synthesis approach.67  Polystyrene resin derivatized 
with Rink handle was used to anchor the molecules.  Monomethyltrityl (Mmt)-protected 
cysteine was the first amino acid to be attached followed by two more amino acids 
corresponding to the beta-turn sequence of the neurotrophin target (Scheme 2.1).  The 
prime (′) symbol in the side chains (e.g. R1′) denotes side chain protection where 
applicable.  This process is the same for both compounds. 
 
Scheme 2.1.  Synthesis of tripeptide precursors of compounds 1 and 2 
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 After the dipeptide synthesis, the Fmoc protection of the N-terminal amino acid 
was cleaved and the organic template, which is different for both compounds set, is 
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attached.  For compounds 1, 5-fluoro-2-nitrobenzoyl chloride was used and this was 
coupled to the free amino group giving the linear precursors.  The sulfur protection was 
then deblocked under mild acidic conditions to liberate the free thiol that will act as 
nucleophile in the following macrocyclization step.  This was done under basic 
conditions to give the cyclized compounds.  Finally, the compounds were cleaved from 
the resin under strong acidic conditions (Scheme 2.2). 
 
Scheme 2.2.  Synthesis of compounds 1 
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 Compounds 2 have 2-fluoro-5-nitrophenylacetic acid as the organic template.  
This one does not need to be converted to the acid chloride because it can couple 
smoothly to the amine using DIC/HOBt.  After its attachment, the same cyclization 
protocol was followed for compounds 2 (Scheme 2.3). 
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Scheme 2.3.  Synthesis of compounds 2 
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 The yields and purities of the compounds from their syntheses are given in Tables 
2.1 and 2.2.  The compounds were isolated via preparative HPLC using a reverse-phase 
C18 column and were characterized by MALDI-MS and proton NMR.  The synthesis of 
compounds 1a-e is complicated by what we call ‘dimer’ (Figure 2.7; 1-1 in the table) 
formation which arises from intermolecular cyclization.  This phenomenon has been 
observed in previous studies on peptidomimetics from our group.68  Although it can be 
suppressed by using a low resin loading, it is still hard to avoid as seen in this case.  As 
such, the purities and the yields are significantly lower than those of compounds 2. 
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Figure 2.7.  Structure of the ‘dimeric’ byproduct in the cyclization of compounds 1. 
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The syntheses of compounds 2a-e proved to be more efficient as the 
intermolecular macrocyclization byproducts are less significant.  This does not mean that 
the competing side reaction has been completely eliminated; in fact, MS data showed that 
there are small amounts of the byproducts present, but HPLC data showed these are 
insignificant amounts that isolating them are not productive. 
 
Table 2.1.  Isolated yields and purities for 1a-e and their corresponding dimers, 1-1. 
 
Purities 
(%) 
Isolated 
yields (%) Compound R1 R2
1 1-1 1 1-1 
       
1a CH2CONH2 (CH2)4NH2 72 15 28 1 
1b (S)-CH(CH3)CH2CH3 (CH2)4NH2 67 25 17 4 
1c (S)-CH(CH3)CH2CH3 (CH2)3NHC(=NH)NH2 70 29 21 5 
1d (R)-CH(CH3)(OH) H 62 28 26 8 
1e CH2CO2H (S)-CH(CH3)CH2CH3 36 60 10 4 
 
Table 2.2.  Isolated yields and purities for 2a-e. 
 
Compound R1 R2 Purities (%) 
Isolated 
yields (%) 
     
2a CH2CONH2 (CH2)4NH2 89 57 
2b (S-)CH(CH3)CH2CH3 (CH2)4NH2 92 50 
2c (S-)CH(CH3)CH2CH3 (CH2)3NHC(=NH)NH2 86 37 
2d (CH2)3NHC(=NH)NH2 H 76 40 
2e (CH2)4NH2 (R)-CH(CH3)(OH) 85 59 
 
2.4 Conformational Analyses 
 Compounds 1a and 2a (Figure 2.8) were selected as representative structures for 
conformational analyses to assess whether or not the compounds can adopt beta-turn 
structures.  The following experiments were done to assess beta turn propensity: CD, 1-D 
and 2-D NMR and quenched molecular dynamics (QMD) modeling. 
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Figure 2.8.  Representative compounds used for conformational studies. 
 
 
 Circular dichroism provides a fast and convenient method to determine whether 
or not a molecule possesses beta-turn structure.  Compounds 1a and 2a were dissolved in 
20% MeOH/H2O, the ratio of which approximates the dielectric constant of DMSO used 
in the NMR studies.  Overlaid CD spectra of the two compounds are shown in Figure 2.9.  
While there is a negative band around 210 nm for compound 2a, the maxima at 190 nm is 
absent.  Typical type I and type II turns have minima around 205 nm and 225 nm, 
respectively; and maxima around 190 and 205 nm, respectively.44  Clearly, there is no 
definite beta-turn structure that can be deduced from these spectra.  
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Figure 2.9.  CD spectra of compounds 1a and 2a. 
 
 NMR experiments on the compounds were done by Dr. Mookda Pattarawarapan 
to evaluate relevant proton cross peaks, coupling constants and internal hydrogen 
bonding.  Molecular simulations using QMD69,70 were performed by Sudipta Roy.  From 
these calculations, clusters of low energy conformers are generated without applying any 
constraint from NMR experiments.  This provides an unbiased result so that good 
agreement between experimental results would validate the calculations. 
 Temperature coefficient values of hydrogen-bonded or solvent-shielded protons 
normally have values less negative than -4 ppb/K.71,72  For compounds 1a and 2a, if they 
adopt beta turn conformation, the amino hydrogen of cysteine is expected to hydrogen-
bond with the carbonyl oxygen of the template.  Measured temperature coefficient values 
for the NH of cysteine for 1a and 2a (-4.49 and -7.25, respectively) reveal that this is not 
the case for the two compounds.  This is supported by HD exchange experiments, which 
show that these protons are exchanged at a fast rate.  There are other amine protons such 
as the LysNH for both compounds that exhibited values that can be regarded as 
hydrogen-bonded or solvent-shielded (LysNH for 1a and 2a is 3.44 and 0.79 ppb/K, 
respectively) but these have no implications on any turn structure.  It is possible that 
those protons are hydrogen bonded with the carbonyl functionality of the adjacent 
asparagine side-chain. 
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 QMD calculations generated four families for each compound.  Table 2.3 shows 
the data of the lowest energy conformer family of 1a.  Coincidentally, the data for this 
family best match the NMR data.  However, the dihedral angles measured from QMD do 
not correspond to any type of beta-turn.  Correlation of the QMD-measured distances 
with those from ROE data (Figure 2.10) indicated low correspondence.  These, together 
with temperature coefficients of amide NH’s and H/D exchange experiments suggest that 
the solution conformer is not a beta-turn. 
 
Table 2.3.  QMD results for the lowest energy conformer of 1a. 
 
Amino acid residue Dihedral angle (°) Lowest energy conformer of 1a 
   
Asn (R1) φ -116.6 
 ψ -41.40 
Lys (R2) φ -168.5 
 ψ 45.52 
Distance (Å)COtemp.-NHi+3  5.224 
Type of beta turn  none 
 
 
 
 
 
Hydrogen ROE QMD distance (Å)
Asn NH - Lys NH strong 1.707 
Asn CαH - Lys NH weak 3.518 
Lys NH - Cys NH medium 2.261 
Lys CαH - Cys NH strong 2.656 
 
Figure 2.10.  Top: Lowest energy conformer for 1a generated by QMD.  Bottom: 
Correlation between NMR ROE cross-peaks and distances from QMD. 
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For 2a, the lowest energy conformer of the most populated family fits poorly with 
NMR experimental results.  While calculations support the assumption that compounds 2 
can adopt a turn structure, experimental evidence suggests otherwise (Table 2.4 and 
Figure 2.11).  It is possible that the methylene group of the template renders the 
macrocycle more flexible than previous designs that in solution, the preferred 
conformation is not a beta turn. 
 
Table 2.4.  QMD results for the lowest energy conformer of 2a. 
Amino acid residue Dihedral angle (°) Lowest energy conformer of 2a 
   
Asn φ -78.57 
 ψ -31.22 
Lys φ -73.34 
 ψ -18.44 
Distance (Å)COtemp.-NHi+3  2.648 
Type of turn  III 
 
 
 
Hydrogen ROE QMD distance (Å)
Asn NH - Lys NH medium 2.255 
Asn CαH - Lys NH very weak 3.486 
Lys NH - Cys NH weak 2.499 
Lys CαH - Cys NH medium 3.443 
Figure 2.11.  Top: Lowest energy conformer for 2a generated by QMD.  Bottom: 
Correlation between NMR ROE cross-peaks and distances from QMD. 
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 While experimental (NMR) and QMD results do not fit very well, it is possible 
that for compounds 2, a more ordered structure is being adopted that facilitated the 
macrocyclization and minimized the dimer byproduct that is prevalent in the syntheses of  
compounds 1.  One final experiment was to determine the distance between the thiol 
(SH) nucleophile and the carbon bonded to fluorine (C-F) electrophile, the elements 
needed for cyclization.  Open analogs of 1a and 2a were minimized in a normal QMD 
protocol and then subjected to dynamics simulation experiment.  This was done for 600ps 
at 298 K.  One conformer was downloaded every 1 ps.  The distance between S and C are 
measured for each conformer and plotted against time (Figure 2.12).  The data showed 
that for 2a, there is a marked decrease in the distance after 200 ps and this distance did 
not go out of range of 6 – 10 Å throughout the rest of the dynamics simulation.  This 
leveling is absent for 1a and even though there is also a drop in distance, the variation is 
greater. 
 
 
Figure 2.12.  Nucleophile-electrophile distance before macrocyclization 
for compounds 1a (left) and 2a (right). 
 
 
2.5 Biological Assay 
 Cell survival assay was done to assess the biological activity of the 
peptidomimetics.  In this assay, cells that express the receptor are cultured in serum free 
media (SFM) and eventually die via apoptosis.  However, the cells can be ‘rescued’ if 
functional neurotrophins are expressed within the cells.  Test wells are then supplemented 
with suboptimal (100 pM) or optimal (2 nM) concentrations of the corresponding 
neurotrophin and then observed for growth or death. 
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 Thus, these tests were designed to first check for agonism or antagonism, and then 
other tests such as receptor selectivity and specificity and toxicity can be conducted.  
Tests for agonism/antagonism use the fact that suboptimal neurotrophin concentrations 
afford limited protection from apoptosis (e.g. 25 %, throughout).  Antagonism occurs 
when a non-cytotoxic peptidomimetic induces less than the sub-optimal 25% cell 
survival, and potentiation of activity occurs where survival is enhanced above that value.  
Additional agonism by the peptidomimetics can be tested by their ability to rescue cells 
from apoptosis in serum free media, in the absence of neurotrophins.  Receptor 
specificity occurs, for instance, if a biological effect is observed for TrkC-expressing NIH 
cells (NIH-TrkC) but not for NIH-TrkA.  Additional assays with wild type cells that do 
not express neurotrophin receptors are used to gauge general Trk receptor selectivity and 
lack of toxicity. 
 Table 2.5 shows the cell survival assay for compounds 1a-e and 2a-e.  These 
assays were done in triplicates.  The compounds did not show any significant agonistic 
properties even at suboptimal concentration of neurotrophin. 
 
Table 2.5.  Cell survival assay for compounds 1 and 2. 
% survival of  
E25/TrkA cells 
% survival of  
NIH3T3/TrkC cells Compound 
SFM NGF low SFM NT-3 
     
untreated 0 0 0 0 
1a 0.43 ± 0.48 -4.55 ± 2.58 0.41 ± 1.35 5.75 ± 1.68 
1b -1.14 ± 0.54 -6.0 ± 5.00 1.6 ± 0.64 -3.1 ± 1.45 
1c -1.99 ± 1.07 -13 ± 4.50 1.53 ± 1.04 -3.1 ± 1.95 
1d -2.26 ± 0.74 -11.5 ± 3.25. -1.95 ± 1.03 -1.15 ± 2.98 
1e 2.27 ± 0.93 3.5 ± 0.35 -3.8 ± 0.42 -3.25 ± 2.33 
2a -4.7 ± 0.00 -8.0 ± 0.00 -3.7 ± 1.2 -2.6 ± 3.30 
2b -1.3 ± 0.99 -5.5 ± 0.25 -0.47 ± 0.01 -2.45 ± 3.38 
2c -4.7 ± 0.14 -25.7 ± 9.85 0.18 ± 2.81 -1.3 ± 4.45 
2d -2.05 ± 1.10 -6.75 ± 3.08 -0.85 ± 3.15 4.0 ± 2.65 
2e -0.95 ± 0.25 -6.8 ± 3.30 -1.92 ± 2.04 2.85 ± 1.48 
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2.6 Summary 
 Molecular models of cyclic peptidomimetics 1 and 2 implied that the latter could 
adopt beta-turn structures and the former could not.  This was the hypotheses at the outset 
of this study.  However, after NMR and QMD experiments with representative structures 
of both compounds, it is clear that in solution, the preferred conformation for both 
compounds is not a beta-turn structure.  It is not conclusive from NMR experiments if the 
asparagine side chain has affected this or the backbone has favored a different 
conformation other than a beta-turn.  Yields from the syntheses indicated that the 
cyclization reactions to form compounds 2 are indeed more facile and cleaner.  It is 
possible that this is due to some adaptation of a more ordered structure.  While this is not 
fully supported by experimental results, theoretical calculations prove that compounds 2 
have some bias toward a turn structure. 
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CHAPTER III 
PEPTIDOMIMETICS THAT INCORPORATE THREE RESIDUES 
OF THE TETRAPEPTIDE BETA-TURN SEQUENCE 
 
3.1 Introduction 
 The design of a peptidomimetic involves the successful incorporation of the 
necessary elements responsible for the biological activity of a particular protein or 
peptide target.  In designing beta-turn mimetics, the main focus has been on the dipeptide 
at the tip of the turn wherein the beta-turn is centered.  Inclusion of this sequence or its 
side-chains into a small molecule is perhaps the first goal in designing a peptide mimic.  
The rational for zeroing in on the beta-turn dipeptide sequence is that most interactions 
involved beta-turns 73,74  Thus, most small molecule mimics have featured only the beta-
turn sequence or side-chains. 26 75  While this have proved to be successful, there are 
some biologically relevant proteins or peptides whose activities are mediated by more 
than two amino acid residues.  Examples of such compounds include somatostatin,76 the 
enkephalins77 and the well-known RGD sequence.78  Although more than two amino 
acids determine the biological activity of these compounds, the beta-turn conformation, is 
still present within or in the vicinity of these sequences.  For example in somatostatin, a 
beta-turn is observed that projects the residues Phe7, Trp8 and Lys9 in the proper three-
dimensional arrangement to interact with the receptor.79  It is apparent that designing 
peptidomimetics which can accommodate more than a dipeptide sequence/side chain and 
still exhibit beta-turn conformation is very desirable.  Outlined in the next few paragraphs 
are examples of such compounds applied to mimic biologically active peptides. 
 Somatostatin, or more appropriately, SRIF-14, is a cyclic tetradecapeptide which 
belongs to the family of somatotropin-release inhibiting factors (SIRFs).80  They bind to 
G-protein-coupled receptors and in doing so, act as neuromodulators or 
neurotransmitters.  They are also involved in inhibiting secretory pathways and cell 
proliferation.81  The critical sequence that is believed to be responsible for its activity is 
the Phe7-Trp8-Lys9-Thr10 tetrapeptide moiety.76  Hirschmann’s group has done 
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extensive studies on somatostatin and they have developed several peptidic and non-
peptidic mimics for the peptide.82  A novel approach that was applied in their research is 
using what later would be termed to as privileged structures.83  These are compounds that 
have inherent ability to adopt conformations (like alpha helices or beta-turns) of 
biological interest.  One of their designs was the use of D-glucose as a scaffold that 
projects the necessary side chains of the bioactive tetrapeptide sequence of somatostatin 
(Figure 3.1).84,85 
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Figure 3.1.  Hirschmann’s somatostatin mimic based on a sugar scaffold. 
 
 
 Analogous to the work described above was inclusion of a sugar amino acid 
(SAA) in a peptide backbone.  In contrast however, the pyranose structure in this case is 
used a dipeptide isostere.  Kessler have successfully applied this approach on the same 
somatostatin sequence by incorporating glucosyluronic acid methylamine as the SAA 
moiety.86  This work was extended by synthesizing other sugar amino acids capable of 
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dictating the peptide backbone to adopt a desired conformation.34  Examples of these are 
shown in Figure 3.2. 
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Figure 3.2.  Top: Somatostatin mimic (right) that includes the sugar amino acid on the 
left.  Bottom: Other turn-inducing dipeptide isosteres. 
 
 
 The highly active Arg-Gly-Asp (RDG) sequence, also known as the “universal 
cell recognition sequence” is found in many extracellular matrix proteins.78,87  It is 
believed that the tripeptide is involved in a turn structure in the protein’s bioactive 
conformation that is the key to binding integrins.  Indeed, several X-ray structures of 
biologically active proteins with this sequence show that the tripeptide is found along the 
tip of a flexible loop region of the protein.88  Despite of this common sequence, it was 
shown that the conformation around or near this sequence can dictate the specificity 
between different integrins.89  Kessler have used several known dipeptide turn mimetics 
to make cyclic peptide analogs containing the RGD sequence.90  These turn mimics 
replaced the D-Phe-Val dipeptide sequence of cyclo-(RGDfV), a highly active and αvβ3 
selective cyclic peptide (Figure 3.3).88 
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Figure 3.3.  Kessler’s application of turn-inducing heterocycles in making cyclic 
RGD mimetics. 
 
 
 While Kessler’s work on RGD mimics have focused on dipeptide beta-turn 
surrogates, DeGrado’s approach in designing analogs of the same sequence involved the 
use of an organic template to constrain the cyclic peptide.33,91  In principle, this method is 
related to our approach.  It is interesting to note that a change in beta-turn structure 
involving Arg (as the i + 2 residue in the XX-Arg sequence) can change the specificity of 
the peptidomimetic to a particular integrin (Figure 3.4).89 
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Figure 3.4.  DeGrado’s template-constrained cyclic RGD mimics. 
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 It can be inferred from DeGrado’s work that the organic template, m-aminomethyl 
benzoic acid (Mamb), they have used is versatile in the sense that it can, together with the 
amino acids in the peptide backbone, impose different types of beta-turn conformations.  
It is therefore, very desirable to use other templates similar in structure in our attempts to 
make cyclic peptidomimetics of neurotrophins. 
3.2 Solid-phase SN2 Macrocyclizations 
 The previous chapter has presented the rationale in our design to make beta-turn 
mimics of neurotrophins.  Those initial mimics from our laboratories involved only 
dipeptides that occupy the tip of the beta-turn sequence (compounds A below).  However, 
as pointed out in the discussion above, there are amino acid residues other than those in 
the beta-turn itself that contribute to the protein’s biological activity.  While this is true, 
the beta-turn conformation can not be discounted because the other residues can be found 
in the vicinity of the secondary structure.  It is therefore ideal to make peptidomimetics 
that incorporate more than a dipeptide and still adopt a beta-turn conformation. 
 In our synthetic scheme, adding an extra or even two amino acids is not difficult 
because it is based on peptide synthesis.  However, the flexibility of the molecule is being 
compromised with each amino acid being added.  The template of choice plays a crucial 
role in maintaining the desired constraint within the molecule.  It was mentioned before 
that a template similar to that of Mamb is ideal in this situation.  Consequently, 
compounds 3 were designed.  It features three amino acid residues which make the ring 
size larger (18-membered) than the usual 14-membered ring designs.  Also, the 
cyclization mode is now SN2 instead of SNAr.  Unlike for aromatic substitution, there are 
relatively few reports that feature an intramolecular SN2 reaction as the macrocyclization 
step and those works are not related to peptide mimicry92,93.  Our group have employed 
this type of ring closure strategy before with 14-membered ring SN2 compounds.66  From 
this early work, it can be noted that intermolecular cyclization still occurs at a 
considerable degree that significantly lowers the purities of the desired products.94  So at 
the outset, it is not known if the same phenomenon will be observed with a larger ring 
size. 
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3.3 Template Design 
 The template that was used for the synthesis of compounds 3 resembles the Mamb 
(m-aminomethyl benzoic acid) template that DeGrado and co-workers utilized in their 
work on RGD peptidomimetics.33  These cyclic RGD mimics are also 18-membered 
macrocycles and were made on an oxime resin (Figure 3.5).  One significant difference of 
our work from DeGrado’s is that we did not use turn-inducing residues to force beta turn 
conformations on our molecules.89 
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Figure 3.5.  DeGrado’s solid-phase synthesis of cyclic RGD mimics 
constrained by Mamb template. 
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 The synthesis of the organic template used to constrain compounds 3 is shown 
Scheme 3.1.  Radical bromination of m-toluic acid was done to install the benzylic 
bromide.95  The carboxylic acid functionality was later converted to the acid chloride 
using oxalyl chloride.  This makes it activated for coupling with the peptide on the solid 
support. 
 
Scheme 3.1.  Synthesis of the organic template 
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3.4 Synthesis of Compounds 3 
 Fmoc peptide synthesis was utilized to make the linear tetrapeptide precursors 
(Scheme 3.2).96,97  FmocCys(Mmt)-OH was the first amino acid to be coupled to the resin 
and was followed by three amino acids that make up the three residues found in the turn 
regions of interest in NGF and NT-3.  After the last amino acid was attached, the Fmoc 
group was removed and the resulting amine, which is at the N-terminus, was capped with 
the template.  Removal of the thiol protection, cyclization and then cleavage from the 
resin afforded the final peptidomimetics which is now expanded to three amino acid 
residues.  One main difference with regard to an SNAr cyclization and the SN2 mode 
applied here is that for the latter, ring closure can be done in milder basic conditions and 
also, the rate of the cyclization is faster.  Another significant and somewhat surprising 
result is that formation of the head to tail dimer is very much suppressed.  Although MS 
can still detect it, UV and ELS detections in HPLC suggest this side product is not 
significant. 
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Scheme 3.2.  Synthesis of compounds 3 
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3.5 Resin Performance Comparison 
 Solid phase synthesis of short (less than 5 residues) linear peptides is somewhat 
trivial and most resins in general will give clean short linear products.  It is in reactions 
(examples in this case would be template attachment and cyclization) that divert the 
peptidic nature of the compound being synthesize that resins could give varying results in 
terms of the purities of the product being generated.  To assess the generality of the 
synthesis of compounds 3, different resins were employed on three trial sequences.  The 
resins can be divided as either having the Rink handle (amino resins) or those that have 
the Wang handle (hydroxyl resins).98,99  Figure 3.6 illustrates the two types of resin used.  
Aside from the difference in the handle, the spacer can also be varied to give the polymer 
matrix swelling characteristics absent in a mainly hydrophobic polystyrene (PS) core. 
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Figure 3.6.  Illustrations of two major resin types used. 
 
 
 Table 3.1 shows the result of the resin comparison study.  Six Rink-type resins 
and three Wang-type resins were used for three different sequences (NKK, ENN and 
DGK).  Except for the Synphase Lanterns, all the others follow the same washing 
procedure.  The one for the lanterns had to be modified because of its built and properties 
are different from the rest.  It turned out that it was not a suitable solid support for this 
purpose as shown by the lower purities of the compounds cleaved from this type of resin.  
On the other hand, the rest of the amino resins gave excellent purities consistently.  The 
hydroxyl resins are not as consistent and this is probably due to the dependence on the 
sequence being installed.  While the loadings are different in each resin, it is not to be 
concerned about because we are just screening the overall applicability of the reaction; 
and it turned out that the reaction sequence to synthesize the compounds like 3 is 
tolerated well by resins with the Rink handle. 
 To make a small library of compounds 3, TentaGel S Ram Fmoc resin was 
chosen.  Table 3.2 shows the result of the syntheses.  The purities and the yields are high 
except for about three compounds.  Some of the yields are lower because of sampling of 
few beads after certain stages in the synthesis to monitor the progress and the efficiency 
of the reaction.  Like in the three trial sequences used in the resin study, the formation of 
head to tail dimer side product is not significant in these reactions.  After cleavage from 
the resin, the compounds were purified via reverse phase HPLC and their purities were 
assessed under UV and ELS (Sedex) detectors.  Finally, the solutions from HPLC were 
concentrated in vacuo, flash frozen and freeze dried to afford solid, powdery white 
compounds. 
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Table 3.1.  Resin comparison study on three trial sequences. 
 
3-AA1-AA2-AA3
NKK ENN DGK 
resin handle 
 
loading 
(mmol/g) 
 
supplier % purity 
UV 
(Sedex) 
%purity 
UV 
(Sedex) 
% purity
UV 
(Sedex) 
       
Tenta Gel S 
RAM Fmoc Rink 0.30 
Advanced 
ChemTech 99 (96) 88 (94) 66 (75) 
Tenta Gel S 
RAM Fmoc Rink 0.22 
Rapp 
Polymere 90 (93) 88 (93) 91 (97) 
Argo Gel 
Rink NH 
Fmoc 
Rink 0.33 Argonaut 95 (99) 88 (96) 83 (91) 
Hypo Gel 
400 RAM Rink 0.53 
Rapp 
Polymere 94 (99) 88 (95) 82 (88) 
Rink Amide 
MBHA Rink 0.61 NovaBiochem 95 (98) 89 (94) 85 (94) 
Synphase 
Lantern Rink 0.036 Mimotopes 75(91) 67 (84) 89 (92) 
Tenta Gel S 
AC Wang 0.24 
Rapp 
Polymere 90 (84) 83 (97) 44 (52) 
Hypo Gel 
400 PHB Wang 0.61 
Rapp 
Polymere 82 (95) 67 (76) 56 (67) 
Nova Syn 
TGA Wang 0.25 NovaBiochem 90 (100) 36(29) n/a 
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Table 3.2.  Crude Purities and Isolated Yields for Compounds 3. 
 
purity (%) 
compound sequence 
UV ELS 
isolated yield 
(%) 
 
3a 
 
IKG 
 
92 
 
95 
 
27 
3b DIK 72 77 45 
3c NNS 92 97 16 
3d INN 93 92 29 
3e DGK 66 75 69 
3f GKQ 81 84 16 
3g IRG 87 91 36 
3h DIR 83 79 34 
3i KTG 91 89 68 
3j NNK 97 97 21 
3k ENN 89 94 46 
3l NKQ 64 67 36 
3m DNK 67 81 20 
 
 
3.6 Conformational Analyses of Compounds 3 
 To asses if compounds 3 adopt beta-turn structures, QMD, NMR experiments (1-
D, ROESY,100 temperature coefficient), and CD were performed on two representative 
structures (3a and 3g).  These two were chosen because of their displayed bioactivity in 
initial cell-survival assay (see section on assay data).  Table 3.3 shows the QMD analysis 
of compound 3a.  The lowest energy conformer belongs to the most populated family of 
the three families generated.  The dihedral angles around the Ile and Lys residues 
correspond well with a type I beta-turn (-60°, -30°, -90° and 0°, normally, this last one is 
either omitted or the angle should be within 30 degrees).  Also the distance between the 
oxygen of the carbonyl (C=O) of the template (ie i residue) and the NH hydrogen of the i 
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+ 3 residue (Gly) is within acceptable distance that could indicate H-bonding at these 
sites. 
 
Table 3.3.  QMD results for the lowest energy conformer of compound 3a. 
Amino acid residue Dihedral angle (°) Lowest energy conformer of 3a 
   
Ile (R1) φ -74.32 
 ψ -36.92 
Lys (R2) φ -95.28 
 ψ -22.36 
Distance (Å)COi – NH i + 3  3.096 
Type of beta-turn  Type I 
 
 
 One-dimensional (1-D), DQFCOSY101, and TOCSY102 experiments were utilized 
to verify the structure of the compound.  To evaluate crosspeaks that suggest beta turn 
properties, ROESY, temperature coefficient experiments and coupling constants from the 
1-D NMR were employed.  Type I beta-turn in general will show correlation peak 
between the i + 1 and i + 2 amide hydrogens because the carbonyl of the latter is oriented 
in such a way that the hydrogen is cis to the side chains of the residues.  ROESY results 
showed that this is indeed the case for 3a (Figure 3.7).  The observed ROE cross peaks 
(particularly those for Ile and Lys NH’s, and Lys and Gly NH’s) correspond well with 
accepted intensities ( eg. medium for i + 1 residue) for a type 1 beta-turn and these 
ROE’s fit nicely with QMD-measured distances. 
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Hydrogen ROE QMD distance (Å)
Ile NH - Lys NH medium 2.283 
Ile CαH - Lys NH not obsd. 3.486 
Lys NH - Gly NH weak 2.079 
Lys CαH - Gly NH not obsd. 3.458 
 
Figure 3.7.  Top: Lowest energy conformer of 3a from QMD.  Bottom: Correlation 
between ROE cross-peaks and distances from QMD. 
 
 For compound 3g, similar results were observed in QMD but this time, two 
families were almost equally populated.  Table 3.4 shows the results.  Both families 
behave in almost the same way and the dihedral angles correlate very well with those for 
Type I turn.  The ROE crosspeaks for relevant protons were measured and tabulated with 
distances from QMD (Figure 3.8).  Again, the results are similar to that of 3a indicating 
the 3g adopts type 1 beta-turn structure.  The main difference between the QMD 
structures of the two families is the orientation of the Arg side chain.  For Family 1, the 
guanidine side chain is involved in a pi-cation interaction with the aromatic ring that 
made the former bend over the latter.  Family 2 shows a structure in which this side chain 
is flipped back and away from the ring.  It is possible that in solution, these two 
conformers are interconverting, hence, the observed coupling constants are more of an 
average of the calculated ones (e.g. for ArgNH, calculated: 8.7 and 5.7 Hz for Family 1 
and 2 respectively; observed: 8.1 Hz).. 
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Table 3.4.  QMD results for the lowest energy conformer of compound 3g. 
Lowest energy 
conformer of 3g Amino acid residue Dihedral angle (°) 
Family 1 Family 2 
    
Ile (R1) φ -73.40 -73.57 
 ψ -37.13 -29.89 
Arg (R2) φ -98.3 -72.13 
 ψ -21.58 -15.93 
Distance (Å)COi – NH i + 3  3.117 2.344 
Type of beta turn  Type I Type I 
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Hydrogen ROE QMD distance (Å)
  Family1 Family2
Ile NH - Arg NH medium 2.310 2.234 
Ile CαH - Arg NH not obsd. 3.490 3.459 
Arg NH - Gly NH weak 2.042 2.520 
Arg CαH - Gly NH not obsd. 3.453 3.418 
 
Figure 3.8.  Top: Low energy conformers of the two families of 3g from QMD.  Bottom: 
Correlation between ROE crosspeaks and distances from QMD. 
 
 
 Temperature coefficients (Tc) of the amide NH’s were measured to assess internal 
hydrogen bonding at the carbonyl (C=O) of the template and the GlyNH.  The Tc values 
measured were -3.3 and -2.8 for 3a and 3g, respectively.  These values are indicative of 
either hydrogen bonding or solvent shielding.36  QMD measurements of the distance 
between these two sites show that they are within hydrogen bonding range.  The CD 
spectra for 3a and 3g are shown in Figure 3.9.  They have similar patterns that can be 
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associated to a type 1 beta-turn profile: a negative band around 220 nm and a positive 
band near 190 nm.44  The latter one is obscured because of instrument limitations.  
However, this spectrum is close to a class C which is associated to well-described type I 
beta-turn systems.43  Thus, these temperature coefficients and CD spectra complement 
each other, giving a strong indication that the compounds adopt a type 1beta-turn 
conformation in solution. 
 
 
 
Figure 3.9.  CD spectra of compounds 3a and 3g. 
 
 
3.7 Assay Results for Compounds 3 
 The compounds in Table 3.2 were submitted for a cell survival assay (see 
previous chapter for description of the assay).  However, some compounds have limited 
solubility and so were not assayed.  The activities of those tested were tabulated in Table 
3.5.  Most of the compounds show no interesting activity, however, compounds 3a and 
3g showed significant agonistic properties (% survival in bold) in TrkC expressing cells 
at suboptimal concentrations.  It is interesting to note that 3a, whose sequence correspond 
to that of NGF, did not show any activity for TrkA cells, but was active for TrkC cells.  
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These results showed that monovalent mimics can function as agonists to promote cell 
survival. 
 
Table 3.5.  Cell survival data for compounds 3. 
% survival of  
E25/TrkA cells 
% survival of  
NIH3T3/TrkC cells Compound 
SFM NGF low SFM NT-3 low 
     
Untreated 0 0 0 0 
3a -3.23 ± 0.78 -14.9 ± 6.37 1.48 ± 0.62 14.12 ± 3.99 
3b -3.94 ± 0.48 -27.1 ± 5.23 0.21 ± 2.44 -17.8 ± 2.05 
3c -5.87 ± 2.58 -16.4 ± 3.80 3.22 ± 1.48 -9.53 ± 0.26 
3e -1.29 ± 2.18 -10.4 ± 0.00 2.17 ± 0.42 0.39 ± 0.31 
3g 3.55 ± 1.12 -8.47 ± 0.88 2.65 ± 1.45 15. 8 ± 5.76 
3j -0.18 ± 2.14 -5.62 ± 1.15 2.83 ± 0.52 0.41 ± 2.00 
3k -6.38 ± 2.80 -20.7 ± 3.23 3.18 ± 0.76 -12.5 ± 1.71 
 
 
3.8 Summary 
 Larger (18-membered vs. 14-membered) macrocyclic peptidomimetics 3 were 
made employing solid phase synthesis.  Compared to previous peptidomimetics that are 
smaller in ring size (14-membered), the SN2 cyclizations used to afford these larger cyclic 
compounds are less prone to head-to-tail dimer formation.  The synthetic procedure 
applied to make the compounds is tolerated well by resins with the Rink handle and less 
by those with Wang-type resins.  This assertion was verified when good to excellent 
purities were attained in the synthesis of a small library corresponding to NGF and NT-3 
sequences was synthesized using Tenta Gel S Ram resin (Rink handle). 
 Conformational analyses of representative compounds show that these 18-
membered macrocycles adopt type 1 beta-turn conformation.  Both theoretical (QMD) 
and experimental (NMR and CD) experiments support this inherent bias. 
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 Cell survival assay of the compounds reveal that 3g, whose sequence mimics one 
turn of NT-3 have agonistic properties at suboptimal concentrations of NT-3. 
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CHAPTER IV 
SYNTHESIS OF MONOVALENT PEPTIDOMIMETICS FOR 
DIMERIZATION 
 
4.1 Introduction 
 Protein-protein interactions are wide-spread in biological systems.  These 
interactions produce diverse effects, for example in antibody-antigen recognition, signal 
transduction and metabolism among others, that are critical in regulating cellular 
functions.  A lot of these interactions are mediated by dimeric protein complexes.103  
These dimers can be regarded as homocomplexes or heterocomplexes depending on the 
nature of association of the individual protein components.  Most homocomplexes 
involve permanent association while heterocomplexes are rather short-lived and 
transitory in nature.104  Protein-protein interactions occur at the protein surface and these 
can be considered as biophysical events dictated by the conformation, chemical 
composition and flexibility of the proteins involved.105  Knowing how proteins interact is 
paramount in understanding how these proteinaceous assemblies mediate different 
biological responses.   
 A great deal of study has been devoted on how protein complexes are formed.  
The findings from these contributions reveal that the total area buried by the residues in 
the protein-protein recognition site is about 1600 Å.106  This is very much bigger 
compared to an enzyme binding pocket.  Also, the surface patch at the binding interface 
can be described as flat.107  It is difficult to identify lead compounds to study protein-
protein interactions if there are no naturally occurring small molecules that bind these 
proteins.  Despite of this problem, there are small molecules that can modulate protein-
protein interactions.  Schreiber, Crabtree et al. have shown that naturally occurring 
immunosuppressants (FK506, cyclosporine and rapamycin) can induce protein 
dimerization.108,109  Although these compounds are not dimeric, they act as dimerizers 
through bivalency and were shown to affect certain pathways leading to T-lymphocyte 
activation. 
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 The need for synthetic molecules to study bivalent (or multivalent) interactions 
has generated extensive efforts to produce dimeric compounds in scale and in high 
purities.110  Bivalent compounds offer advantages that monovalent ones cannot provide. 
For example, they promote proximity to interacting species like in many cell surface 
receptors.111  They also enhance protein-protein or protein-DNA interactions by 
providing an enlarged surface area which results in increased specificity 103,112.  Bivalent 
compounds can be used to probe ligand-receptor binding at the cell surface as in the case 
of neurotrophins and their Trk receptors.  They can be a potential antagonist if it prevents 
dimerization by binding to one unit of the receptor dimer.  On the other hand, it can be an 
agonist or a functional mimic if it induces receptor dimerization by binding at two 
monomeric receptor sites (Figure 4.1) 
 To avoid confusion, it is important early on to set a working definition for 
‘dimeric’ and ‘bivalent’ that will be used in the discussion.  While dimeric, refers to the 
chemical structure of a compound, bivalent relates more to function.  For simplicity, 
dimeric compounds in the discussion will be regarded as ‘bivalent’ and whenever 
bivalent is used, it is regarded as a dimeric compound except for the one in Section 4.3.2. 
 
 
 
Figure 4.1.  (a) A monomeric small molecule may bind to one site and act as an 
antagonist.  (b) A bivalent analog binding at two sites on the same receptor unit can be an 
even stronger antagonist.  (c) A bivalent analog can bridge two monomeric receptor units 
and act as an agonist. 
 
 
 While it is trivial to make just one or few dimeric compounds, the full potential of 
exploiting the combinatorial advantage of making dimers out of monomeric precursors 
will not be realized if we lack methods in making these dimers selectively.  In other 
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words, what we want is a situation in which monomers are simply mixed in reaction 
vessels that will give one dimeric species exclusively (i.e. if one monomer is reacted with 
another, only one dimeric product results).  This is easy for homobivalent compounds; 
however, the situation is not the same if heterobivalent compounds are desired.  The 
illustration in Figure 4.2 depicts this concept. 
 
NOT
+
homobivalent
+
heterobivalent
or
homobivalent
(a)
(b)
 
Figure 4.2.  Illustration of heterobivalent selectivity. 
 
 
 Reactions of the kind implied above can be used to harness their potential to form 
bivalent compounds efficiently combinatorial chemistry.  This possibility is illustrated in 
Figure 4.3.  For n monomers, n (n + 1)/2 dimers will be produced; if such a highly 
efficient method exists, five different monomers, for example, can give 32 dimeric ones.  
This does not seem much, however, in the case of 100 monomers, 5050 dimers will be 
produced.  Thus, the combinatorial advantage becomes very significant with larger 
numbers of monomers. 
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Figure 4.3.  The number of bivalent compounds increases exponentially with unit 
increase in monovalent starting materials. 
 
 
4.2 Illustrative Non-selective Approaches to Dimeric Compounds 
 There is a plethora of chemical reactions that can be used to make dimeric 
compounds.  However, some of these reactions do not give exclusively one dimeric 
product as there are limitations (e.g. stereochemical issues) inherent to the reactions 
involved.  This section gives examples of the most common techniques employed to 
make bivalent compound in a non-selective fashion (i.e. other products are formed as 
well). 
4.2.1 Disulfide Bond Formation 
 One of the most common modes of dimerization is disulfide bond formation.  The 
mild oxidative conditions used to form the S-S bond are tolerated by a lot of functional 
groups including those in amino acid side-chains.  On the other hand, S-S bonds can be 
broken and reformed to make new disulfide-linked dimers.  Nicolaou et al. have applied 
this ‘combinatorial disulfide exchange’ method to make dimeric analogs of the antibiotic 
psammaplin A.113  The exchange however is not driven to completion as statistical 
mixtures of the heterodimer and the homodimeric starting materials are produced (Figure 
4.4). 
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Figure 4.4.  (a) Structure of psammaplin A.  (b) Combinatorial disulfide exchange to 
produce homo-and heterodimeric psammaplin A analogs. 
 
 
4.2.2 Olefin Cross-Metathesis 
 Boger and co-workers have employed this type of reaction to make libraries of 
EPO mimics (Figure 4.5).114  A cyclic anhydride was used to attach the olefin fragment 
that will be used to link with another alkene via metathesis.  This method can make 
homo- as well as heterobivalent compounds depending on the alkene monomers used, 
however, this method is not stereoselective as cis and trans isomers are produced. 
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Figure 4.5.  Boger’s synthesis of dimeric EPO mimics via olefin methathesis. 
 
 
4.2.4 Dimerization Using a Linker Molecule 
 The disulfide bond formation and cross-metathesis examples are dimerization 
methods in which there are no other starting materials needed to form the dimers other 
than the monomers themselves.  Another way of forming dimeric species is to link two 
monomers via a ‘bridging’ molecule.  One example of this approach is the work of 
Ellman on diaminoalkanediol-linked aldehyde monomers (Figure 4.6).115  This approach 
takes advantage of the fact that oxime bond formation is fast and efficient.  Also, rapid 
access to the dimers is made possible by using commercially available aldehyde and 
linker starting materials.  In spite of these advantages, this process has one major draw 
back in that statistical mixtures of homo- and heterodimers are produced. 
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Figure 4.6.  Ellman’s diaminoalkanediol-linked dimers. 
 
 
4.3 Selective Formation of Bivalent Compounds 
4.3.1 Olefin Cross-Metathesis 
 Unlike, non-selective approaches, there are relatively few methods that have been 
discovered or applied to give bivalent compounds exclusively.  Although it is hard to 
control the alkene geometry in a metathesis reaction in solution, Verdine et al. reported a 
solid-phase variant in which the trans isomer predominates very significantly (~ 96 % 
pure) (Figure 4.7).  The starred positions were varied to produce 16 compounds that 
mimic endomorphine-2, an endogenous ligand for µ−opioid receptor. 
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Figure 4.7.  Solid-phase cross-metathesis that gives almost exclusively trans isomer. 
 
 
4.3.2 Enzyme-catalyzed [3 + 2] Cycloadditions 
 One of the most used reactions recently is the [3 + 2] alkyne-azide cyclization 
(click chemistry).116  While this reaction is often influenced by Cu catalysis,  Sharpless, 
Finn, Kolb and their co-workers demonstrated that an enzyme can be used to bring the 
starting materials in close proximity, causing them to react without metal catalysis.117  
This approach not only produces bivalent compounds selectively, but also screens for 
compounds that can bind to the enzyme because only those that bind the enzyme are 
brought near to each other.  Thus, the method serves as an in situ binding assay in effect.  
This is depicted in Figure 4.8.  Five different alkyne and azide starting materials are 
incubated with the enzyme Acetylcholinesterase (AChE).  But after incubation, only 2 of 
the possible 25 compounds are identified.118  This work was extended by using different 
azide and alkyne pharmacophores that are previously not known to bind AchE.119  
Moreover, the applicability of this reaction with other another enzyme was 
demonstrated.120 
 It should be noted that while the compounds produced by this method are not 
dimeric, they are, however, bivalent in nature as two units interact with the enzyme. 
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Figure 4.8.  Production of bivalent ligands via click chemistry. 
 
 
4.4 Sequential Nucleophilic Substitution 
 The techniques in Section 4.3 demonstrated that, although scarce, there are 
methods that can be applied to make bivalent compounds selectively.  However, not all of 
those methods are convenient when applied to a library format.  In medicinal chemistry, 
it is important to incorporate pharmacologically relevant functional groups in synthesis.  
Most of these pharmacophores can be found in amino acid side chains (e.g. guanidine, 
amine, thiol, alcohol, indole and imidazole).  An ideal method of introducing diversity 
could be by simple substitution of leaving groups by nucleophiles which contain the 
desired pharmacophores.  Although the idea seems obvious and simplistic, the chemistry 
was introduced only a few years ago.  Zaragoza has coined the term sequential 
nucleophilic substitutions as a means of introducing diversity.  This could be achieved by 
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using a polyelectrophile containing the leaving groups that will be replaced by 
nucleophilic compounds with the requisite pharmacophores 121.  The concept can be 
expanded by using different polyelectrophiles and most work on this area has focused on 
this aspect.  Furthermore, the technique is greatly facilitated by employing resin-bound 
reagents.  This will minimize laborious purification steps otherwise encountered in 
conventional solution-phase synthesis.  Suitable compounds that have been used as 
polyelectrophiles are shown in Figure 4.9.121-123 
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trichloropurine trichloropyrimidinedichloro-
nitropyrimidine  
Figure 4.9.  Polyelectrophiles used in sequential nucleophilic substitution reactions. 
 
 
 The feature common to all structures in Figure 4.9 is that they all have halogens 
as leaving groups.  Thus, in sequential substitution reactions the mechanism is either SN2 
or SNAr.  Of all those structures, only the polychlorinated triazines, purines and 
pyrimidines were used to make cyclic peptidomimetics.  Scharn et al. demonstrated that 
these polychloro heterocycles can be used as a template for cyclization.  Cyclic peptides 
incorporating two to 10 amino acids were synthesized via the SPOT-synthesis124 
methodology and were cyclized using the amino group of the lysine side-chain Figure 
4.10.  One limitation of this technique is that if there are potential nucleophiles from 
amino acid side-chains (e.g. thiol, alcohol, amine or guanidine) then the cyclization 
reaction may give undesired products. 
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Figure 4.10.  Examples of cyclic peptides using polychloro triazine and purine as 
templates for macrocyclizations. 
 
 
 Our method to assemble dimeric compounds evolved from an interesting 
observation by a co-worker (Dr. Mookda Pattarawarapan) on a solid-supported triazine 
derivative.125  She observed that with a monochlorinated triazine substrate, only the 
amino group from isonipecotic acid (Inp) was able to displace chlorine under the reaction 
condition used (Scheme 4.1). 
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Scheme 4.1.  Selective displacement on monochlorinated triazine 
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 The unusual selectivity of the piperidine amino group can be applied to make 
bivalent compounds in a step-wise fashion.  The addition can be controlled, so one 
monomeric species bearing the reactive amine can be added on a fluoresceinated 
dichlorotriazine to give a labeled monomeric species.  This in turn can be reacted with the 
same monomer or a different one to give fluoresceinated homo- or heterobivalent 
compounds (Scheme 4.2). 
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Scheme 4.2.  Selective synthesis of homo- and heterodimers using 
dichlortriazinylaminofluorescein (DTAF) linker 
 
O
NH
N
NH
N
N
Cl
Cl
TFA
protected 
mimic
(i)
            (ii) TFA
F*
 
O
NH
O
N N
NN
Cl
NHF*
F*
O
N N
NN
NH
O
N
unprotected 
mimic
unprotected 
mimic
K2CO3, DMSO
24 h, 25 °C
unprotected 
mimic
unprotected 
mimic
+
homo- or heterodimers  
 
 
4.5 Synthesis of Starting Monomers 
4.5.1 Template Modification and Incorporation in Peptide Synthesis 
 For the monomers to be suited in the dimerization strategy depicted in Scheme 
4.2, they have to have a site of attachment wherein we can link the required isonipecotic 
amino acid (Inp) fragment.  The monomers in this case were compounds 3a and 3g and 
compound B (in Chapter III).  These three were chosen based on their displayed activity 
in cell survival assays.  The modification has to be on the organic template and not on the 
mimetic part because it is desirable to have the amino acid side-chains unencumbered,.  
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The design that we sought to make is to have a nitro group attached onto the benzene ring 
(Figure 4.11).  This can later be reduced to the amine to serve as the coupling partner of 
Inp. 
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Figure 4.11.  Monomer modifications for dimer assembly. 
 
 
 The modification to make the nitro derivative of compound B is straight forward 
(Scheme 4.3).  A simple nitration procedure of the template will favor the 5-position (1 
being the carboxylic acid group) because of the cooperative directing effect of the 
carboxyl and the bromomethyl groups.  For compounds 3a and 3g, the nitration of the 
template will result in a mixture of products due to the difference in directing effects of 
the two groups.  To circumvent this, an indirect route to modify the template was 
employed.  Instead of doing nitration, a compound that already has the nitro group was 
considered.  Initially, a radical bromination was attempted for 3-methyl-4-nitrobenzoic 
acid.  However, the bromination is too slow and ineffective as TLC of the reaction 
showed spots for the product and starting material that are near to each other (Scheme 
4.4a). 
 
Scheme 4.3.  Nitration of the organic template for compound B derivative 
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Scheme 4.4.  Modification of the template for derivative of compounds 3a and 3g 
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 A different strategy was developed because bromination is ineffective.  Starting 
with 5-nitroisophthalic acid monomethyl ester, the carboxylic acid part was reduced to 
the alcohol to give the 3-hydroxymethyl derivative.  The methyl ester was then 
hydrolyzed under basic condition to the corresponding acid.  Finally, conversion of the 
alcohol to the bromide was achieved using 6M HBr with toluene as a solvent.  This two-
phase reaction was surprisingly efficient as all of the alcohol was converted to the desired 
3-bromomethyl compound (Scheme 4.4b). 
 With the necessary templates in hand, synthesis of the required monomeric 
peptidomimetics is straight forward.  After conventional Fmoc peptide synthesis, the 
activated templates were attached to give linear precursors.  Scheme 4.5 shows the 
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synthesis of compounds 3a-NO2 and 3g-NO2 (nitro analogs of compounds 3a and 3g, 
respectively). 
 
Scheme 4.5.  Synthesis of compounds 3a-NO2 and 3g-NO2
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 The synthesis of compound B derivative follows the same pattern and is shown in 
Scheme 4.6.  Like our previous experience with 14-membered rings, this suffers from 
significant production of head-to-tail dimer. 
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Scheme 4.6.  Synthesis of compound B-NO2
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4.5.2 On-resin Reduction and Couplings with Glycine, Inp and DTAF 
 With the required nitro handle in place, the three cyclic peptidomimetics can now 
be reduced to their corresponding aniline derivatives.  The use of tin(II) chloride is one of 
the most convenient ways to reduce a nitro group on resin.  A common method is to 
shake the resin with the dissolved reagent in DMF for 24 hours.  However, a faster and 
equally effective way is to do the reaction twice, each for two hours but with a higher 
concentration of tin.126  This procedure was applied and the reduction proceeded 
smoothly to give the corresponding amino derivatives (Scheme 4.7) 
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Scheme 4.7.  On-resin reduction of cyclic nitro peptidomimetics 
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 Before installation of the essential piperidine moiety, FmocGly-Cl was coupled to 
the aniline.  Glycine served as a spacer between the cyclic peptidomimetic and the 
triazine heterocycle which bears the fluorescent label.  Other spacer molecules can be 
used to accommodate different loop distances in the NGF or other neurotrophin 
homodimer.  After glycine attachment, FmocInp-Cl was then reacted.  Final Fmoc 
deprotection gave the free secondary cyclic amine which can be cleaved from the resin, 
or can be reacted to DTAF to give monomeric, fluorescein-labeled peptidomimetics.  
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Both of these variations were done to give monomers PEPT-Inp and PEPT-InpF* 
(Figure 4.12). 
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Figure 4.12.  Structures of unlabeled (with only the Inp end) and labeled (with 
fluorescein attached) monomeric peptidomimetics. 
 
 
 The compounds PEPT-Inp and PEPT-InpF* were coupled to different 
peptidomimetics to make a 78-compound library.125  The coupling can only be one way, 
that is only one monomer with the Inp couples with another that has the fluorescent label, 
following the one in Scheme 4.2. 
 
4.6 Biological Assay 
 The compounds in the library were screened using fluorescence-activated cell 
sorting (FACS) assay.  This technique is an application of flow cytometry.  Test 
compounds were incubated in a binding buffer which contains receptor-expressing cells 
(e.g. NIH3T3 cells which express TrkA).  After incubation, the cells travel in the 
instrument and intercepts with a laser of choice.  The choice of fluorochrome depends on 
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what wavelength of excitation is being monitored.  If a cell passing through the laser is 
fluorescent, the laser will cause excitation of the fluorescent molecule and the 
fluorochrome will emit at a higher wavelength typically associated to that particular 
compound.  The emitted light passes through filters which allow only the wavelength of 
choice to pass.  This signal is then translated and the machine is instructed whether a 
particular cell has to be sorted or not by charging the stream just as the cells enter the 
break-off point.  The cells of interest leaves the break-off point charged either positive or 
negative and are sorted by being deflected by oppositely charged plates to collection 
vessels (Figure 4.13). 
 
 
Figure 4.13.  A diagram of the FACS assay. 
 
 
 One of the compounds in the 78-member library is compound 4.  This 
heterobivalent compound was made by coupling 3g-NHGlyInp and compound DTAF-
labeled 5 (Figure 4.14).  In the initial FACS assay compound 4 showed significant 
staining of TrkA- and TrkC-expressing cells and was subsequently resynthesized so that 
further binding assays can be done.  Compound 6 is a lead compound in our studies and 
this has already been shown to bind TrkA expressing cells with an affinity of 100 nM.  A 
second FACS assay on heterobivalent compound 4 indicated that it binds to both TrkA 
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and TrkC expressing cells, with an even greater affinity for TrkC.  More importantly, its 
binding affinity is higher than compound 6 (Figure 4.15).  In a competitive assay with 
mAb 5C3 and I25-NGF (Figure 4.16), compound 4 was measured to have an IC50 which is 
200 times higher than NGF competing itself (2000 nM vs. 10 nM, respectively).  Hence, 
the Kd for compound 4 was estimated at ~20 nM.  These results validate our approach to 
make bivalent mimics from lead monovalent compounds and further, the use of 
fluorescent label on our mimics greatly facilitates identification of active compounds. 
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Figure 4.14.  Structures of lead compounds 4 and 6. 
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Figure 4.15.  Representative data from FACS assay of compounds 4 and 6. Left.  
Binding to TrkA cells with mIgG-FITC as negative and mAb 5C3 as positive controls.  
Right.  Binding to TrkC cells with mIgG-FTIC as negative and mAb 2B7 as positive 
controls.  A shift of the curve to the right indicates specific labeling. 
 
 
 
Figure 4.16.  Binding affinity measurement of compounds 4 and 5 for TrkA.  A shift of 
the curve to the left (to NGF competition) indicates higher affinity. 
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4.7 Summary 
 Protein-protein interactions are important in biological processes.  Such 
interactions involve permanent formation of stable protein complexes, while others 
involve transient formations.  Some of these interactions involve dimeric protein 
complexes.  Dimerization of proteins plays a major role in regulating the function of 
many cell surface receptors.  Synthetic small-molecules have contributed to the goal of 
understanding cellular pathways that are influence by dimeric protein complexes. 
 Although there are chemical methods available to make a specific dimeric (and 
bivalent) compound, there are relatively few methods that can give, exclusively, one 
dimeric species.  Even fewer are methods that very convenient to be applied in a library 
format.  If such a method exists, then its combinatorial advantage can be greatly 
appreciated as more compounds can be made easily and at a faster rate. 
 One of the methods that have emerged recently that was applied to meet the 
demand for making dimers selectively is sequential nucleophilic substitution.  Our 
approach involves a fluoresceinated dicholoraminotriazine (DTAF) which undergoes 
substitution by nucleophilic groups bearing the peptidomimetics of choice.  This method 
offers two advantages.  One, the dimeric molecule has a fluorescent tag in it that greatly 
facilitates the assay.  Two, the linker separating the cyclic peptidomimetic and the 
triazine scaffold can be varied so as to produce different distances in that region.  These 
distances can correspond to different loops within the NGF or other neurotrophin 
homodimer. 
 The dimerization strategy produced lead compounds that show significant binding 
to cells that produces the Trk receptors.  One compound, 4 was shown to have a binding 
affinity of 20nM.  This result gives validation that our approach to targeting 
neurotrophin-receptor interaction can lead to compounds that have significant binding. 
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CHAPTER V 
ATTEMPTS AT BICYCLIC GUANIDINE MIMICS AND ON THE 
STRUCTURE OF ACETYL 2-THIOHYDANTOIN 
 
5.1 Introduction 
 The guanidine group is an important pharmacological moiety that is featured in 
many compounds that have diverse biological activities.  Some of the therapeutic 
applications of molecules that possess the guanidine or guanidinium functionality are: 
anti-inflammatory,127 antibacterial,128 Na+ and Ca2+ channel blockers,129 anti-seizure 
agents,130,131 and HIV-1 protease inhibitors.132,133  Guanidine-containing drugs that have 
been sold in the market include cimetidine (against ulcer) and pinacidil (for 
hypertension).134  While there are numerous examples of compounds with pendant 
guanidine, a small portion has it locked in a bicyclic form.  As such, there have been few 
syntheses of bicyclic guanidines.  Examples of these compounds are shown in Figure 
5.1.135-139  Of these, only compounds M were made via solid-phase (Scheme 5.1) and the 
rest were made in solution. 
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Figure 5.1  Structures of bicyclic guanidines. 
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Scheme 5.1.  Solid-phase approach to bicyclic guanidines M 
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 We are also interested in making bicyclic guanidines but in solution phase to 
facilitate the preparation of the compounds on scale.  Our initial approach to achieve this 
is depicted in Scheme 5.2.  It starts with a dipeptide with a suitable N-terminal protection 
and a free carboxylic end for thiohydantoin formation.  The thiocarbonyl part is then 
activated, followed by deprotection of the amine to effect the cyclization.  Although our 
mimic resembles structure N in Figure 5.1, we set out to make a focused library of 
bicyclic guanidines and not just one compound. 
 
Scheme 5.2.  Approach to bicyclic guanidine mimetics via dipeptide thiohydantoins 
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 The synthesis of peptide thiohydantoins is straight forward.  This C-terminal 
modification of peptide chains has been used as an alternative to Edman degradation to 
sequence peptides from the C-terminus (Figure 5.2).140  Most of the progress in this field 
has focused on developing new reagents that will facilitate thiohydantoin formation.  
Reagents include NH4SCN,140 trimethylsilyl isothiocyanate (TMSNCS),141,142 
ethoxycarbonyl isothiocyanate143 and acetyl isothiocyanate.144  The formed peptidyl 
thiohydantoins are then subjected to either acidic or basic condition, and sometimes at 
elevated temperatures, liberating the C-terminus amino acid thiohydantoin and the 
truncated peptide fragment which can be monitored by mass spectrometry.145 
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Figure 5.2.  Peptide sequencing from the C-terminus. 
 
 
5.2 Attempts at Bicyclic Guanidines 
5.2.1 The Dipeptide Thiohydantoin Approach 
 Carbobenzyloxycarbonyl (Cbz)-protected phenylalaninylglycine 7a was reacted 
with ammonium thiocyanate in a weakly acidic medium at 85 °C to afford the dipeptide 
thiohydantoin 8a (Scheme 5.3).  This transformation can also be done under microwave 
irradiation at a higher temperature but at a shorter time.  Attempts to cyclize this 
compound to 9a by activating the thiocarbonyl group with MeI and then by doing 
hydrogenolysis to deblock the amine prior to cyclization proved to be not productive.  
 72
Other dipeptide thiohydantoins (8b-c) with different N-protection and side chains were 
also prepared but like the first one, the cyclization condition did not work as planned  
 
Scheme 5.3.  Attempts to form bicyclic guanidines via dipeptide thiohydantoins 
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 Interestingly, increasing the reaction time by just 2 minutes under microwave 
irradiation for dipeptide thiohydantoin formation resulted in the cleavage of the C-
terminal 2-thiohydantoin as shown in Scheme 5.4.  This was verified by an independent 
synthesis of 1-acetyl-5-methyl-2-thiohydantoin from L-alanine (see Scheme 5.8).  
Thermal reaction for the formation of dipeptide thiohydantoin proved to be more easily 
controlled. 
 
Scheme 5.4.  Cleavage of C-terminal thiohydantoin amino acid by  
microwave irradiation 
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5.2.2 The 2-Thiohydantoin-Iminohydantoin Approach 
 It is evident at this juncture that dipeptide thiohydantoins are very labile to 
cleavage and so an alternative approach was considered (Scheme 5.5).  Instead of making 
dipeptide thiohydantoins and cyclizing, amino acid thiohydantoins (i.e. 2-thiohydantoins, 
11) can be made and then activated to add the next amino acid.  This will produce an 
iminohydantoin 12 which is envisioned to cyclize via amide bond formation to give the 
bicyclic guanidine core.  This route was the one used in the synthesis of compound N (in 
Figure 5.1); and because it has the same skeletal framework as our target, it is appealing 
to try this approach. 
 
Scheme 5.5.  Alternative route to bicyclic guanidine via 2-thiohydantoins 
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 The 2-thiohydantoin precursors 11 can be made from amino acids and 
isothiocyanate or thiocyanate sources.  Figure 5.3 shows the two routes leading to 2-
thiohydantoins.  With an amino acid methyl ester (Route A), an alkyl isothiocyanate can 
be the coupling partner to give a 2-thiohydantoin which is substituted at the N3 position.  
On the other hand, a free amino acid can be reacted with ammonium thiocyanate (or other 
thiocyanate equivalent) to give 2-thiohydantoin in which the amides are unsubstituted 
(Route B). 
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Figure 5.3.  Two routes to 2-thiohydantoins. 
 
 
 Following Route A in Figure 5.3, L-alanine methyl ester was reacted with 
benzylisothiocyanate to give the alkylated 2-thiohydantoin (Scheme 5.7).146  The 
thiocarbonyl group was then activated with MeI and the resulting isothiourea was 
coupled with glycine methyl ester to give the iminohydantoin derivative 13.  The proton 
NMR of this compound is hard to assign but the MS shows a clear [M + H]+ for the 
product.  The methyl ester was then hydrolyzed to the acid to set the stage for cyclization.  
The cyclization however is not productive as was verified by a messy TLC during the 
monitoring of the reaction. 
 
Scheme 5.6.  Synthesis of iminohydantoin from 2-thiohydantoin 
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 Applying Route B (Figure 5.3), amino acids 10a-c are reacted with ammonium 
thiocyanate in acetic anhydride at elevated temperature to give the 2-thiohydantoins 8a-c 
with an acyl group at N1 position (Scheme 5.8)147.  This was then deactylated under 
acidic condition to afford the amino acid 2-thiohydantoins 5a-c.  Activation of the 2-
thiohydantoins with MeI gave the isothiourea derivatives but this supposedly activated 
intermediate failed to couple with an amino acid methyl ester as supported by the NMR 
of the crude reaction. 
 
Scheme 5.7.  Synthesis of 2-thiohydantoins from amino acids 
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5.3 The Acylation of 2-Thiohydantoins: 1-Acetyl or 3-Acetyl? 
 At this point all the plans that were employed to make the bicyclic guanidine 
target has been futile and the focus has shifted to an interesting discrepancy in the 
literature that was discovered in making the 2-thiohydantoins.  The reaction where there 
are ‘inconsistencies’ found in the literature is the one in which glycine is reacted with 
NH4SCN in acetic anhydride to give an acylated 2-thiohydantoin (the synthesis of 14a, 
Scheme 5.7).  Before going on further, it is important to give a brief background on the 
nomenclature system that is followed regarding 2-thiohydantoin whose structure can be 
regarded as a thio- derivative of 2-hydantoin.  The name 2-hydantoin is a trivial name, 
however, 2-thiohydantoin, having the prefix thio is considered semi-trivial because one 
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part follows a prefix system.148  Nevertheless, the IUPAC has recognized the advantages 
of using a combined trivial and semi-trivial system and has adopted their usage.  Since 
both compounds are related, they follow the same ring atom numbering (Figure 5.4).148  
Note that positions 1 and 3 are not the same.  With regard to numbering of the ring, there 
were two systems that were adopted at different time periods.149  One is the numbering 
before 1907 and the other, after 1907.  The numbering system that will be used in the 
following discussion refers to the post 1907 system, which is also the one that was 
adopted by Chemical Abstracts. 
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Figure 5.4.  Chemical Abstracts numbering system on 2-hydantoin and 2-thiohydantoin. 
 
 
 Going back to the reaction of glycine and NH4SCN in acetic anhydride, we 
depicted the structure of the product to be acylated at the N1 position; hence, the product 
can be termed as 1-acetyl-2-thiohydantoin (Scheme 5.8a).  The structures were redrawn 
instead of writing labels to give a clear depiction about the discrepancies found in the 
literature.  That the acylation occurred at this position (N1) was verified via NMR 
methods and will be discussed in a later section.  The procedure that was followed in the 
synthesis is the one used by Johnson in 1911.147  His reaction is shown in Scheme 5.8b.  
While Johnson depicted the structure of his product the same as ours, he named it 3-
acetyl-2-thiohydantoin.  Clearly, Johnson followed the nomenclature before1907.  Other 
works on acylated 2-thiohydantoins that followed Johnson’s protocol are shown in 
Schemes 5.8c-e.  The reaction in Scheme 5.8c,150 while showing no structure followed 
the name given by Johnson and has the same melting point, 175°C.  This is close to our 
recorded value of 173-174 °C.  It may be inferred that all these compounds are the same.  
The one in Scheme 5.8d, which was done by Marton151 follows the correct structure and 
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current naming of the product, and is the same as ours.  However, the one in Scheme 
5.8e, done separately by Villemin152 and Davis153 shows the product of the same reaction 
to be 3-acetyl-2-thiohydantoin.  Note that the name may be similar to Johnson’s and is 
correctly depicted (by IUPAC standard), but as was hinted above, the acylation occurred 
at the N1 position and not at N3, hence, Villemin and Davis have written the structure of 
the product wrong. 
 
 
Scheme 5.8.  Reported syntheses of acetyl-2-thiohydantoin from glycine 
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 To prove that the acylation occurred at the N1 position, 2-D COSY NMR was 
done on the 2-thiohydantoin 8a.  A cross peak between the C5H and N1H would not be 
observed if the latter is acylated; on the other hand, a cross peak will exist if N3 is 
acylated and not N1.  The COSY of the product in DMSO-d6 is shown in Figure 5.5a.  
Clearly, no cross peak can be seen that will suggest acylation at N1.  However if the 
acetylated product is subjected to acid hydrolysis to produce 2-thiohydantoin, then a 
cross peak between C5H and N1H is observed (Figure 5.5b). 
 
a      b 
N1H
C5
 
Figure 5.5.  COSY spectrum of (a) acetyl-2-thiohydantoin and; (b) deacetylated 
product, 2-thiohydantoin. 
 
 
 The COSY of the isolated product shows evidence of acylation at the N1 position.  
Another indication that could support this is to consider chemical shifts of the two free 
NH’s (i.e. the N1H and the N3H of 2-thiohydantoin).  The one observed for the acylated 
product is more downfield to where normally common cyclic thioamides resonates (ca 
9.15 ppm)154and indicates that the proton is probably highly deshielded.  Furthermore, 
when the product was deacylated, the new NH signal gave a chemical shift consistent 
with typical cyclic amides.  We have tried to make 3-acetyl-2-thiohydantoin so that we 
could have a direct comparison with the 1-acetyl-isomer but all the syntheses we have 
applied failed to give the desired compound (Scheme 5.9). 
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Scheme 5.9.  Attempts to make 3-acetyl-2-thiohydantoin 
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 The best we could do is to use 3-benzyl-5-methyl-2-thiohydantoin (see Scheme 
5.6) which has the N1, free.  This would show that (1) there is an observed cross peak 
between N1H and C5H if the former is unsubstituted and (2) the chemical shift for a free 
N1H is indeed slightly upfield than that for a free N3H (Figure 5.6). 
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Figure 5.6.  Two-dimensional COSY spectrum of 3-benzyl-5-methyl-2-thiohydantoin. 
 
 The original workers have proposed a mechanism 155 based on known 
observations on the behavior of glycine under the conditions employed.  While they used 
hippuric acid to outline the transformation, an analogous mechanism can be applied to 
glycine (Figure 5.7).  This mechanism is based on the following observations155:(1) 
glycine forms N-acetylglycine in Ac2O; (2) acylated amino acids are known to form 
lactone anhydrides under the same conditions, and; (3) lactone anhydrides react with 
thiocyanic acid (HSCN), which was liberated from the reaction of Ac2O and NH4SCN, to 
form an acylisothiocyanate derivative which cyclizes to 1-acetyl-2-thiohydantoin.  This 
last reaction is similar to reactions of lactone anhydrides with HCl to form acid chlorides. 
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Figure 5.7.  Johnson’s proposed mechanism for the formation of  
1-acetyl-2-thiohydantoin. 
 
 
 Villemin, on the other hand, proposed the mechanism152 shown in Figure 5.8 for 
the formation of ‘3-acetyl-2-thiohydantoin’: 
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Figure 5.8.  Villemin’s  proposed mechanism for the formation of  
1-acetyl-2-thiohydantoin. 
 
 
Note that the name of the compound is in quotation because Villemin’s (including Davis’ 
and Thielmann’s) product should also be 1-acetyl-2-thiohydantoin.  One thing that is 
contradictory to what Johnson has claimed is that the glycine nitrogen (N1) was not 
acylated even under refluxing conditions.  Table 5.1 summarizes the proton NMR 
chemical shifts of the ‘product(s)’ obtained from Villemin’s , Davis’, Marton’s and our 
data.  Marton’s and our NMR are conspicuously the same.  On the other hand, Davis’ and 
ours, while having different structures show almost identical chemical shifts.  This 
implied that Davis’ product is the same as ours and that they just followed Villemin’s 
drawing (Davis cited Villemin’s work) without checking which site was acylated.  
Villemin’s NMR, however, has one chemical shift that is possibly way off (the one with 
the 3.90 ppm).  It was also not mentioned why a mixture of solvent was used in their 
sample.  We have tried to do the same for our sample using a mixture of DMSO-d6 and 
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CDCl3 (ca 1:1)) but the NH peak observed was at 12.33 ppm.  Although there is a 
disagreement in the drawing of the structures, the position of the acyl group is of no 
consequence since it was removed in later steps.  However, one-step conversion of amino 
acids to heterocycles is important in medicinal chemistry and researchers have to be 
cautious in interpreting the literature in this area. 
 
Table 5.1.  Comparison of reported proton chemical shifts of acylated 2-thiohydantoin 
from glycine. 
 
Chemical Shift/ppm 
Structure Solvent N1H N3H C5H CH3
     
CDCl3/DMSO-d6 3.90  4.35 2.65 
(Villemin)     
DMSO-d6 12.56  4.39 2.67 
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5.4 Summary 
 One of the easiest ways to make dipeptide thiohydantoins is using ammonium 
thiocyanate.  While this is relatively trivial, cyclization to the target bicyclic guanidine 
proved to be not favorable under the conditions employed.  One reason is that the formed 
amino acid 2-thiohydantoin at the C-terminus is prone to cleavage.  In fact, by just 
microwaving the reaction, the thiohydantoin will be cleaved.  This undesirable reactivity 
inhibits the activation of the thiocarbonyl for cyclization to bicyclic guanidines. 
 Acylated 2-thiohydantoins are formed from the reaction of amino acids and 
NH4SCN in acetic anhydride.  Two-dimensional COSY NMR experiments of the 
compound isolated from this reaction and the deacylated analog proved that the acyl 
group is in the N1 position.  Further evidence on observable vicinal coupling between 
C5H and N1H if the latter is unsubstituted is demonstrated by synthesizing 3-benzyl-5-
methyl-2-thiohydantoin. 
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CHAPTER VI 
SOLUTION PHASE SYNTHESIS OF NON-PEPTIDE MIMETICS 
USING DIHALOGENATED NITROBENZENE AS A SCAFFOLD 
AND ATTEMPTS TO MAKE SPIROTETRACYCLIC MIMICS VIA 
SPIROCYCLIC DIKETOPIPERAZINE 
 
6.1 Introduction 
 Over the course of the last two decades, combinatorial chemistry has emerged as a 
separate field of organic synthesis.  The genesis of doing organic reactions 
combinatorially can be traced to peptide synthesis.58  Innovative methods of making 
peptide libraries such as those by Geysen (multi-pin),156 Houghten (teabag),157 Furka 
(split and pool)158 and Lam (one-bead, one compound)159 had revolutionized this area of 
organic synthesis that gave way to what is now known as combinatorial synthesis.  Those 
early works can be regarded as an extension of solid-phase peptide synthesis, and thus, 
were done on-resin.  As more reactions were applied and developed for solid-phase 
synthesis, it has become possible to make small molecules other than peptides in a 
combinatorial format.  However, both solid- and solution-phase syntheses, in principle, 
can be applied in combinatorial chemistry.  There are several advantages of doing 
synthesis on-resin: ease of purification, use of excess reagents and automation are some 
the attractive features of solid-phase synthesis.  However, there are also drawbacks like 
cost of resin and its stability in doing a particular reaction.  Indeed, most reactions are not 
as clean as peptide bond formation when applied to solid phase and this will require time 
for optimization.  Because of these limitations, solution-phase approaches can not be 
discounted as an alternative to do combinatorial synthesis.  One obvious advantage of 
doing solution-phase synthesis is that it does not have the restrictions resins impose 
during the synthesis.  Those restrictions include, resin compatibility, reaction monitoring 
and purification at each reaction sequence.  Also, solution-phase synthesis is easy to scale 
up to get more (i.e. mass) of the targeted products. 
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 One main disadvantage in doing solution-phase combinatorial synthesis is 
purification after each reaction step.  This is especially true, and very tedious, if the 
reaction is not very efficient to all substrates.  Boger and co-workers have realized this 
problem and to circumvent this, they have employed simple liquid-liquid or liquid-solid 
extractions to purify intermediates at each stage of the reaction sequence.160,161  Their 
strategy is based on using reactive anhydrides as templates wherein different building 
blocks are attached (Figure 6.1).  This technique is easily adopted to make thousands of 
compounds.  However, the reactions that can be conducted that give clean intermediates 
are limited to amide bond formation.  Subsequent reactions that are not as efficient 
involved alkene cross-metathesis and Pd-catalyzed aryl halide coupling to form dimeric 
species. 
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Figure 6.1.  Boger’s solution-phase syntheses using cyclic anhydride templates. 
 
 
 Another notable illustration of the potential of solution-phase combinatorial 
synthesis is by Pirrung et al.162,163  Their work involved mixing a fixed substrate with 
variable number of reagents to produce a ‘sublibrary’ of a mixture of compounds (Figure 
6.2).  In their work, nine alcohols/phenols and six isocyanates are used to demonstrated 
the concept.  For the alcohols/phenols, one of each are mixed with the six isocyanates 
(total number of moles of alcohols/phenols and isocyanates are the same) to give nine 
sublibraries.  The same is done for the isocyanates to give another six sublibraries.  The 
15 sublibraries are then assayed for inhibition of acetylcholinesterase (Ache).  The one 
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giving the highest activity was identified and all the members of that sublibrary were 
resynthesized and resubjected for assay to confirm the activity observed when it was a 
member of the mixture. 
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Figure 6.2.  Pirrung’s ‘indexed’ combinatorial libraries via solution-phase synthesis. 
 
 
 Recent developments in solution-phase combinatorial synthesis include the 
application of several purification strategies such as fluorous synthesis,164precipitation 
techniques,165 resin-capture approaches,166,167 and polymer-supported scavengers of 
excess reactants.168,169  Related to using resins in solution-phase synthesis is the 
application of resin-bound reagents as reactants in conduction reactions.170,171  All these 
factors have significantly improved productivity in doing solution-phase combinatorial 
synthesis and placed it in equal standing with solid-phase as a viable and robust method 
in doing combinatorial synthesis for drug discovery.172 
 The field of peptidomimetic chemistry have benefited from the development of 
combinatorial synthesis.  While peptide-like compounds can be easily synthesized this 
way, these molecules suffer from limited proteolytic stability and bioavailability.  More 
recently, efforts are being done to address these limitations by making compounds that 
are less peptidic in Nature.173-176  In general, there are two ways to do this; one is to 
install an amide bond replacement and another is to use scaffolds that will serve as points 
 86
of attachment so the molecule will retain critically important side-chains. Substitution of 
a peptide bond by another group reduces its amide character, hence, alters the physical 
and chemical properties of the compound.  Several modifications can be done to replace 
an amide bond and a review had been published regarding these methods.177  Some well-
known amine bond isosteres are shown in Figure 6.3. 
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Figure 6.3.  Common amide bond isosteres. 
 
 
 On the other hand, a scaffold utilizes cyclic compounds in which important side 
chains are attached and displayed to approximate the desired three-dimensional layout.  
Some of the common scaffolds include natural products (like steroids and sugars) and 
heterocycles (like diketopiperazines and benzodiazepines) (Figure 6.4). 178-180 
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Figure 6.4.  Examples of scaffolds to make non-peptide mimetics. (a) RGD mimics 
based on steroidal structure. (b) Mimics based on benzodiazepines. 
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6.2 Solution-Phase Synthesis of Non-Peptide Mimetics 
 Our efforts to develop compounds with less peptidic character started by using a 
simple substituted nitrobenzene that will serve as a scaffold to attach groups that contain 
side-chains found in the amino acids in the loop regions of the neurotrophins.  The 
strategy is illustrated in Figure 6.5: 
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Figure 6.5.  Strategy to make non-peptide mimics based on a 
1,2-dihalogenated nitrobenzene scaffold. 
 
 
Again, sequential substitutions181 were utilized to append reactive groups that contain the 
side-chains of interest.  Either the SNAr or the Sonogashira cross-coupling182 can be done 
first, provided that no complications occur for the second reaction.  The resulting 
compounds have more conformational freedom than the cyclic peptidomimetics made 
previously in our group.  Nevertheless, these new mimics are non-peptidic and could 
potentially be more stable to proteases. 
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Figure 6.6.  Structures of non-cyclic mimetics with important side-chains. 
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 Part of a small library of non-peptide mimetics include compounds 16, 17 and 18 
(Figure 6.6).  The side-chains that are installed in the compounds include that of 
norleucine, arginine and lysine (with S and O acting as methylene equivalent), and 
isoleucine.  All the precursors for these side-chains are commercially available except for 
the one bearing the guandino group.  Scheme 6.1 shows the synthesis of this side-chain.  
Double Boc protection of thiourea produced the bis-protected derivative 19 which was 
reacted to cysteamine to afford thiol 20 which contains the required bis Boc-protected 
guanidine moiety. 
Scheme 6.1.  Synthesis of guanidine side-chain mimic 
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 At the outset, the scaffold that we were using was 4-fluoro-3-iodonitrobenzene;183 
however, the synthesis of this compound required expensive trifluorosulfonic acid for 
iodination.  This, plus the inherent light sensitivity of the resulting iodo compound make 
it unattractive for a large scale synthesis.  Substituting bromine in place of iodine solved 
the stability and reagent cost constraints.  3-Bromo-4-fluoronitrobenzene (21) was 
synthesized by brominating the parent fluoro-nitro compound with NaBrO3 and H2SO4 at 
65 ºC for 3 h.184  Although the yield of the bromination reaction is less than that for the 
iodination,  it is more feasible to scale up the former due to cheaper starting materials and 
stability of the brominated product. 
 Inspection of open mimics 16 and 17 reveal that they can be made from a 
common intermediate 22.  Cross-coupling of 21 and n-hexyne using Pd0 catalysis 
afforded compound 22 (Scheme 6.2a) in high yield.  Nucleophilic aromatic substitution 
(SNAr  reactions of intermediate 22 with nucleophiles 20 and N-Boc protected 3-
hydroxypropylamine yielded compounds 16 and 17, respectively (Scheme 6.2b). 
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Scheme 6.2.  Synthesis of compounds 16 and 17 
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 Synthesis of compound 18 is not as straight forward.  The alkyne-containing 
cysteamine derivative shown below poisons the Pd catalyst hence, cross-coupling with 
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the brominated scaffold did not work.  As it turned out, installation of the necessary 
guanidine moiety required an indirect route.  First, SNAr reaction on scaffold 21 with (±)-
2-butanol was employed to append the isoleucine side-chain.  Then, the resulting 
intermediate was coupled with propargyl alcohol under Sonogashira conditions.  This 
incorporated the alkyne without any complications.  The alcohol was then converted to 
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the mesylate which was displaced by the cysteamine derivative 20 to afford compound 18 
(Scheme 6.3). 
 
Scheme 6.3.  Synthesis of compound 18 
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 The monovalent non-peptidic compounds in Figure 6.6 were combined with other 
compounds with different side-chain mimics installed in them to produce a small library 
of non-peptidic monovalent mimetics.  These mimics were later dimerized by a co-
worker, via the Inp-DTAF method similar to that discussed in Chapter IV (Figure 6.7).  
Homo- or heterobivalent non-peptidic mimics 24 can be assembled depending upon 
intermediate 23. 
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Figure 6.7.  Strategy to make bivalent non-peptidic mimics using DTAF-Inp method. 
 
 
6.3 Attempts to Make Peptidomimetics Based on Spirocyclic Diketopiperazine 
 Our efforts were shifted to prepare less peptidic mimics that can potentially 
contain three side chains, but unlike with the more flexible open mimics, these are cyclic 
ones that will have more rigidity in their structures.  Consequently, we have designed and 
attempted to make the spirotetracyclic compound 25 shown in Figure 6.8.  Retrosynthetic 
analysis of this compound traces it to the spirocyclic 26 which can be made from the 
spirocyclic diketopiperazine (DKP) 27 via activation of the carbonyl groups and two 
nucleophilic additions.  The DKP in turn can be made from the corresponding dipeptide 
28 whose one amino acid component is the α,α-disubstituted amino acid 29. 
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Figure 6.8.  Retrosynthetic analysis toward the synthesis of peptidomimetics 25. 
 
 
 Syntheses of spirocyclic diketopiperazines (DKPs) like 27, although not as many 
as those for non-spirocyclic analogs have been reported and some compounds that have 
this fragment were found to exhibit interesting conformational and biological 
properties.185,186  Published syntheses of spirocyclic DKPs involved coupling of two 
amino acids, one of which is the necessary α,α-disubstituted amino acid to make the 
linear precursors.  A synthesis of a close analog of spirocyclic DKP 27 had been reported 
almost 15 yrs ago.187  Compound O was made from the dipeptide formed by 1-amino-1-
carboxymethylcyclohexane and another amino acid (Figure 6.9a). 
 A solid-phase approach was reported by Schafmeister et al. to make oligomeric 
DKPs based on amino acids P and Q.  NMR experiments reveal that these oligomeric 
DKPs are capable of adopting rod-like and folded structures.(Figure 6.9b-c).188,189 
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Figure 6.9.  Structures of DKPs related to spirocyclic DKP 27. 
 
  Recently, an elegant approach was reported by Herranz et al. to make spirocyclic 
2,6-diketopiperazines (Figure 6.10).190  A three-component Strecker reaction between 
cyclopentanone, a carboxyl-protected amino acid and TMSCN was conducted to give α-
amino nitrile derivatives S.  Formation of this intermediate depends on stabilizing the 
imine intermediate R.  Optimum condition for imine formation required addition of 
ZnCl2 and increasing the temperature to 65 °C.  The nitrile group was converted to the 
amide under strong acidic conditions.  This produced the amides T and the desired 
spirocyclic DKP U in varying yields depending on the amino acid present.  This 
incomplete reaction can be remedied by treating the amide with NaH to make it cyclize to 
the DKP. 
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Figure 6.10.  Synthesis of 2,6-DKP using a three-component Strecker reaction. 
 
 
6.3.1 Attempt to Make Spirocyclic Diketopiperazines (DKPs) via Ugi 
 Reaction 
 To make the synthesis of tetracyclic spiro compound 25 more amenable in 
parallel format, fast access to the critical spiro diketopiperazine intermediate 27 is 
required.  As shown the Figure 6.8, this can be made from dipeptide precursor 28.191  
Obtaining this DKP precursor via normal amino acid coupling will make the synthesis 
longer because the required amino acid 29 has to be independently made first.  It is 
appealing, therefore, to try alternative routes to make the dipeptide.  One of these is via a 
multi-component reaction of a ketone, an amine, an isonitrile, and a carboxylic acid, also 
known as the Ugi 4-component coupling, (4-CC).192,193  This reaction generates a carbon 
skeleton of a dipeptide which, depending on the isonitrile used can be converted to 
several functionalities.194,195  Hulme et al. have used this approach to make DKP libraries 
using Armstrong’s ‘universal’ isonitrile (Figure 6.11).196  They have found that by 
subjecting the dipeptide-derived Ugi product under TFA conditions and with mild 
heating, the very reactive N-acyliminium ion intermediated suffered an internal 
nucleophilic attack by the liberated amine to form the DKP 30 with potentially 4 sites of 
diversity. 
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Figure 6.11.  Route to 2,5-DKPs via Ugi reaction using Armstrong’s ‘universal’ 
isonitrile. 
 
 
 Depending on the isonitrile used, the reaction can be stopped at the dipeptide 
stage.  Other notable convertible isonitriles that were applied in this manner include 32 
and 33 (Scheme 6.4).  These were made from 4,4-dimethyloxazoline 31.197,198  Under 
basic conditions, the N=CH proton is abstracted generating the isonitrile and an alkoxide 
which can be quenched by a chloroformate, generating a carbonate ester at the other end 
of the molecule. 
 
 
Scheme 6.4.  Synthesis of convertible isonitriles 32 and 33 
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 While applying Armstrong’s convertible isonitrile for the 4-CC reaction to 
produce a dipeptide is very attractive, its synthesis is quite laborious and its stability is 
very limited even if stored under argon at -30 °C.197  Attempts to make analog of 
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dipeptide 28 were therefore done using isonitrile 32 (Scheme 6.5).  This isonitrile was 
condensed with the Schiff base generated by the reaction of benzylamine and Cbz-
protected 4-piperidone 34, then, Boc-Val-OH was added to give Ugi product 35. 
 
Scheme 6.5.  Attempted synthesis of dipeptide analog of 28 via Ugi reaction 
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Its conversion to the corresponding oxazolidinone 36 using potassium tert-butoxide was 
not successful.  The isolated product of the basic reaction was analyzed via NMR and it 
still showed an extra amide NH peak, plus the gem dimethyls are still observed.  It is 
evident that deprotonation to produce the oxazolidinone did not occur; instead, hydrolysis 
of the carbonate was the dominant reaction observed (Figure 6.12).  Other conditions 
(e.g. NaH, KOtBu/molecular sieves) were tried, but all failed.  Each time, hydrolysis 
occurred to produce alcohol 38.198 
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Figure 6.12.  Attempts to form oxazolidinone 36 give hydrolyzed product 38. 
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 It is possible that deprotonation of the Ugi product 35 is very hard because of the 
steric hindrance contributed by the nearby piperidine ring.  In this case, making the 
dipeptide derivative 27 has to be done via amino acid coupling.  In order to apply this 
route, the cyclic α,α-disubstituted amino acid 41 was synthesized. 
 
Scheme 6.6.  Synthesis of Cbz-protected 4-amino-4-carboxypiperidine 41 
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6.3.2 Synthesis of Spiro Cyclic Diketopiperazine from Cyclic α,α-Disubstituted 
Amino Acid 
 Quaternary or α,α-disubstituted amino acids are non-natural variants that possess 
severe rotational freedom around the N-C-α and C-α-C=O bond.  This inherent 
constraint imparts specific conformational preferences for inducing conformations when 
they are imbedded into a polypeptide chain.  For example, aminoisobutyric acid (Aib) is a 
known inducer of helical structure.199,200  More recently, when incorporated as part of a 
cyclic peptide, it was found that it can also adopt an extended conformation and can 
occupy the (i + 1) position of a type II΄ beta-turn.201  Alpha-methyl phenylalanine [(α-
Me)Phe] has a propensity to impart both β-turn and helical conformations better than 
Phe.202  The reduced conformational freedom is more pronounced with cyclic quaternary 
amino acids such as compound 41.  In most cases these cyclic analogs have a preference 
to adopt folded structures.  Indeed, studies on quaternary cyclic analogs of Phe (cnPhe) 
(V) gave evidence that these amino acids can induce beta-turn folding.203-205  
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Interestingly, the conformational restriction imposed by analogs W and X when they are 
used as Phe substitute in aspartame produced extreme tastes.  The aspartame derivative 
with compound W was found to be sweet while that of X was bitter.206  Other similar 
compounds is the quaternary cyclic analog of serine (c6Ser) whose cis-analog Y was 
found to induce a type I beta-turn.207. 
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 Synthesis of the required amino acid 41 utilized another multi-component 
reaction.  This time, the Bucherer-Bergs reaction was conducted using Cbz-protected 4-
piperidone 34, ammonium carbonate and potassium cyanide (Scheme 6.6).188,208  This 
reaction produced the spirocyclic hydantoin 39 which was fully Boc-protected using 
catalytic DMAP in THF/DMF.  Full protection of the amides is required to activate the 
hydantoin prior to its opening under basic condition because it makes the process more 
facile.  Ring opening will give a carboxylate salt so in order to isolate the desired 
compound the pH was adjusted to ~6.5 using dilute HCl.  This precipitated out amino 
acid 41 in good yield.  It is an interesting observation that if the 4-piperidone used was 
Boc- or Alloc-protected, there were problems along the synthesis.  With Boc-protection, 
the spirocyclic hydantoin product after Bucherer-Bergs reaction, surprisingly, is not very 
soluble in THF/DMF and so global Boc protection is not efficient.  In the case of Alloc-
protection, the Bucherer-Bergs reaction is not clean as it gives a lot of spots on TLC. 
 To be able to be used in peptide synthesis, amino acid 41 has to be converted to a 
protected or activated form.  The methyl ester derivative 42, the Boc-protected analog 43 
and the activated anhydride 44 where synthesized under the conditions indicated in 
Scheme 6.7.  It was unusual that in making the methyl ester, normal acidic conditions like 
SOCl2 in MeOH did not give the desired product. 
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Scheme 6.7.  C- and N-terminal modifications on amino acid 41 
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 To make the dipeptide derivative of 28, protected amino acids 42 and 43 were 
tested in normal peptide coupling procedure using the HOBt/ EDCI method (Figure 
6.13).  Surprisingly, no amide bond formation occurred as indicated by TLC.  In the case 
of the methyl ester, after considerable time, the reaction was worked-up and only the 
methyl ester was recovered.  It seems that coupling of cyclic α,α-disubstituted amino 
acid is very difficult and might require different activating reagent.  Indeed even the N-
carboxyanhydride derivative 44 failed to give a dipeptide. 
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Figure 6.14.  Attempts to make dipeptides of compounds 42 and 43 based on  
HOBt-EDC coupling. 
 
 
 Several reports on coupling an α,α-disubstituted amino acid have indicated an 
inherent difficulty due to steric effects208,209  One of the improved activating reagents 
used to improve coupling efficiency is HOAt.  Introduced by Carpino as a substitute for 
HOBt, reactions mediated by this reagent were in general faster and cleaner.210  It was 
noted that this aza derivative incorporates within its structure key elements of the 1:1 
mixture of HOBt and a tertiary amine which drives amide bond formation faster than just 
using HOBt in peptide coupling reactions.211  Gratifyingly, using HOAt to couple amino 
methyl ester 42 with BocVal-OH and BocLys(Boc)-OH gave the corresponding linear 
dipeptides 45 and 46, respectively, in high yields (Scheme 6.8).  Removal of the Boc 
protection followed by cyclization under weak acidic conditions in toluene gave the 
spirocyclic diketopiperazines 47 and 48 in modest to good yields.  The yield for 48 is 
lower because of its solubility in toluene.  On the other hand, DKP 47 is almost insoluble 
as it precipitated out of solution. 
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Scheme 6.8.  Synthesis of dipeptides based on amino methyl ester 42 using 
HOAt/EDC method and conversion to DKP’s 
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6.4 Future Directions 
 While the synthesis of the critical spirocyclic DKP took some time, the next 
direction should be focused on activating the 2,5-dioxo carbonyls.  Normal activation of 
this functionality in DKP’s involves POCl3/PCl5 activation.  However, this reaction is not 
very efficient as yields of the resulting substituted compounds are low.  On the other 
hand, other reactions can be tried as well.  These include the use of Lawesson’s reagent to 
convert to thiocarbonyl which can be activated by methylation.  Another reaction that can 
also be tried is carbonyldiimidazole (CDI)-tetrazole/POCl3 activation.212  The fact that a 
general reaction for carbonyl activation could be hard to find can of course increase the 
time to make the ultimate target which is the spirotetracyclic mimic 25.  Another thing to 
consider is the stability of its structure.  It is possible that it can adopt an imidazole form 
(Im-25) which will lose the chirality at the two side-chains.  This in turn can affect its 
conformational and biological properties. 
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6.5 Summary 
 Synthesis of non-peptidic mimics normally involve using peptide bond isosteres 
or using a scaffold wherein the critical side-chains are retained and presented in the 
proper three-dimensional manner to maintain the desired biological properties.  One of 
the simplest ways to use a scaffold is to do sequential substitutions to introduce the side-
chains of interest.  Our first efforts toward the synthesis of non-peptide mimetics have 
utilized this approach.  3-Bromo-4-fluoronitrobenzene was the scaffold of choice and the 
side-chains were introduced via Sonogashira and SNAr reactions.  This method produced 
non-peptide mimics 16, 17 and 18.  These compounds contain side-chain analogs of 
norleucine, isoleucine, arginine and lysine.  The nitro group can be further reduced to the 
amine and a method for dimerization similar to the DTAF-Inp protocol can be used. 
 Another non-peptidic compound that we sought to make is the spirotetracyclic 
compound 25.  This compound can contain up to three side-chains and it already has the 
important amino piperidine moiety that can be used for dimerization.  While this 
compound contains amide bonds, its rigidity could make it more resistant to proteolysis.  
A critical fragment in its synthesis is diketopiperazine (DKP) 27.  Attempts to make this 
DKP from its dipeptide precursor via Ugi reaction failed mainly because of the steric 
hindrance imposed by the quaternary cyclic side-chain.  However, the dipeptide was 
made via conventional peptide synthesis using the cyclic α,α-disubstituted amino acid 
42.  Using this route, two dipeptides were made and converted to their corresponding 
DKP derivatives. 
 Although the route to the DKP intermediate is slow, a proven procedure to make 
it has been developed.  To make the eventual target 25, the DKP has to be activated at the 
carbonyls and this may require time.  Also, the stability of compound 25 has to be 
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considered.  If it exists in an imidazole-like ring structure (Im-25), it loses its chirality at 
the α-carbon which may have drastic effect in its conformation and biological behavior. 
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CHAPTER VII 
CONCLUSIONS 
 
 Solid-phase synthesis of 14-membered ring cyclic peptidomimetics using two 
different organic templates but the same mode of cyclization indicated that conformation 
can influence the ease these compounds are formed.  SNAr cyclizations that give a 
strained ring structure like those peptidomimetics 1 gave poor yields which are 
complicated by head-to-tail ‘dimer’ formation.  On the other hand, less strained cyclic 
peptidomimetics like compounds 2 cyclize more efficiently, giving less amount of the 
‘dimer’ by-product.  These cyclizations were not proven unambiguously to be influenced 
by an anticipated beta-turn structure; although by QMD, compounds 2 were shown to be 
capable of adopting a type III beta-turn conformation. 
 Expanding the dipeptide that mimics the tip of the tetrapeptide turn sequence by 
adding an extra residue was done by synthesizing compounds 3.  These compounds were 
cyclized via an SN2 reaction to afford 18-membered ring systems.  While these are bigger 
in ring size than our previous mimics, their syntheses proved to be more efficient as only 
insignificant ‘dimers’ were formed.  A resin comparison study showed that our protocol 
for solid-phase synthesis is better suited for resins that have the Rink handle.  Eventually, 
TentaGel Rink resin was chosen to make a small library of compounds 3 that mimics 
NGF and NT-3 loop regions.  By adding an extra residue, the chances of mimicking a 
turn is improved as two mimics were shown to have agonistic properties for NT-3 in cell 
survival assays. 
 Dimerization of monovalent mimics to bivalent ones can give even better mimics 
since the neurotrophins function as dimers.  Synthesis of bivalent compounds was 
achieved by doing sequential substitutions on dichlortriazinylaminofluorescein (DTAF) 
This involved using peptidomimetics with a pendant piperidine ring from an isonipecotic 
acid residue that served as the nucleophile in the SNAr reaction.  Synthesis of monovalent 
units were done on resin and then cleaved to give either those with a reactive nucleophile 
(i.e. with the amino group of Inp) or those with an electrophile (i.e. with a labeled 
DTAF).  Dimerization was done in solution by mixing solutions of one of each of the two 
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types of monomers.  This simple technique gave homo- and heterobivalent 
peptidomimetics very efficiently.  Bivalent mimic 4, whose individual components are 3g 
and another one that was also active on preliminary cell survival assays, were synthesized 
using this dimerization strategy.  Our rationale that bivalent mimics made from 
monovalent ones can give better biological activities was justified when compound 4 was 
shown to bind TrkA with high affinity (20 nM).  More importantly, but unsurprisingly, it 
also binds TrkC, since it has turn residues corresponding to NT-3, with an even higher 
affinity. 
 One-step reactions of amino acids that give products considered as 
pharmacophores such as thiohydantoins are important in medicinal chemistry.  Acylation 
of amino acids with NH4SCN in acetic anhydride was shown to give thiohydantoins that 
are acylated at the nitrogen of the amino acid (i.e. N1 position).  This was proven by 2-D 
NMR methods to clarify mislabeling and incorrect structure representation of the product 
that was reported in the literature. 
 Solution-phase combinatorial synthesis can be an alternative to solid-phase 
methods in making libraries of peptidomimetics.  In our efforts to make less peptidic 
compounds, a simple dihalogenated nitrobenzene was used as a scaffold to attach side-
chains of interest.  Employing SNAr and Sonogashira reactions, non-cyclic mimics 16, 17 
and 18 were made.  These compounds contain side-chains having lipophilic and 
hydrophilic properties (e.g. isopropyl and guanidine).  Because nitro group can be 
reduced to the amine these non-peptidic mimics can be easily dimerized by adopting the 
method described in Chapter III. 
 A compound that we have sought to make was the spirotetracyclic analog of 25.  
A critically important intermediate to make this is the spirocyclic diketopiperazine (DKP) 
27.  Initial approach to synthesize the DKP using Ugi reaction proved to be difficult as 
the 4-CC product was too hindered to be converted to the dipeptide DKP precursor.  A 
longer route to the DKP was achieved by synthesizing the quaternary cyclic amino acid 
41 via Bucherer-Bergs reaction.  The methyl ester derivative of this amino acid, 42, was 
found to couple smoothly only with HOAt as the activating agent.  Dipeptides 45 and 46 
were prepared using this coupling procedure.  The dipeptides were deprotected and 
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cyclized in toluene under mildly acidic conditions to give the corresponding DKPs 47 
and 48. 
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APPENDIX A 
EXPERIMENTAL FOR CHAPTER II 
 
 General Methods.  All α-amino acids used had the L-configuration. All 
chemicals were obtained from commercial suppliers and used without further 
purification. Diisopropylcarbodiimide (DIC), N-hydroxybenzotriazole (HOBt), 
trifluoroacetic acid (TFA), oxalyl chloride, piperidine and triisopropylsilane (TIS) were 
purchased from Aldrich.  Dimethylformamide (DMF), methanol (MeOH) and 
dichloromethane (DCM) were bought from EMScience. 5-Fluoro-2-nitrobenzoyl chloride 
was made by reacting  5-fluoro-2-nitrobenzoic acid (from Fluorochem USA) with oxalyl 
chloride for 30 min - 1 h. 2-Fluoro-5-nitrophenylacetic acid was obtained by nitration of 
2-fluorophenylacetic acid (from Aldrich).  Rink Amide MBHA resin was purchased from 
NovaBiochem while Tenta Gel S Ram Fmoc resin was obtained from Advanced 
ChemTech. All amino acids used were purchased from either NovaBiochem, Advanced 
ChemTech or Chem-Impex. 
 All peptidomimetic syntheses were done in a fritted polypropylene syringe (5 mL 
capacity) purchased from Torviq.  Reverse-phase high-performance liquid 
chromatography (HPLC) was carried out on Vydac C-18 columns with the following 
dimensions: 25 x 0.46 cm for analysis and 25 x 2.2 cm for preparative work). All HPLC 
analyses were done using gradient conditions.  Eluents used were solvents A (H2O with 
0.1% TFA) and B (CH3CN with 0.1% TFA).  Flow rates applied were 1.0 mLmin-1 and 
6.0 mLmin-1 for analytical and preparative HPLC respectively. 
 General experimental procedure for the preparation of peptidomimetics: 
Synthesis of compound 1a.  Rink Amide MBHA resin (0.1 mmol, 0.5 mmolg−1) was 
swelled in DMF (ca10 mLg-1) in a fritted syringe for 1 h.  The resin was then washed 
with DMF (3 x at ca 10 mLg-1, each time for 1 min and all other washings throughout, 
except otherwise indicated).  The Fmoc protecting group on the Rink handle was 
removed by treating the resin with 20 % piperidine in DMF (2 x, first for 5 min, then for 
25 min).  The resin was washed with DMF (3x), MeOH (3x) and DCM (3x).  This Fmoc 
removal and washings thereafter are the same throughout.  Then, Fmoc-Cys(Mmt)-OH (3 
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eq), DIC (5 eq) and HOBt (5 eq) dissolved in DMF (1.5 - 2 mL) were added.  After 
gentle shaking for about 4-6 h, a ninhydrin test on sample resin beads gave a negative 
result.  The reaction mixture was then drained and the resin washed with DMF (4 x).  The 
above deprotection, coupling and washing cycles were repeated to attach Fmoc-
Lys(Boc)-OH and Fmoc-Asn(Trt)-OH, respectively.  After final Fmoc deprotection and 
washing, the resin was washed with CH2Cl2 (3x) and then coupled with 5-fluoro-2-
nitrobenzoyl chloride in CH2Cl2 and DIEA.  After 2h, sample beads were tested 
ninhydrin negative and the resin washed with CH2Cl2 (5x).  Removal of the Cys side-
chain protecting group (Mmt, 4-methoxytrityl) was carried out using 1 % TFA and 5 % 
TIS in CH2Cl2 (6 x, each time for 10 min).  The resin was then washed with CH2Cl2 (4 x) 
and was dried for 1 h prior to cyclization.  Cyclization was effected by adding K2CO3 (5 
eq) in DMF at 25°C and gently shaking the mixture for ca 24-30 h.  The reaction mixture 
was then drained, the resin was washed with H2O (5x), DMF (3x), MeOH (3x) and 
CH2Cl2 (3x), and then dried in vacuo for 6 h.  The peptide was cleaved by treating the 
resin with a mixture of 90 % TFA, 5 % TIS and 5 % H2O.  The cleavage solution was 
then separated from the resin by filtration.  The resin was given a final wash with CH2Cl2 
(3x).  Most of the cleavage cocktail (ca 90 %) was evaporated in vacuo after which, 
precipitation of the peptide was achieved via trituration with anhydrous diethyl ether.  
The crude peptide was then dissolved in DMF (<2 mL), purified via preparative HPLC 
(Rainin System, 18-20% B in 20 min) and then lyophilized to give a yellow solid (14.0 
mg, 27.5 %).  Analytical HPLC: homogeneous single peak, tR = 8.3 min (8 - 70 % B in 
30 min).  1H NMR (500 MHz, DMSO-d6, 25°C): δ =  8.37 (d, J= 9.0 Hz, 1H), 8.01 (d, 
J= 9.0 Hz, 1H), 7.97 (d, J= 9.0 Hz, 1H), 7.78 (d, J= 8.5 Hz, 1H), 7.70 (bs, 1H), 7.53 - 
7.49 (unresolved, 3H), 7.51 (s, 1H), 7.49 (s, 1H), 7.40 (unresolved, 2H), 7.02 (s, 1H), 
4.90 - 4.87 (m, 1H), 4.44 - 4.42 (m, 1H), 3.85 - 3.84 (m, 1 H), 3.67 - 3.42 (m, 2H), 2.77 - 
2.76 (m, 2H), 2.61 - 2.47 (m, 2 H), 1.80 - 1.77 (m, 1H), 1.54 - 1.51 (m, 3H), 1.31 - 1.24 
(m, 2 H).  13C NMR (DMSO-d6, 75 MHz, 25°C): δ=171.5, 171.1, 170.8, 170.4, 167.9, 
148.5, 140.8, 132.6, 127.7, 124.6, 122.1, 54.5, 52.4, 51.1, 38.6 (overlap with DMSO), 
37.2, 22.4, 29.7, 26.7, 21.8.  MALDI MS: calcd for C20H27N7O7S (M + H)+ 510.5, found 
510.1. 
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 Compound 1b. Rink Amide MBHA (0.05 mmol, 0.54 mmolg-1) was used to 
synthesize this compound.  The second and third amino acids attached were 
FmocLys(Boc)-OH and FmocIle-OH, respectively.  After cleavage from the resin, the 
crude peptide was purified by preparative HPLC and was lyophilized to give a yellow 
solid (4.4 mg, 17.3 %). Analytical HPLC: homogeneous single peak, tR = 14.5 min (8 - 
70 % B in 30 min).  1H NMR (300MHz, DMSO-d6, 25°C): δ=8.99 (d, J=8.4 Hz, 1H), 
8.33 (d, J=10.5 Hz, 1H), 8.07–7.98 (m, 3H), 7.85 (d, J=8.4 Hz, 1H), 7.70 (d, J=8.7 Hz, 
1H), 7.62 (s, 3H), 6.89 (d, J=2.1 Hz, 1H), 4.80–4.77 (m, 1H), 4.52–4.50 (m, 1H), 3.65–
3.51 (m, 2H) 3.16–3.11 (m, 1H), 2.74–2.72 (m, 2H), 1.74–1.72 (m, 2H), 1.54–1.48 (m, 
4H), 1.26–1.16 (m, 3H), 0.931–0.775 (m, 6H).  MALDI MS: calcd for C22H32N6O6S (M 
+ H)+ 509.6, found 509.2. 
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 Compound 1c.  Rink Amide MBHA (0.05 mmol, 0.54 mmolg-1) was used to 
synthesize this compound.  The second and third amino acids attached were 
FmocArg(Pmc)-OH and FmocIle-OH, respectively.  After cleavage from the resin, the 
crude peptide was purified by preparative HPLC and was lyophilized to give a yellow 
solid (5.6 mg, 20.8 %). analytical HPLC: homogeneous single peak, tR = 15.9 min (8 - 70 
% B in 30 min).  1H NMR (300 MHz, DMSO-d6, 25°C): δ= 9.00 (d, J=8.4 Hz, 1H), 8.35 
(d, J=10.2 Hz, 1H)8.10–7.98 (m, 3H), 7.87 (d, J=8.7 Hz, 1H), 7.63 (s, 1H), 7.55–7.47 
(m, 5H), 6.89 (d, J=2.4 Hz, 2H), 4.79–4.78 (m, 1H), 4.58–4.40 (m, 2H) 4.28–4.18 (m, 
1H) 3.61–3.51 (m, 2H), 1.75–1.73 (m, 2H), 1.52–1.48 (m, 4H), 1.22–1.19 (m, 1H), 
0.934–0.774 (m, 6H).  MALDI MS: calcd for C22H32N8O6S (M + H)+ 537.6, found 537.2. 
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 Compound 1d.  Rink Amide MBHA (0.05 mmol, 0.54 mmolg-1) was used to 
synthesize this compound.  The second and third amino acids attached were FmocGly-
OH and FmocThr(tBu)-OH, respectively.  After cleavage from the resin, the crude 
peptide was purified by preparative HPLC and was lyophilized to give a yellow solid (5.6 
mg, 26.3 %).  Analytical HPLC: homogeneous single peak, tR = 8.1 min (8 - 70 % B in 
30 min).  1H NMR (300 MHz, DMSO-d6, 25°C): δ=8.15–8.09 (m, 2H), 7.72 (d, J=9.9 
Hz, 1H), 7.63 (dd, J=1.8, 2.1 Hz, 1H), 7.45 (s, 1H), 7.30 (s, 1H), 7.23 (d, J=9 Hz, 1H), 
7.16 (d, J=2.1 Hz, 1H), 6.53 (s, 1H), 4.91 (bs, 1H), 4.71 (bs, 1H), 4.97 (bs, 1H), 3.79, (d, 
J=6.3 Hz, 1H), 3.69 (d, J=5.7 Hz, 1H), 3.55–3.50 (m, 2H), 1.16–1.09 (m, 3H).  MALDI 
MS: calcd for C16H19N5O7S (M + H)+ 426.4, found 426.1. 
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 Compound 1e.  Rink Amide MBHA (0.05 mmol, 0.54 mmolg-1) was used to 
synthesize this compound.  The second and third amino acids attached were FmocIle-OH 
and FmocAsp(tBu)-OH, respectively.  After cleavage from the resin, the crude peptide 
was purified by preparative HPLC and was lyophilized to give a yellow solid (2.5 mg, 
10.1 %).  Analytical HPLC: homogeneous single peak, tR = 13.0 min (8 - 70 % B in 30 
min).  1H NMR (300 MHz, DMSO-d6, 25°C): δ=8.29 (d, J=6.6 Hz, 2H), 8.05 (d, J=9 Hz, 
1H), 7.82 (d, J=1H), 7.53 (s, 1H), 7.48 (dd, J=2.4, 2.4 Hz, 1H), 7.45 (s, 1H) 6.98 (d, 
J=2.1 Hz, 1H), 4.78–4.76 (m, 1H), 4.34 (t, J=9.6 Hz, 1H), 3.64–3.59 (m, 3H), 1.77 (bs, 
1H), 1.43 (bs, 2H), 1.04–0.999 (m, 2H), 0.834–0.757 (m, 6H).  MALDI MS: calcd for 
C20H25N5O8S (M + H)+496.5, found 496.1. 
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 Solid-phase synthesis of Compounds 2a-e.  The same procedure as in the 
synthesis of 2a-e was followed except for the following variations.  The resin used was 
Tenta Gel S RAM Fmoc (0.05 mmol, 0.26 mmolg-1) and the tripeptide was coupled to 2-
fluoro-5-nitrophenylacetic acid using DIC and HOBt. 
 Compound 2a.  Tenta Gel S RAM Fmoc resin (0.05 mmol, 0.26 mmolg-1) was 
used to synthesize this compound.  The second and third amino acids attached were 
FmocLys(Boc)-OH and FmocAsn(Trt))-OH, respectively.  After cleavage from the resin, 
the crude peptide was purified by preparative HPLC and was lyophilized to give a yellow 
solid (15 mg, 57 %).  Analytical HPLC: homogeneous single peak, tR=9.5 min (8–70% B 
in 30 min).  1H NMR (500 MHz, DMSO-d6, 25°C): δ=8.10 (s, 1H), 8.06 (dd, J=2.5, 8.5 
Hz, 1H), 7.71 (s, 3H), 7.62 (d, J=8 Hz, 1H), 7.47 (unresolved, 1H), 7.46 (s, 1H), 7.41 (s, 
1H), 7.36 (d, J=8 Hz, 1H), 7.28 (bs, 1H), 7.20 (d, J=9 Hz, 1H), 6.94 (s, 1H), 4.62–4.57 
(m, 1H), 4.51–4.46 (m,1H), 4.19–4.15 (m, 1H), 3.67–3.10 (m, 2H), 3.65–3.79 (m, 2H), 
2.75–2.72 (m, 2H), 2.61–2.47 (m, 2H), 1.69–1.56 (m, 2H), 1.57–1.50 (m, 2H), 1.26–1.21 
(m, 2H); 13C NMR (DMSO-d6, 75 MHz, 25°C): δ=171.3, 171.0, 170.9, 170.7, 168.7, 
147.4, 144.1, 134.9, 125.9, 125.7, 122.5, 69.8, 52.8, 52.0, 50.0, 40.4, 38.8, 37.3, 30.0, 
26.9, 22.2.  MALDI MS: calcd for C21H29N7O7S (M + H)+ 524.6, found 524.2.   
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 Compound 2b.  Tenta Gel S RAM Fmoc resin (0.05 mmol, 0.26 mmolg-1) was 
used to synthesize this compound.  The second and third amino acids attached were 
FmocLys(Boc)-OH and FmocIle-OH, respectively.  After cleavage from the resin, the 
crude peptide was purified by preparative HPLC and was lyophilized to give a light 
yellow solid (13.1 mg, 50 %).  Analytical HPLC: homogeneous single peak, tR = 13.7 
min (8 - 70 % B in 30 min).  1H NMR (DMSO-d6, 300 MHz, , 25°C): δ = 8.28 - 8.23 (m, 
2H), 8.107 (d, J = 2.4 Hz, 1H), 8.07 (dd, J= 2.4 Hz, 1H), 7.70 - 7.68 (m, 4H), 7.48 - 7.44 
(m, 2H), 7.33 (s, 1H), 4.66 - 4.58 (m, 1H), 4.25 - 4.18 (m, 1H), 3.97 (t, J= 9 Hz, 1H), 
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3.83 - 3.77 (m, 1H), 3.67 - 3.62 ( m, 2 H), 3.11 (t, J= 11.7 Hz, 1H), 2.76 - 2.72 (m, 2 H), 
1.78 - 1.71 (m, 2 H), 1.56 - 1.49 (m, 4 H), 1.29 - 1.12 (m, 3H), 0.865 - 0.815 (m, 6 H).  
MALDI MS: calcd for C23H34N6O6S (M + H)+ 523.6, found 523.2. 
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 Compound 2c.  Tenta Gel S RAM Fmoc resin (0.05 mmol, 0.26 mmolg-1) was 
used to synthesize this compound.  The second and third amino acids attached were 
FmocArg(Pmc)-OH and FmocIle-OH, respectively.  After cleavage from the resin, the 
crude peptide was purified by preparative HPLC and was lyophilized to give a light 
yellow solid (10.3 mg, 37 %). analytical HPLC: homogeneous single peak, tR = 15.5 min 
(8 - 70 % B in 30 min).  1H NMR DMSO-d6, 300 MHz, 25°C): δ=8.29–8.23 (m, 2H), 
8.11 (d, J=2.4 Hz, 1H), 8.07 (dd, J=2.4, 2.4 Hz, 1H), 7.72 (d, J=8.1 Hz, 1H), 7.62–7.58 
(m, 1H), 7.52 (s, 1H), 7.45 (d, J=8.7 Hz), 7.33 (s, 1H), 4.66–4.58 (m, 1H), 4.27–4.20 (m, 
1H), 4.00–3.94 (m, 1H), 3.82–3.77 (m, 1H) 3.69–3.61 (m, 2H), 3.15–3.07 (m, 3H), 1.76–
1.71 (m, 2H), 1.56–1.41 (m, 4H), 1.77–1.13 (m, 1H).  MALDI MS: calcd for 
C23H34N8O6S (M + H)+  551.6, found 521.2. 
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 Compound 2d.  Tenta Gel S RAM Fmoc resin (0.05 mmol, 0.26 mmolg-1) was 
used to synthesize this compound.  The second and third amino acids attached were 
FmocGly-OH and FmocArg(Pmc)-OH, respectively.  After cleavage from the resin, the 
crude peptide was purified by preparative HPLC and was lyophilized to give a yellow 
solid (9.5 mg, 40 %).  Analytical HPLC: homogeneous single peak, tR = 10.3 min (8 - 70 
% B in 30 min).  1H NMR (DMSO-d6, 300 MHz, , 25°C): δ =  8.68 (d, J= 7.8 Hz, 1H), 
8.46 (t, J= 5.7 Hz, 1H), 8.12 (d, J= 2.7 Hz, 1H), 8.04 (dd, J= 2.4 Hz, 1 H), 7.65 - 7.62 
(m, 2H), 7.37 (s, 1H), 7.15 (s, 1H), 4.36 - 4.34 (m, 1H), 4.24 - 4.21 (m, 1H), 3.88 - 3.78 
(m, 3H), 3.57 (d, J= 5.1 Hz, 1H), 3.53 - 3.35 (m, 7H covered by H2O signal), 3.13 - 3.09 
(m, 2H), 1.71-1.65 (m, 1 H), 1.57 - 1.42 (m, 3H).  MALDI MS: calcd for C19H26N8O6S 
(M + H)+ 495.1, found 495.0. 
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 Compound 2e.  Tenta Gel S RAM Fmoc resin (0.05 mmol, 0.26 mmolg-1) was 
used to synthesize this compound. The second and third amino acids attached were 
FmocThr(tBu)-OH and FmocLys(Boc)-OH, respectively.  After cleavage from the resin, 
the crude peptide was purified by preparative HPLC and was lyophilized to give a white 
solid (15.1 mg, 59 %).  Analytical HPLC: homogeneous single peak, tR = 9.3 min (8 - 70 
% B in 30 min).  1H NMR (DMSO-d6, 300 MHz, 25°C): δ =  8.56 - 8.54 (m, 1H), 8.11 
(d, J= 2.4 Hz, 1H), 8.07 (dd, J= 6.3 Hz, 1H), 7.86 (d, J= 8.7 Hz, 1H) 7.7 (bs, 3H), 7.6 (d, 
J= 8.4 Hz, 1H), 7.5 (d, J= 9 Hz, 1 H), 7.33 (unresolved, 1H), 7.25 (unresolved, 1H), 4.54 
- 4.51 (m, 1H), 4.25 - 4.20 (m, 1H), 4.13 - 4.05 (m, 2H), 3.85 - 3.71 (m, 2H), 3.60 - 3.55 
(m, 1 H), 2.77 (unresolved, 3H), 2.57 - 2.53 (m, 1H), 1.73-1.70 (m, 2H), 1.59-1.50 (m, 
2H), 1.41 (unresolved, 2H), 1.04 - 1.01 (m, 3H).  MALDI MS: calcd forC20H27N7O7S (M 
+ H)+ 1 510.5, found 510.1. 
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APPENDIX B 
EXPERIMENTAL FOR CHAPTER III 
 
 
 General Methods.  All α-amino acids used have the L-configuration and were 
purchased from NovaBiochem, Advanced ChemTech or Chem-Impex.  Chemicals were 
obtained from commercial suppliers and used without further purification.  
Diisopropylcabodiimide (DIC), N-hydroxybenzotriazole (HOBt), trifluoroacetic acid 
(TFA), oxalyl chloride, diisopropylethylamine (DIEA), piperidine and triisopropylsilane 
(TIS) were purchased from Aldrich.  Dimethylformamide (DMF), methanol and 
dichloromethane were bought from EMScience. The resins were obtained from Rapp 
Polymere, Advanced ChemTech, Nova Biochem, Argonaut Technologies and Chiron 
Mimetopes. 
 Peptidomimetic syntheses were performed in fritted polypropylene syringes (5 
mL capacity) from Torviq. Reverse-phase high-performance liquid chromatography 
(HPLC) analyses were carried out using a Beckman SystemGold instrument and a Vydac 
C-18 column (catalog no. 218TP54, length: 250 mm; inner diameter: 4.6 mm). 
Preparative purifications were done on an SSI HPLC system using a Vydac C-18 column 
(catalog no. 2181022, length: 250 mm, inner diameter: 22 mm).  All HPLC analyses were 
done under gradient conditions.  Eluents used were solvent A (H2O with 0. 1 % TFA) and 
solvent B (CH3CN with 0.1% TFA).  Flow rates applied were 1.0 and 6 mL/min for 
analytical and preparative HPLC respectively. 
 General experimental procedure for the preparation of peptidomimetics: 
Synthesis of compound 3a.  In a 5 mL fritted syringe, TentaGel S RAM Fmoc (0.05 
mmol, 0.30 mmol g-1) was swelled in DMF (ca 10 mL g-1) for 1 h.  The resin was washed 
with DMF (3 x ca 10 mL g-1, each time for 1 min; this amount of solvent and washing 
time were used for all other washings throughout).  The Fmoc protecting group was 
removed by treating the resin with 20 % piperidine in DMF (2x, first 10 min, then for 20 
min).  The resin was washed with DMF (3x), MeOH (3x) and CH2Cl2 (3x), after which a 
solution of FmocCys(Mmt)-OH (3 eq), DIC (5 eq) and HOBt (5 eq) in 1.5 mL DMF was 
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added.  After shaking for 10 h, a Kaiser test27 on sample beads indicated a negative result. 
The reaction mixture was drained and the resin washed with DMF (3x).  The above 
deprotection, coupling and washing cycles were repeated to attach FmocGly-OH, 
FmocLys-OH and FmocIle-OH. After the final Fmoc deprotection, the resin was washed 
with DMF (3x), MeOH (3x) and CH2Cl2 (3x).  The resin was dried for 2 h in vacuo, then 
a solution of 3-bromomethylbenzoylchloride (3 eq) and DIEA (5 eq) in 2 mL CH2Cl2 
were added.  After 1 h of shaking, a Kaiser test gave a negative result.  The resin was 
washed with CH2Cl2 (5x).  The Mmt group on cysteine was removed by treating the resin 
with 1% TFA and 5 % TIS in CH2Cl2 (6x, each time for 10 min).  The resin was then 
washed with CH2Cl2 (4x) and DMF (3x).  Cyclization was carried out by adding 8 eq of 
DIEA in ca 2.0 - 2.5 mL DMF and shaking the resin for 12 h.  The resin was then washed 
with DMF (3x), MeOH (3x) and CH2Cl2 (3x) before it was dried for 2 h in vacuo.  The 
product was cleaved by treating the resin with 90 % TFA, 5 % TIS and 5 % H2O (ca 3.5 
– 4 mL) for 2 – 4 h. The resin was then washed with 50 % TFA in CH2Cl2 (2x).  The 
collected filtrate and washings were concentrated and the product was precipitated by 
adding Et2O (ca 3 mL).  The white precipitate was isolated by centrifugation of the 
mixture and carefully decanting the ether.  The residue was washed with Et2O two more 
times.  The crude peptide was then dissolved in the minimum volume of H2O with a little 
CH3CN added (total volume <2.5 mL) and was purified via preparative HPLC (SSI 
System, 20 – 30 % B in 25 min).  The dominant fraction was concentrated and 
lyophilized to give a white fluffy solid (7.2 mg, 27%). 1H NMR (500 MHz, DMSO-d6, 25 
°C): δ = 8.41 (d, J = 7.94 Hz, 1H), 8.23 (d, J = 8.23 Hz, 1H), 8.07 (d, J = 8.30 Hz, 1H), 
7.77 (s, 1H), 7.72-7.67 (m, 4H), 7.52-7.49 (m, 2H), 7.42 (t, J = 7.65 Hz, 1H), 7.24 (s, 
1H), 4.41 (q, J = 7.46 Hz, 1H), 4.22-4.15 (m, 2H), 4.03 (dd, J = 7.22, 16.85 Hz, 1H), 
3.90-3.82 (m, 2H), 3.59 (dd, J = 3.94, 16.85 Hz, 1H), 2.82-2.73 (m, 3H), 2.42 (dd, J = 
7.44, 13.84 Hz, 1H), 1.96-1.90 (m, 1H), 1.88-1.83 (m, 1H), 1.67-1.60 (m, 1H), 1.58-1.51 
(m, 3H), 1.37-1.26 (m, 2H), 1.25-1.16 (m, 1H), 0.92 (d, J = 6.80 Hz, 3H), 0.88 (t, J = 
7.59 Hz, 3H); 13C NMR (75 MHz, DMSO-d6, 25 °C): δ  = 173.6, 171.6, 171.4, 171.1, 
168.4, 168.0, 167.0, 158.3, 157.8, 139.2, 139.1, 135.4, 122.1, 117.2, 59.8, 52.8, 51.9, 
42.5, 35.8, 30.6, 26.6, 25.2, 22.4, 15.6, 10.7; analytical HPLC: homogeneous single peak, 
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tR=13.05 min (8-70% B in 30 min); MALDI MS: calcd for C25H38N6O5S (M + H)+ 
535.67, found 535.20. 
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 Compound 3b.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocLys(Boc)-OH, FmocIle-OH and FmocAsp(tBu)-OH, respectively.  After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white fluffy solid (13.2 mg, 45 %).  1H NMR (300 MHz, DMSO-d6, 
25 °C): δ = 8.34 (d, J = 7.71 Hz, 1H), 8.25 (d, J = 7.71 Hz, 1H), 8.03 (d, J = 6.73 Hz, 
1H), 7.80-7.74 (m, 2H), 7.70-7.63 (m, 2H), 7.55-7.41 (m, 3H), 7.29 (s, 1H), 7.26 (s, 1H), 
4.98-4.90 (m, 1H), 4.81 (dd, J = 7.09, 15.05 Hz, 1H), 4.56-4.37 (m, 3H), 4.29-4.21 (m, 
1H), 3.91-3.75 (m, 4H), 3.64-3.59 (m, 1H), 2.80-2.69 (m, 3H), 2.68-2.59 (m, 1H), 2.30 
(dd, J = 6.04, 13.10 Hz, 1H), 1.63-1.46 (m, 2H), 1.41-1.23 (m, 2H), 1.17-1.03 (m, 1H), 
0.85 (d, J = 6.88 Hz, 3H), 0.35 (d, J = 7.13 Hz, 3H); analytical HPLC: homogeneous 
single peak, tR=10.48 min (8-70% B in 30 min); MALDI MS: calcd for C27H40N6O5S (M 
+ H)+ 593.71, found 593.19. 
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 Compound 3c.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocSer(tBu)-OH, FmocAsn(Trt)-OH and FmocAsn(Trt)-OH, respectively.  After 
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cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (4.3 mg, 16 %).  1H NMR (500 MHz, DMSO-d6, 25 °C): 
δ = 8.71 (d, J = 7.83 Hz, 1H), 8.28 (d, J = 7.26 Hz, 1H), 8.19 (d, J = 8.37 Hz, 1H), 7.85-
7.83 (m, 2H), 7.72-7.70 (m, 1H), 7.49-7.51 (m, 1H), 7.46-7.43 (m, 3H), 7.41 (s, 1H), 7.24 
(s, 1H), 6.93 (s, 2H), 4.85 (t, J = 5.86 Hz, 1H), 4.66-4.62 (m, 1H), 4.42 (q, J = 7.25 Hz, 
1H), 4.32-4.28 (m, 1H), 4.26-4.22 (m, 1H), 3.89-3.79 (m, 2H), 3.72-3.68 (m,1H), 3.64-
3.59 (m, 1H), 2.79-2.74 (m, 2H), 2.72-2.69 (m, 2H), 2.65-2.58 (m, 1H) 2.31 (dd, J = 
2.31, 13.80 Hz, 1H); 13C NMR (75 MHz, DMSO-d6, 25 °C): δ = 172.6, 172.5, 172.3, 
171.7, 171.6, 170.4, 167.4, 139.2, 134.5, 132.9, 129.4, 128.7, 126.6, 62.2, 56.0, 52.5, 
52.3, 52.2, 37.1, 36.9, 34.6, 32.3; analytical HPLC: homogeneous single peak, tR=7.46 
min (8-70% B in 30 min); MALDI MS: calcd for C22H29N7O8S (M + Na)+ 574.57, found 
574.11. 
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13C NMR of compound 3c 
 
 
 Compound 3d.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocAsn(Trt)-OH, FmocAsn(Trt)-OH and FmocIle-OH, respectively.  After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (8.3 mg, 29 %).  1H NMR (500 MHz, DMSO-d6, 25 °C): 
δ = 8.45 (d, J = 9.15 Hz, 1H), 8.41 (d, J = 8.42 Hz, 1H), 8.22 (d, J = 8.65 Hz, 1H), 8.12 
(d, J = 6.56 Hz, 1H), 7.73 (s, 1H), 7.67-7.65 (m, 1H), 7.54 (s, 1H), 7.52-7.48 (m, 3H), 
7.42 (t, J = 7.55 Hz 1H), 7.23 (s, 1H), 7.03 (s, 1H), 6.97 (s, 1H), 4.50-4.46 (m, 1H), 4.41-
4.34 (m, 2H), 4.23 (t, J = 9.75 Hz, 1H), 3.89-3.78 (m, 2H), 3.44-3.41 (m, 1H), 3.0 (dd, J 
= 6.70, 13.86 Hz, 1H), 2.69-2.63 (m, 1H), 2.61-2.54 (m, 2H), 2.39 (dd, J = 8.51, 13.86 
Hz, 1H), 1.86-180 (m, 1H), 1.54-1.47 (m, 1H), 1.16-1.07 (m, 1H), 0.87 (d, J = 5.53 Hz, 
3H), 0.85 (t, J = 7.24 Hz, 3H); analytical HPLC: homogeneous single peak, tR=12.61 min 
(8-70% B in 30 min); MALDI MS: calcd for C25H35N7O7S (M + Na)+ 600.65, found (M 
+ Na)+ 600.30. 
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 Compound 3e.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocLys(Boc)-OH, FmocGly-OH and FmocAsp(tBu)-OH, respectively.  After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (18.6 mg, 69 %).  1H NMR (500 MHz, DMSO-d6, 25 
°C): δ = 12.3 (bs, 1H), 9.30 (d, J = 7.64 Hz, 1H), 8.25 (dd, J = 3.86, 8.56 Hz, 1H), 8.01 
(s, 1H), 7.91 (d, J = 9.10 Hz, 1H), 7.80-7.78 (m, 1H), 7.71 (bs, 2H), 7.59 (d, J = 7.79 Hz, 
1H), 7.50-7.45 (m, 2H), 7.29 (s, 1H), 7.24 (s, 1H), 4.55 (q, J = 6.79 Hz, 1H), 4.49-4.44 
(m, 1H), 4.23-4.15 (m, 2H), 3.90-3.82 (m, 2H), 3.75-3.73 (m, 1H), 3.54-3.50 (m, 2H), 
3.08 (dd, J = 6.68, 16.21 Hz, 1H), 2.83 (dd, J = 5.28, 12.24 Hz, 1H), 2.68 (dd, J = 6.68, 
16.21 Hz, 1H), 2.18 (dd, J = 8.75, 12.24 Hz, 1H), 1.93-1.84 (m, 1H), 1.83-1.77 (m, 1H), 
1.60-1.56 (m, 2H), 1.46-1.38 (m, 1H), 1.37-1.34 (m, 1H); analytical HPLC: 
homogeneous single peak, tR=9.26 min (8-70% B in 30 min); MALDI MS: calcd for 
C23H32N6O7S (M + H)+ 537.60, found 537.15. 
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 Compound 3f.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocGln(Trt)-OH, FmocLys(Boc)-OH and FmocGly-OH, respectively.  After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (18.6 mg, 69 %). 1H NMR (500 MHz, DMSO-d6, 25 
°C): δ = 8.64-8.63 (m, 2H), 8.52 (d, J = 8.68 Hz, 1H), 8.20 (d, J = 7.32 Hz, 1H), 7.90 (s, 
1H), 7.76-7.70 (m, 4H), 7.50 (d, J = 7.26 Hz, 1H), 7.45 (t, J = 7.71 Hz, 1H), 7.29 (s, 1H), 
7.26 (s, 1H), 6.77 (s, 1H), 4.67-4.62 (m, 1H), 4.28-4.24 (m, 2H), 4.04 (dd, J = 4.92, 
14.50 Hz, 1H), 4.0-3.95 (m, 2H), 3.78-3.73 (m, 2H), 3.44-3.40 (m, 1H), 2.56 (dd, J = 
9.89, 13.67 Hz, 1H), 2.18 (dd, J = 4.85, 13.67 Hz, 1H), 2.03 (t, J = 8.34 Hz, 2H), 1.90-
1.85 (m, 1H), 1.81-1.74 (m, 2H), 1.72-1.63 (m, 1H), 1.60-1.48 (m, 2H), 1.44-1.29 (m, 
2H); analytical HPLC: homogeneous single peak, tR=8.62 min (8-70% B in 30 min); 
MALDI MS: calcd for C24H35N7O6S (M + Na)+ 572.64, found 572.15. 
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 Compound 3g.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocGly-OH, FmocArg(Pmc)-OH and FmocIle-OH, respectively.  After cleavage 
from the resin, the crude peptide was purified by preparative HPLC and was lyophilized 
to give a white solid (18.6 mg, 69 %).  1H NMR (500 MHz, DMSO-d6, 25 °C): δ = 8.44 
(d, J = 7.90 Hz, 1H), 8.22 (d, J = 8.36 Hz, 1H), 8.10 (d, J = 8.10 Hz, 1H), 7.77 (s, 1H), 
7.73-7.70 (m, 2H), 7.57 (t, J = 5.7 Hz, 1H), 7.52-7.51 (m, 2H), 7.49 (s, 1H), 7.24 (s, 1H), 
4.40 (q, J = 7.15Hz, 1H), 4.22-4.15 (m, 2H), 4.04 (dd, J = 6.89, 16.70 Hz, 1H), 3.86 (q, J 
= 13.12 Hz, 2H), 3.59 (dd, J = 3.95, 16.70 Hz, 1H), 3.12 (q, 6.59 Hz, 2H), 2.79 (dd, 7.16, 
J = 14.05 Hz, 1H), 2.41 (dd, J = 7.16, 14.05 Hz, 1H), 1.96-1.85 (m, 2H), 1.68-1.61 (m, 
1H), 1.53-1.49 (m, 2H), 1.47-1.40 (m, 1H), 1.25-1.15 (m, 1H), 0.92 (d, J = 6.81 Hz, 3H), 
0.88 (t, J = 7.43 Hz, 3H); 13C NMR (75 MHz, DMSO-d6, 25 °C): δ = 174.1, 172.1, 
171.8, 171.6, 168.9, 168.5, 167.5, 157.2, 139.7, 139.6, 135.8, 123.6, 122.6, 117.7, 60.3, 
53.8, 52.4, 43.0, 36.2, 34.9, 32.9, 28.9, 25.7, 16.1, 11.1; analytical HPLC: homogeneous 
single peak, tR=13.45 min (8-70% B in 30 min); MALDI MS: calcd for C25H38N8O5S (M 
+ H)+ 563.69, found 563.19. 
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 Compound 3h.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocArg(Pmc)-OH, FmocIle-OH and FmocAsp(tBu)-OH, respectively.  After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (18.6 mg, 69 %).  1H NMR (500 MHz, DMSO-d6, 25 
°C): δ = 10.84 (bs, 1H), 8.34 (d, J = 6.71 Hz, 1H), 7.78 (s, 1H), 7.66 (d, J = 7.18, 1H), 
7.63 (d, J = 8.50 Hz, 1H), 7.47-7.45 (m, 3H), 7.37 (t, J = 6.95 Hz, 1H), 7.32-7.25 (m, 
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2H), 7.19-7.07 (m, 3H), 6.55 (s, 1H), 4.83-4.77 (m, 1H), 4.73-4.66 (m, 1H), 4.47-4.45 
(m, 1H), 4.44 (dd, J = 6.54, 17.11 Hz, 1H), 3.76-3.71 (m, 3H), 3.42 (dd, J = 5.83, 11.10 
Hz, 1H), 3.14-3.05 (m, 2H), 2.86-2.78, (m, 1H), 2.74-2.68 (m, 1H), 1.77-1.66 (m, 2H), 
1.64-1.56 (m, 1H), 1.55-1.49 (m, 2H), 1.48-1.42 (m, 1H), 1.24-1.20 (m, 1H), 0.89 (d, J = 
6.67 Hz, 3H), 0.86 (t, J = 7.17, 3H); analytical HPLC: homogeneous single peak, 
tR=10.87 min (8-70% B in 30 min); MALDI MS: calcd for C28H40N8O7S (M + H)+ 
621.72, found 621.25. 
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 Compound 3i.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocGly-OH, FmocThr(tBu), FmocLys(Boc), respectively.  After cleavage from 
the resin, the crude peptide was purified by preparative HPLC and was lyophilized to 
give a white solid (17.7 mg, 68 %). 1H NMR (500 MHz, DMSO-d6, 25 °C): δ = 8.45 (d, J 
= 7.94 Hz, 1H), 8.38 (d, J = 8.51 Hz, 1H), 8.17 (d, J = 7.76 Hz, 1H), 7.85 (d, J = 8.92 
Hz, 1H), 7.78-7.70 (m, 3H), 7.57 (s, 1H), 7.51 (s, 1H), 7.44 (t, 7.78 Hz, 1H), 7.43-7.40 
(m, 1H), 7.26 (s, 1H), 4.50-4.41 (m, 1H), 4.40-4.36 (m, 1H), 4.27-4.20 (m, 1H), 4.18 (dd, 
J = 2.47, 8.92 Hz, 1H), 4.04 (dd, J = 6.29, 16.92 Hz, 1H), 3.96-3.92 (m, 1H), 3.94-3.83 
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(m, 2H), 3.65 (dd, J = 3.71, 16.92 Hz, 1H), 2.90 (dd, J = 5.74, 14.03 Hz, 1H), 2.79 
(unresolved, 1H), 2.42 (dd, J = 8.07, 14.03 Hz, 1H), 1.84-1.80 (m, 2H), 1.63-1.57 (m, 
2H), 1.50-1.35 (m, 3H), 1.04 (d, J = 6.43 Hz, 3H); analytical HPLC: homogeneous single 
peak, tR=7.51 min (8-70% B in 30 min); MALDI MS: calcd for C23H34N6O6S (M + H)+ 
523.62, found 523.34. 
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 Compound 3j.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocLys(Boc)-OH, FmocAsn(Trt)-OH and FmocAsn(Trt)-OH, respectively After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (17.7 mg, 68 %).  1H NMR (500 MHz, DMSO-d6, 25 
°C): δ = 9.16 (d, J = 7.46 Hz, 1H), 8.11 (d, J = 7.08 Hz, 1H), 7.99 (s, 1H), 7.84 (d, 8.86 J 
= Hz, 1H), 7.80-7.77 (m, 2H), 7.67 (unresolved, 1H), 7.49-7.44 (m, 2H), 7.36 (s, 1H), 
7.23 (s,1 H), 7.19 (s, 1H), 7.13 (s, 1H), 7.03 (s, 1H), 6.91 (s, 1H), 6.88 (s, 1H), 4.46-4.38 
(m, 2H), 4.26-4.20 (m, 2H), 3.86-3.83 (m, 2H), 2.91-2.85 (m, 2H), 2.84-2.74 (m, 4H), 
2.61 (dd, J = 8.01, 15.75 Hz, 1H), 2.22 (dd, J = 7.78, 12.77 Hz, 1H), 1.91-1.85 (m, 1H), 
1.84-1.77 (m, 1H), 1.63-1.51 (m, 2H), 1.46-1.39 (m 1H), 1.38-1.31 (m, 1H); 13C NMR 
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(75 MHz, DMSO-d6, 25 °C): δ = 173.0, 172.9, 172.4, 172.0 171.8, 171.3, 167.7, 138.5, 
134.0, 133.1, 129.2, 128.8, 126.0, 53.2, 52.7, 52.4, 51.7, 39.5, 36.4, 35.7, 34.4, 32.5, 31.4, 
27.2, 22.7 analytical HPLC: homogeneous single peak, tR=8.19 min (8-70% B in 30 
min); MALDI MS: calcd for C25H34N8O7S (M + H)+ 593.67, found 593.18. 
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 Compound 3k.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocAsn(Trt)-OH, FmocAsn(Trt)-OH and FmocGlu(tBu)-OH, respectively After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (13.7 mg, 46 %).  1H NMR (500 MHz, DMSO-d6, 25 
°C): δ = 12.07 (bs, 1H), 8.64 (d, J = 8.22 Hz, 1H), 8.21 (d, J = 7.91 Hz, 1H), 8.44 (d, J = 
8.44 Hz, 1H), 8.02 (d, J = 7.60 Hz, 1H), 7.85 (s, 1H), 7.76-7.74 (m, 1H), 7.50-7.48 (m, 
2H), 7.46-743 (m, 3H), 7.19 (s, 1H), 7.01 (s, 1H), 6.91 (s, 1H), 4.60-4.53 (m, 1H), 4.46-
4.42 (m, 1H), 4.39-4.31 (m, 3H), 3.83-3.78 (m, 2H), 2.86 (dd, J = 6.93, 13.55 Hz, 1H), 
2.69-2.66 (m, 1H), 2.59-2.56 (m, 2H), 2.40 (dd, J = 7.23, 13.55 Hz, 1H), 2.32 (t, J = 
7.60, 2H), 2.09-2.02 (m, 1H), 1.94-1.85 (m, 1H); 13C NMR (75 MHz, DMSO-d6, 25 °C): 
δ = 174.1,172.5, 172.0, 170.9, 170.7, 170.1, 166.8, 138.5, 133.5, 132.0, 128.6, 128.0, 
126.0, 69.8, 53.6, 51.7, 51.0, 50.2, 36.6, 36., 34.4, 32.4, 30.3, 25.7; analytical HPLC: 
homogeneous single peak, tR=8.64 min (8-70% B in 30 min); MALDI MS: calcd for 
C24H31N7O9S ( M + Na)+ 616.61, found 616.11. 
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13C NMR of compound 3k 
 
 
 Compound 3l.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocGln(Trt)-OH, FmocLys(Boc)-OH and FmocAsn(Trt)-OH, respectively After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (10.8 mg, 36 %).  1H NMR (500 MHz, DMSO-d6, 25 
°C): δ = 8.55 (d, J = 7.94 Hz, 1H), 8.28 (d, J = 8.31 Hz, 1H), 8.19 (d, J = 7.22 Hz, 1H), 
7.97 (d, J = 7.20 Hz, 1H), 7.81 (s, 1H), 7.71-7.68 (m, 3H), 7.53-7.50 (m, 3H), 7.46 (t, J = 
7.65 Hz, 1H), 7.28 (s, 1H), 7.25 (s, 1H), 6.99 (s, 1H), 6.79 (s, 1H), 4.72-4.68 (m, 1H), 
4.46-4.41 (m, 1H), 4.25-4.21 (m, 1H), 3.89-3.80 (m, 3H), 2.85 (dd, J = 6.83, 15.57 Hz, 
1H), 2.79-2.74 (m, 2H), 2.67 (dd, J = 8.41, 13.25 Hz, 1H), 2.61 (dd, J = 6.53, 15.57 Hz, 
1H), 2.29 (dd, J = 6.13, 13.25 Hz, 1H), 2.08 (t, J = 8.33 Hz, 2H), 1.96-1.87 (m, 2H), 
1.86-1.77 (m, 2H), 1.59-1.46 (m, 2H), 1.40-1.25 (m, 2H); analytical HPLC: 
homogeneous single peak, tR=8.00 min (8-70% B in 30 min); MALDI MS: calcd for 
C26H38N8O7S (M + H)+ 607.70, found 607.23. 
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 Compound 3m.  TentaGel S RAM Fmoc resin (0.05 mmol, 0.30 mmol g-1) was 
used to synthesize this compound.  The second, third and fourth amino acids attached 
were FmocLys(Boc)-OH, FmocAsn(Trt)-OH and FmocAsp(tBu)-OH, respectively After 
cleavage from the resin, the crude peptide was purified by preparative HPLC and was 
lyophilized to give a white solid (6.0 mg, 20 %).  1H NMR (500 MHz, DMSO-d6, 25 °C): 
δ = 12.23 (bs, 1H), 8.16 (d, J = 7.11 Hz, 1H), 8.0 (s, 1H), 7.82 (d, J = 8.34 Hz, 1H), 
7.79-7.77 (m, 1H), 7.75-7.68 (m, 3H), 7.5-7.45 (m, 2H), 7.36 (unresolved, 2H), 7.20 (s, 
1H), 6.89 (s, 1H), 6.55 (s, 1H), 4.44-4.38 (m, 2H), 4.24-4.20 (m, 2H), 3.89-3.81 (m, 2H), 
3.05-3.01 (m, 1H), 2.9-2.83 (m, 3H), 2.81-2.74 (m, 2H), 2.71-2.64 (m, 1H), 2.23-2.19 (m, 
1H), 1.85-1.81 (m, 2H), 1.58-1.52 (m, 2H), 1.48-1.42 (m, 1H), 1.37-1.33 (m, 1H); 
analytical HPLC: homogeneous single peak, tR=9.17 min (8-70% B in 30 min); MALDI 
MS: calcd for C25H35N7O8S (M + H)+ 594.65, found 594.22. 
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APPENDIX C 
EXPERIMENTAL FOR CHAPTER IV 
 
 Preparation of Nitro Template for Compound B.  2-Bromomethyl benzoic acid 
(0.5 g, 2.34 mmol) was placed in a 25 mL round bottom flask.  The flask was cooled to -
10 °C and then 5 mL of conc. H2SO4 was added dropwise.  A cold (~0 °C) mixture of 
H2SO4/HNO3 (0.5 mL/0.3 mL) was then added dropwise via a dropping funnel to the 
reaction flask.  The addition took ~5 min.  Then the mixture was stirred for 1 hr, after 
which it was poured over an ice/water mixture (~25 mL).  The nitrated compound which 
came out as white precipitate was filtered and washed with copious amount of water and 
then dried in vacuum.  1H NMR (500 MHz, acetone-d6): δ = 8.75 (d, J = 2.53 Hz, 1 H), 
8.40 (dd, J = 8.56, 2.49 Hz, 1 H), 7.89 (d, J = 8.57 Hz, 1 H), 5.17 (s, 2 H).  MS (ESI) 
calcd for C8H6BrNO4 259.0416 (M – H)-found 259.9638. 
 
 
CO2H
Br
O2N
nitro template for
compound B derivative
1H NMR of 2-bromoymethyl-5-nitrobenzoate 
 
 
 Methyl-3-hydroxymethyl-5-nitrobenzoate.  In a dry 250 mL round bottom 
flask, 1-Nitroisophthalic acid monomethyl ester (5.0 g, 0.0222 mol) was dissolved in 20 
mL dry THF.  BF3·OEt2 (5.63 mL, 0.0444 mol) was added and the flask was cooled to 0 
to -5 °C.  NaBH4 (1.13 g, 0.02997) was added portion by portion for 10 min.  The 
mixture was stirred for 2 hr, after which, ethanol (5 mL) was slowly added, followed by 
water (10 mL) and Et2O (30 mL).  The resulting layers were separated and the aqueous 
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component was extracted once with Et2O (10 mL).  The organic extracts were combined 
and washed with 20 mL saturated NaHCO3 and dried over Na2SO4.  The colorless liquid 
was filtered, concentrated and dried in vacuum to give methyl-3-hydroxymethyl-5-
nitrobenzoate as a white solid (3.52 g, 75 %).  1H NMR (500 MHz, acetone-d6): δ = 8.58 
(m, 1 H), 8.45 (m, 1 H), 8.35 (m, 1 H), 4.86 (s, 2 H), 3.95 (s, 3 H). 
 
CO2Me
OH
O2N
methyl-3-hydroxymethyl-
5-nitrobenzoate
1H NMR of Methyl 3-hydroxymethyl-5-nitrobenzoate 
 
 
 3-Hydroxymethyl-5-nitrobenzoic acid.  The methyl ester alcohol (0.0167 mol, 
3.52 g) product from the above procedure was placed in a 100 mL round bottom flask.  
Ten mL of THF was added, and then the flask was cooled to 0 °C.  A cold solution of 
LiOH (0.840 g, 0.0200 mmol) dissolved in H2O/THF (2 ml/8 mL) was slowly added to 
the reaction mixture via a dropping funnel.  The addition was complete in 10 min, after 
which the mixture was stirred for 3 hr.  After this time, TLC indicated that the reaction 
was competed.  Then, Et2O (20 mL) and water (20 mL) were added.  The layers were 
separated and to the water layer, 25-30 mL of 1M HCl was added slowly until the 
solution is acidic.  The acidic solution was then extracted with EtOAc (3x, ca15 mL).  
The EtOAc extracts were combined with the original Et2O extract and the solution was 
dried over Na2SO4 and concentrated in vacuo to give 3-hydroxymethyl-5-nitrobenzoic 
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acid as a white solid (2.83 g, 86 %).  1H NMR (500 MHz, acetone-d6): δ = 8.63 (m, 1 H), 
8.46 (m, 1 H), 8.39 (m, 1 H), 4.87 (s, 2 H). 
 
CO2H
OH
O2N
3-hydroxymethyl-
5-nitrobenzoic acid
1H NMR of 3-hydroxymethyl-5-nitrobenzoic acid 
 
 
 3-Bromomethyl-5-nitrobenzoic acid.  The acid product (1.0 g, 0.005 mol) from 
the above procedure was placed in a three-neck 100 mL round bottom flask.  Toluene (10 
mL) was added (the compound is not completely soluble), followed by HBr (47 % or 6 
M, 12.5 mL, 0.075 mol).  The necks were sealed and the mixture was degassed for 30 
min by vigorously bubbling nitrogen through a needle passing one of the necks.  After 
this time, the flask was heated to 75 °C and stirred vigorously for 3h.  The layers became 
clear as the temperature is increased.  After 3 h, the solution was cooled to room temp 
and 20 mL toluene was added.  The resulting layers were then separated and the organic 
layer was washed with water (3x, ca10 mL) before concentrating and drying in vacuum 
to give 3-bromomethyl-5-nitrobenzoic acid as white powder (1.30 g, 99 %).  1H NMR 
(500 MHz, acetone-d6): δ = 8.69 (m, 1 H), 8.59 (m, 1 H), 8.50 (m, 1 H), 4.91 (s, 2 H).  
MS (ESI) calcd C8H6BrNO4 259.0416 (M – H)- found 259.9313. 
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Solid-Phase Syntheses 
 General Methods.  All α-amino acids used have the L-configuration and were 
purchased from NovaBiochem, Advanced ChemTech or Chem-Impex.  Chemicals were 
obtained from commercial suppliers and used without further purification.  
Diisopropylcabodiimide (DIC), N-hydroxybenzotriazole (HOBt), trifluoroacetic acid 
(TFA), oxalyl chloride, diisopropylethylamine (DIEA), piperidine and triisopropylsilane 
(TIS) were purchased from Aldrich.  Dimethylformamide (DMF), methanol and 
dichloromethane were bought from EMScience. The resins were obtained from Rapp 
Polymere, Advanced ChemTech, Nova Biochem, Argonaut Technologies and Chiron 
Mimetopes. 
 Peptidomimetic syntheses were performed in fritted polypropylene syringes (5 
mL capacity) from Torviq. Reverse-phase high-performance liquid chromatography 
(HPLC) analyses were carried out using a Beckman SystemGold instrument and a Vydac 
C-18 column (catalog no. 218TP54, length: 250 mm; inner diameter: 4.6 mm). 
Preparative purifications were done on an SSI HPLC system using a Vydac C-18 column 
(catalog no. 2181022, length: 250 mm, inner diameter: 22 mm).  All HPLC analyses were 
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done under gradient conditions.  Eluents used were solvent A (H2O with 0. 1 % TFA) and 
solvent B (CH3CN with 0.1% TFA).  Flow rates applied were 1.0 and 6 mL/min for 
analytical and preparative HPLC respectively. 
 Typical solid phase syntheses of peptidomimetics. Synthesis of 3a-NO2.  In a 5 
mL fritted syringe, HypoGel 400 RAM resin (0.05 mmol, 0.54 mmol g-1) was swelled in 
DMF (ca 10 mL g-1) for 1 h.  The resin was washed with DMF (3 x ca 10 mL g-1, each 
time for 1 min; this amount of solvent and washing time were used for all other washings 
throughout).  The Fmoc protecting group was removed by treating the resin with 20 % 
piperidine in DMF (2x, first 10 min, then for 20 min).  The resin was washed with DMF 
(3x), MeOH (3x) and CH2Cl2 (3x), after which a solution of FmocCys(Mmt)-OH (3 eq), 
DIC (5 eq) and HOBt (5 eq) in 1.5 mL DMF was added.  After shaking for 10 h, a Kaiser 
test on sample beads indicated a negative result. The reaction mixture was drained and 
the resin washed with DMF (3x).  The above deprotection, coupling and washing cycles 
were repeated to attach FmocGly-OH, FmocLys-OH and FmocIle-OH. After the final 
Fmoc deprotection, the resin was washed with DMF (3x), MeOH (3x) and CH2Cl2 (3x).  
The resin was dried for 2 h in vacuo, then a solution of 3-bromomethyl-5-
nitrobenzoylchloride (3 eq) and DIEA (5 eq) in 2 mL CH2Cl2 were added.  After 1 h of 
shaking, a Kaiser test gave a negative result.  The resin was washed with CH2Cl2 (5x).  
The Mmt group on cysteine was removed by treating the resin with 1% TFA and 5 % TIS 
in CH2Cl2 (6x, each time for 10 min).  The resin was then washed with CH2Cl2 (4x) and 
DMF (3x).  Cyclization was carried out by adding 8 eq of DIEA in ca 2.0 - 2.5 mL DMF 
and shaking the resin for 12 h.  The resin was then washed with DMF (3x), MeOH (3x) 
and CH2Cl2 (3x) before it was dried for 2 h in vacuo.  Sample beads were taken and 
compound 3a-NO2 was cleaved by treating the resin with 90 % TFA, 5 % TIS and 5 % 
H2O (ca 3.5 – 4 mL) for 30 min. The resin was then washed with 50 % TFA in CH2Cl2 
(2x).  The collected filtrate and washings were concentrated and the product was 
precipitated by adding Et2O (ca 3 mL).  The white precipitate was isolated by 
centrifugation of the mixture and carefully decanting the ether.  The residue was washed 
with Et2O two more times.  The crude peptidomimetic was then dissolved in the 
minimum volume of H2O with a little CH3CN added (total volume 1 mL) and was 
assayed for purity via analytical HPLC (8 – 70 % B in 25 min). 
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 Synthesis of 3a-NH2.  In a 5 mL fritted syringe, compound 3-NO2 was swollen in 
DMF for 5 min.  The solvent was then washed with DMF (2x) and then 2 mL of 2M 
solution of SnCl2·2H2O was added.  The mixture was shaken for 2 h, then the solution 
was removed and a fresh one was added.  The mixture was shaken for another 2 h, after 
which, the resin was drained, then washed with, H2O (3x), DMF (3x), MeOH (3x) and 
CH2Cl2 (3x).  A small sample was cleaved and subjected via analytical HPLC similar to 
that for 3-NO2 to determine if the compound is pure enough for the next step. 
 Synthesis of 3a-NHGlyInp.  In a 5 mL fritted syringe, compound 3a-NH2 was 
swollen in DMF for 5 min.  The solvent was then washed with DMF (2x) then FmocGly-
Cl (3 eq) and DIEA (5 eq) in 2 mL CH2Cl2 were added.  After 1 h, the resin was washed 
with CH2Cl2 (5x) and DMF (3x).  The Fmoc group was deprotected by treating the resin 
with 20 % piperidine in DMF (2x, first 10 min, then for 20 min).  The resin was washed 
with DMF (3x), MeOH (3x) and CH2Cl2 (3x).  A solution of FmocInp-Cl (3eq) and 
DIEA (5 eq) in 2mL CH2Cl2 were added.  The resin was shaken for 1 h, at which time 
Kaiser test showed negative.  The Fmoc group was deprotected with the same piperidine 
protocol and the resin was then washed with DMF (3x), MeOH (3x) and CH2Cl2 (3x).  
The resin was dried in vacuum the compound was cleaved by treating the resin with 90 % 
TFA, 5 % TIS and 5 % H2O (ca 3.5 – 4 mL) for 30 min. The resin was then washed with 
50 % TFA in CH2Cl2 (2x).  The collected filtrate and washings were concentrated and the 
product was precipitated by adding Et2O (ca 3 mL).  The white precipitate was isolated 
by centrifugation of the mixture and carefully decanting the ether.  The residue was 
washed with Et2O two more times.  The crude peptidomimetic was then dissolved in the 
minimum volume of H2O with a little CH3CN added (total volume < 2 mL) a small 
portion was injected into an analytical HPLC (Beckman, 8 – 70 % B in 25 min) to check 
the purity; the rest was purified via preparative HPLC (SSI system, 20 – 50 % B in 20 
min).  The fraction corresponding to 3a-NHGlyInp was collected, concentrated and dried 
in vacuum to give a white fluffy solid.  1H NMR (500 MHz, DMSO-d6): δ = 10.18 (s, 
1H), 8.60 (m, 1H), 8.40 (d, J = 9.24 Hz, 1H), 8.31 (t, J = 6.01 Hz,1H), 8.26 (d, J = 8.32 
Hz, 1H), 8.11 (d, J = 8.32 Hz, 1H), 7.85 (s, 1H), 7.76 (m, 1H), 7.70 (bs, 2H), 7.59 (s, 
1H), 7.44 (s, 1H), 7.28 (s, 1H), 4.46 (q, J = 7.79 Hz, 1H), 4.20 (m, 2H), 3.98 (dd, J = 
7.42, 10.01 Hz, 1H), 3.88 (m, 3H), 3.76 (m, 3H), 3.58 (dd, J = 3.68, 13.78 Hz, 1H), 3.51 
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(m, 1H), 3.30 (d, J = 11.94 Hz, 2H), 2.93 (m, 2H), 2.76 (m, 2H), 2.55 (m, 1H), 2.33 (m, 
1H), 1.90 (m, 2H), 1.82 (m, 1H), 1.74 (m, 2H), 1.63 (m, 1H), 1.53 (m, 3H), 1.32 (m, 2H), 
1.15 (m, 1H), 0.90 (d, J = 6.63 Hz, 3H), 0.85 (t, J = 7.46 Hz, 3H); LRMS (MALDI): 
calcd for (M+ H)+ 718, found 718; analytical HPLC: homogeneous single peak, retention 
time = 10.91 min (8-50 % B in 30 min). 
 
 
O
HN
NH
O
NH2
O
O
S
HN
O
HN
HN
NH O
O
HN
3a-NHGlyInp
NH2
1H NMR of 3a-NHGlyInp 
 
 
 Synthesis of 3g-NO2.  The synthesis followed the same procedure for 3a-NO2 
except that instead of FmocLys(Boc)-OH, FmocArg(Pmc)-OH was used. 
Syntheses of 3g-NH2 and 3g-NHGlyInp.  The syntheses of these compounds followed 
that for 3a-NH2 and 3a-NHGlyInp, respectively.  For 3a-NHGlyInp:1H NMR (500 
MHz, DMSO- d6):): δ = 10.17 (s, 1H), 8.58 (m, 1H), 8.41 (d, J = 9.33 Hz, 1H), 8.30 (t, J 
= 5.50 Hz, 1H), 8.24 (d, J = 8.62 Hz, 1H), 8.13 (d, J = 7.66 Hz, 1H), 7.84 (s, 1H), 7.78 
(t, J = 5.08 Hz, 1H), 7.75 (s, 1H), 7.59 (m, 2H), 7.43 (s, 1H), 7.27 (s, 1H), 4.55 (q, J = 
 154
7.55 Hz, 1H), 4.22 (t, J = 9.56 Hz, 1H), 4.17 (m, 1H), 3.98 (dd, J = 6.66, 9.76 Hz, 1H), 
3.87 (m, 3H), 3.75 (d, J = 12.48 Hz, 2H), 3.56 (dd, J = 3.49, 13.31 Hz, 1H), 3.50 (m, 
1H), 3.29 (d, J = 11.19 Hz, 2H), 3.11 (m, 2H), 2.92 (q, J = 11.21 Hz, 2H), 2.75 (m, 1H), 
2.54 (m, 1H), 2.33 (m, 1H), 1.89 (m. 3H), 1.82 (m, 1H), 1.73 (m, 2H), 1.64 (m, 1H), 1.46 
(m, 3H), 1.14 (m, 1H), 0.89 (d, J = 6.84 Hz, 3H), 0.85 (t, J = 7.41 Hz, 3H); LRMS 
(MALDI): calcd for (M+ H)+ 746, found 746; analytical HPLC: homogeneous single 
peak, retention time = 11.51 min (8-50 % B in 30 min). 
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 Synthesis of B-NO2.  The synthesis followed the same procedure for 3a-NO2 
except that after FmocCys(Mmt)-OH, FmocTyr(OtBu)-OH and FmocLys(Boc)-OH was 
used.  Only these amino acids were coupled and the template was 2-bromomethyl-5-
nitrobenzoyl chloride. 
 Synthesis of B-NH2 and B-NHGlyInp.  The syntheses of these compounds 
followed that for 3a-NH2 and 3a-NHGlyInp, respectively. 
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 Synthesis of B-NHGlyInpF*.  Compound B-NHGlyInp was swelled in CH2Cl2 
for 30 min. After the solvent was drained, 2 equiv. of dichlorotriazinylaminofluorescein 
(DTAF), DIEA (3 equiv.) in 3:1 mixture of CHCl3/ DMSO were added and the mixture 
was shaken for 3 h. The resin was then washed and subjected to the above cleavage 
condition. The resulting crude product was purified via prep HPLC (SSI system, 8 – 50 
% B in 30 min) to give the dye-tagged peptidomimetic B-NHGlyInpF*.  1H NMR (500 
MHz, DMSO-d6) δ = 10.61 (s, 1H), 10.15 (bs, 1H), 9.17 (s, 1H), 8.56 (d, J = 8.17 Hz, 
1H), 8.45, (bs, 1H), 8.27 (m, 2H), 7.92 (m, 2H), 7.64 (bs, 1H), 7.48 (d, J = 9.06 Hz, 1H), 
7.36 (s, 1H), 7.31 (d, J = 9.06 Hz, 1H), 7.24 (d, J = 8.49 Hz, 2H), 7.20 (s, 1H), 7.02 (d, J 
= 8.49 Hz, 1H), 6.98 (d, J = 8.49 Hz, 1H), 6.67 (d, J = 2.39 Hz, 2H), 6.64 (bs, 1H), 6.63 
(s, 1H), 6.62 (bs, 1H), 6.60 (bs, 1H), 6.56 (m, 1H), 6.54 (m, 1H), 4.59 (m, 1H), 4.53 (d, J 
= 13.34 Hz, 1H), 4.41 (m, 2 H), 4. 14 (q, J = 7.40 Hz, 1H), 3.91 (m, 1H), 3.89 (bs, 1H), 
3.77 (d, J = 12.26 Hz, 1H), 3.04, (m, 1H), 2.94 (m, 1H), 2.88 (m, 2H), 2.80 (m, 1H), 2.76 
(m, 1H), 2.72 (m, 2H), 2.63 (m, 2H), 2.61 (m, 2H), 2.54 (m, 2H), 2.36 (m, 1H), 1.55 (m, 
2H), 1.47 (m, 2H), 1.24 (m, 2H); LRMS (MALDI): calcd for (M+ H)+ 1170, found 1170; 
analytical HPLC: homogeneous single peak, retention time = 10.20 min (8-70 % B in 30 
min) 
Resysnthesis of compound 4.  Culture glass tubes (6 x 50 mm, VWR Scientific 
Products) were used as a reaction vessel. Stock solutions of all reagents in DMSO were 
prepared; 0.030 M of compound 3a-NHGlyInp and 0.033 M of compound 5. Solid 
K2CO3 (ca 1 mg) was first added to each tube, followed by 45 µL of a stock solution of 
3a-NHGlyInp and 45 µL of one of 5. The reaction vessels were sealed with parafilm, 
gently shaken by hand and sonicated for 10 min. The mixtures were left at 25 °C without 
stirring for 24 h. The solutions in each vessel were transferred into 5 mL sample vials 
using a micropipet and then lyophilized to remove DMSO. The solid materials were then 
washed with H2O by adding ca 0.5 mL of H2O into each sample and sonicating for 5 
min. The solution was left to stand for 30 min then the supernatant was carefully 
decanted away. The solid products were re-dissolved in 1:1 mixture of H2O/ CH3CN, 
then lyophilized again to give compound 4. The crude product was analyzed by analytical 
HPLC (crude 4 ~ 90% pure, retention time = 12.05 min (8-70 % B in 30 min).  LRMS 
(MALDI) calcd for (M+ H)+ 1890, found 1890. 
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Analytical HPLC for crude 4. 
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APPENDIX D 
EXPERIMENTAL FOR CHAPTER V 
 
 General Procedure For The Synthesis of Dipeptide Thiohydantoins.  
Synthesis of 8a.  CbzPheGly-OH (0.10 g, 0.28 mmol) and NH4SCN (0.0256 g, 0.336 
mmol) was placed in a 10 mL microwave tube.  Ac2O (0.30 mL) was added and the tube 
was capped and placed in a Discover (CEM) microwave.  The tube was stirred, and 
irradiated to reach 110 °C.  The temperature was maintained for 3 min, after which the 
tube was cooled to room temp.  Then, 5 mL CH2Cl2 was added to the yellow solution 
followed by 5 mL water.  The layers were separated and the aqueous layer was extracted 
2x with 3 mL CH2Cl2.  The organic extracts were combined, dried over Na2SO4 and 
concentrated in vacuum to give a yellow solid (crude product, 83 mg, 75 %).  The proton 
NMR of the crude product is hard to assign.  Half of the product was subjected to 
deprotection.  The Cbz group was deprotected by dissolving the crude material in 10 mL 
MeOH and adding 3 mol % of 5 % Pd/C.  The mixture was stirred until TLC indicates 
consumption of starting material.  Additional 5 mL MeOH was added and the mixture 
was passed thru a packed celite to remove the catalyst.  The solvent was evaporated to 
dryness and the crude solid dried in vacuum to give a light yellow material.  MS (ESI): 
264.1 (M+H)+. 
 
 
N
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 Synthesis of 8b.  The procedure follows that for 8a, except that the dipeptide used 
was CbzPheAla-OH.  This time the crude product appears as yellow viscous oil (94 mg. 
85 %).  The proton NMR is hard to assign because of impurities but the MS shows the 
presence of the product.  MS (ESI): 412.1 (M+H)+. 
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 Synthesis of 8c.  The procedure follows that for 8 a, except that the dipeptide 
used was BocAlaAla-OH.  The crude product appears as yellow solid (98 mg, 85 %).  
The proton NMR is hard to assign due to impurities which can not be seen on TLC.  MS 
(ESI): 302.1 (M+H)+. 
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 Synthesis of Iminohydantoin 13 from 3-benzyl-5-methyl-2-thiohydantoin.  
Benzyl-5-Methyl-2-Thiohydantoin.  To a mixture of L-alanine methyl ester 
hydrochloride salt (0.500 g, 3.58 mmol) and Et3N (0.5 mL, 3.58 mmol) in 10 mL 
CH2Cl2, benzylisothiocyanate (0.475 mL, 3.58 mmol) was added slowly.  The mixture 
was stirred for 1 h at 25 °C, after which a reflux condenser was attached.  The 
temperature was raised to 40 °C and stirring was continued for another hour.  At this 
time, TLC revealed all of the benzylisothiocyanate has been consumed, and a new spot 
appeared.  The solution was cooled to room temperature and the solution evaporated in 
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vacuo.  The residue was redissolved in 15 mL CH2Cl2 and washed with 10 mL water and 
10 mL brine and dried over Na2SO4.  The colorless solution was concentrated and dried 
in vacuo to give 3-benzyl-5-methyl-2-thiohydantoin as a white tiny crystalline material 
(0.410 g, 52%).  1H NMR (500 MHz, DMSO- d6): δ = 10.46 (s, 1H), 7.34-7.24 (m, 5H), 
4.89 (d, J = 15.0 Hz, 1H), 4.84 (d, J = 15.0 Hz, 1H), 4.38 (q, J = 7.1 Hz, 1H), 1.29 (d, J 
= 7.1 Hz, 3H); 13C NMR (125 MHz, DMSO- d6): δ = 182.2(C), 175.6(C), 136.5(C), 
128.5(CH), 127.42(CH), 127.40(CH), 54.7(CH), 43.7(CH2), 16.3(CH3); MS (ESI): 576 
(M+H)+. 
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3-benzyl-5-methyl-
2-thiohydantoin.
1H NMR of 3-benzyl-5-methyl2-thiohydantoin 
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13C NMR of 3-benzyl-5-methyl2-thiohydantoin 
 
 Synthesis of compound 13.  In a 25 mL round bottom flask, the above product 
(0.10 g, 0.454 mmol) was dissolved in 8 mL MeOH and 1.5 mL CH3CN.  To this 
solution, NaOH (0.018 g, 0.454 mmol) dissolved in 0.5 mL water was added followed by 
MeI (0.113 mL, 1.82 mmol).  The flask was stoppered and stirred for 18 h.  After this 
time, 5 mL brine, 5 mL water and 30 mL CHCl3 were added.  The layers were separated 
and the aqueous layer extracted 3x with 10 mL CHCl3.  The organic extracts were 
combined, dried over Na2SO4 and evaporated to dryness to give the crude methyl 
isothiourea as a yellow solid.  Methylation was verified by proton NMR.  The crude 
product was dissolved in 10 mL ethanol, then a solution of HCl·GlyOMe (1eq) and Et3N 
(2 eq) in 5 mL EtOH were added.  The mixture was heated to 70 °C and stirred for 24 h.  
Work up was done by adding 10 mL brine and 20 mL CH2Cl2.  The water layer was 
extracted 2x with 5 mL CH2Cl2 and the organic layers were combined and dried over 
Na2SO4.  The solvent was evaporated to give a crude light yellow semi-solid product (75 
mg, 60 %).  A proton NMR of this crude product was taken and it still shows EtOH 
peaks. 1H NMR (500 MHz, DMSO- d6): δ = 7.33-7.24 (m, 6H), 4.17 (q, J = 7.16 Hz, 
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1H), 4.09 (t, J = 6.16 Hz, 1H), 3.17 (s, 3H), 3.30-3.23 (m, 2H), 3.22-3.18 (m, 1H), 1.23-
1.19 (m, 3H).  MS (ESI): 276.1 (M+H)+. 
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MS(ESI) of compound 13 
 
 General Procedure for the Synthesis of Acyl-2-thiohydantoins.  Synthesis of 
1-Acetyl-2-thiohydantoin (14a).  Glycine (1.0 g, 13.3 mmol) and NH4SCN (1.038 g, 
13.3 mmol) were ground together using a mortar and pestle.  The mixed solid was 
transferred in a 50 mL round bottom flask and was heated in an oil bath at 100 °C for 30 
min, by which time all solids were already dissolved.  The light orange solution was 
poured into an ice/water mixture (20 mL) and stored in a freezer overnight.  The resulting 
light orange solid was filtered and washed with cold water and dried under vacuum to 
afford 2a as a light orange solid which appear as tiny crystalline-like material (1.08 g, 
51%): mp 173-174 °C; 1H NMR (500 MHz, DMSO- d6): δ = 12.58 (s, 1H), 4.40 (s, 2H), 
2.68 (s, 3H); 13C NMR (125 MHz, DMSO- d6): δ = 182.5(C), 170.4(C), 169.3(C), 
52.2(CH), 26.6(CH3); MS (ESI) 576 (M+H)+. 
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13C NMR of compound 14a 
 164
Partial COSY of compound 14a 
 The NH peak around 12.6 shows that no cross peak is observed with the C5H at 
~4.4 ppm. 
 
 
 
 1-Acetyl-5-methyl-2-thiohydantoin (14b).  L-Alanine was used to prepare this 
material which followed the procedure for 14a.  After filtration and washing, the off-
white solid was dried under vacuum to yield 14b (1.30 g, 68%): mp 164-166 °C; 1H 
NMR (500 MHz, DMSO-d6): δ = 12.63 (s, 1H), 4.67 (ddd, J = 7.1, 7.1, 7.1 Hz, 1H), 2.70 
(s, 3H), 1.42 (d, J = 7.1 Hz, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 182.3(C), 
173.9(C), 169.7(C), 59.8(CH), 27.4(CH3), 15.9(CH3); MS (APCI): 173 (M+H)+. 
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13C NMR of compound 14b 
 
 
COSY of compound 14b 
The NH peak around 12.6 shows that no cross peak is observed with the C-alpha H at 
~4.7 ppm 
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 1-Acetyl-5-benzyl-2-thiohydantoin (14c).  L-Phenylalanine was used to prepare 
this material which followed the procedure for 14a.  After filtration and washing, the 
white solid was dried under vacuum to afford 14c (0.850 g, 71%): mp 168-169 °C; 1H 
NMR (500 MHz, DMSO-d6): δ = 12.43 (s, 1H), 7.26 (m, 3H), 6.98 (m, 2H), 4.99 (dd, J = 
5.9, 2.7 Hz, 1H), 3.38 (dd, J = 13.9, 5.9 Hz, 1H), 3.12 (dd, J = 13.8, 2.7 Hz, 1H), 2.69 (s, 
3H); 13C NMR (125 MHz, DMSO-d6): δ = 182.3(C), 172.6(C), 170.02(C), 134.2(C), 
129.2(CH), 128.4(CH), 127.3(CH), 63.5(CH), 34.4(CH2), 27.4(CH3); MS (APCI) 249 
(M+H)+. 
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13C NMR of compound 14c 
 
COSY of compound 14c 
The NH peak around 12.4 shows that no cross peak is observed with the C-alpha H at ~5 
ppm 
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 General Procedure for Deacylation.  Synthesis of 2-Thiohydantoin (11a).  A 
suspension of 14a (0.148 g, 0.94 mmol) and ~5mL of 3M HCl in a microwave tube was 
sealed and heated under microwave irradiation using a CEM microwave (Discover) at 
150 °C for 5 min.  The resulting clear, yellow solution was extracted with 4 x 5ml 
EtOAc.  The combined EtOAc extracts were dried over Na2SO4, concentrated, and dried 
under vacuum to give 4a as a light orange solid (0.081g, 74%). 1H NMR (500 MHz, 
DMSO-d6): δ = 11.66 (s, 1H), 9.86 (s, 1H), 4.08 (s, 2H); 13C NMR (125 MHz, DMSO-
d6): δ = 183.4(C), 174.6(C), 50.3(CH2). 
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13C NMR of compound 11a 
 
 
COSY of compound 11a 
After deacylation, the N1 is now protonated and resonates ~9.9 ppm.  A cross peak is 
observed with the C-alpha H ~4 ppm. 
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 5-Methyl-2-thiohydantoin (11b).  Compound 14b was used to prepare the title 
compound, which followed the above procedure.  After drying of the almost colorless 
solution, 11b appears as white solid (66 mg, 87 %).1H NMR (500 MHz, DMSO-d 6): δ = 
11.64 (s, 1H), 10.01 (s, 1H), 4.23 (dddd, J = 1.1, 7.1, 7.1, 7.1 Hz, 1H), 1.24 (d, J = 7.1 
Hz, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 182.0(C), 177.3(C), 56.3(CH), 
16.1(CH3). 
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13C NMR of compound 11b 
 
COSY of compound 11b 
After deacylation, the N1 is now protonated and resonates ~10 ppm.  A cross peak is 
observed with the C-alpha H ~4.2 ppm 
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 5-Benzyl-2-thiohydantoin (11c).  Compound 14c was used to prepare the title 
compound which followed the above procedure.  After drying of the colorless liquid, 11c 
appears as white solid (0.35 g, 84%). 1H NMR (500 MHz, DMSO-d 6): δ = 11.44 (s, 
1H), 10.07 (s, 1H), 7.27 (m, 2H), 7.22 (m, 1H), 7.17 (m, 2H), 4.56 (t, J = 5.1 Hz, 1H), 
2.98 (dd, J = 5.0, 2.8 Hz, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 182.3(C), 175.8(C), 
135.0(C), 129.7(CH), 128.3(CH), 127.0(CH), 61.5(CH), 35.7(CH2). 
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13C NMR of compound 11c 
 
COSY of compound 11c 
After deacylation, the N1 is now protonated and resonates ~10 ppm.  A cross peak is 
observed with the C-alpha H ~4.5 ppm 
 
 
 
 Synthesis of 5-Acetyl-4-thiohydantoic Acid Ethyl Ester (15).  To a mixture of 
glycine methyl ester hydrochloride salt (0.50 g, 3.98 mmol) and Et3N (0.350 mL, 3.98 
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mmol) in 15 mL dry CH2Cl2, acylisothiocyanate (0.559 mL, 3.98 mmol) was added 
slowly.  The mixture was stirred for 1 h at 25 °C, after which a reflux condenser was 
attached.  The temperature was raised to 40 °C and stirring was continued for another 
hour.  After one hour, a TLC of the reaction showed a faint major spot (Rf = 0.41, 40% 
EtOAc/hexanes).  The red brown mixture was cooled to room temperature and then 
evaporated in vacuo.  The residue was redissolved in 15 mL CH2Cl2 and washed with 10 
mL water and 10 mL brine and dried over Na2SO4.  The solution was concentrated and 
dried in vacuo to give 15 as an off white solid (0.475 g, 75%).  1H NMR (500 MHz, 
DMSO-d6): δ = 11.36 (s, 1H), 10.85 (t, J = 5. 7 Hz, 1H), 4.37 (d, J = 5.7 Hz, 2H), 3.66 
(s, 3H), 2.09 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 181.2(C), 172.3(C), 169.0(C), 
52.1(CH), 46.2(CH3), 23.8(CH3); HRMS (ESI) calcd for C6H10N2O3S 191.0412 (M+H)+, 
found 191.0497. 
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13C NMR of compound 15 
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COSY of compound 15 
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APPENDIX E 
EXPERIMENTAL FOR CHAPTER VI 
 
 Synthesis of 3-bromo-4-fluoronitrobenezene 21.  A two-neck 500 mL round 
bottom flask was charged with 4-fluoronitrobenzene (10 mL, 94.3 mmol), Na2SO4 (0. 15 
g), concd H2SO4 (100 mL) and water (96.2 mL).  The reaction flask was heated to 65 °C 
via oil bath and then NaBrO3 (17.1 g, 113 mmol) was added in portions to maintain the 
temperature at 65 °C.  The addition took 20 min.  The mixture was stirred for another 3 h 
at the same temp.  After this time, the flask was cooled to room temp.  Two layers were 
produced from the reaction.  The layers were separated and the aqueous layer extracted 
with 50 mL EtOAc (3x).  The organic extracts were combined, washed with brine, dried 
over Na2SO$ and concd in vacuum.  The resulting liquid was placed in a vacuum pump 
and after one day, crystals came out.  The crystals were filtered and recrystallized from 
hexane to give the product as light brown crystals (9.7 g, 46 %).  1H NMR (300 MHz, 
acetone- d6): δ = 8.52 (dd, J = 5.9, 2.8 Hz, 1 H), 8.36-8.31 (m, 1H), 7.58 (t, J = 8.6 Hz, 
1H); 13C NMR (75 MHz, acetone- d6): δ = 165.2, 161.9, 130.1, 126.2, 118.3, 110.1. 
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13C NMR of compound 21 
 
 
 Synthesis of BisBocThiourea 19.  To an oven-dried two-neck 250 mL round 
bottom flask, thiourea, (0.571 g, 7.5 mmol) was added.  The flask was stoppered and was 
purged with nitrogen for 5 min.  After this time, 125 mL dry THF was added to dissolve 
thiourea.  The solution was cooled to 0 °C via immersion in an ice-bath.  Then, NaH (60 
% in oil; 1.35 g, 33.8 mmol) was added and the mixture stirred for 5min.  The flask was 
then removed from the ice-bath and stirring was continued for 10 min after which it was 
returned to the ice-bath, then Boc2O (3.6 g, 16.5 mmol) was added.  The slurry mixture 
was stirred for 1h at 0 °C and for 3 h at room temp.  After this time, TLC indicates 
consumption of thiourea.  The reaction was quenched by slowly adding 10 mL saturated 
NaHCO3.  The reaction mixture was then poured into 250 mL water.  The layers were 
separated and the aqueous layer extracted 3x with 75 mL EtOAc.  The combined organic 
extracts were dried over Na2SO4 and concentrated in vacuum to give white solids.  The 
crude product was recrystallized in hexane and a small amount of CH2Cl2 to give 19 as a 
white solid (1.5 g, 72 %).  1H NMR (500 MHz, CDCl3): δ = 1.49 (s, 18 H). 
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 Synthesis of guanidine side-chain mimic 20.  A dry 100 mL round bottom flask 
was charged with cysteamine hydrochloride (0.51 g, 5.0 mmol) and 10 mL anhydrous 
DMF.  To this solution was slowly added Et3N (1.4 mL, 10.0 mmol).and a cloudy 
suspension formed.  Another 5 mL anhydrous DMF was added followed by compound 19 
(1.38 g, 5.0 mmol).  The cloudy mixture was stirred for 15 h at 25 °C.  After this time, 
water (15 mL) and EtOAc (30 mL) were added.  The layers were separated and the 
aqueous solution extracted three more times with 15 mL EtOAc.  The combined organics 
were dried over Na2SO4, concentrated and dried in vacuum to give compound 20 as a 
white solid (1.0 g, 63 %).  1H NMR (500 MHz, CDCl3): δ = 11.47 (s, 1H), 8.64 (s, 1H), 
3.62-3.58 (m, 2H), 2.72-2.67 (m, 2H), 1.47 (s, 18H); 13C NMR (125 MHz, CDCl3): δ = 
163.5, 156.2, 153.1, 83.2, 79.4, 43.5, 28.2, 28.0, 24.2. 
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13C NMR of compound 20 
 
 
 Synthesis of Sonogashira intermediate 22.  A dry two-neck 100 mL round 
bottom flask was charged with compound 21 (2.21 g, 10 mmol) and 40 mL Et3N.  The 
solution was deaerated by bubbling nitrogen through it with a needle for10 min.  After 
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this time, 1-hexyne (1.16 mL, 10 mmol) was added followed by Pd(PPh3)4 (0.35 g, 3 mol 
%) and CuI (0.057 g, 3 mol %).  A reflux condenser was attached and the mixture was 
heated to reflux (ca 100 °C) with good stirring for 10 h.  After this time, the mixture was 
filtered on a filter paper and to the filtrate was added 15 mL Et2O.  The solution was 
evaporated in vacuum leaving a liquid residue.  To this residue was added 20 mL Et2O 
and the solution extracted three times with 20 mL saturated NH4Cl solution.  The Et2O 
solution was then dried over Na2SO4 and purified via column chromatography using 3 % 
Et2O/hexane then 5 % EtOAc/hex as eluents.  Compound 22 was isolated as yellow oil 
(2.14 g, 97 %).  1H NMR (500 MHz, CDCl3): δ = 8.24 (dd, J = 6.05, 3.02 Hz, 1H), 8.11-
8.08 (m, 1H), 7.17-7.13 (m, 1H), 2.44 (t, J = 7.2 Hz, 2H), 1.66-1.55 (m, 2H), 1.49-1.42 
(m, 2H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 167.0, 165.0, 129.7, 
124.5, 116.1, 114.2, 99.1, 71.8, 30.3, 21.9, 19.2, 13.5. 
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13C NMR of compound 22 
 
 
 Synthesis of compound 16.  A dry 25 mL round bottom flask was charged with 5 
mL dry THF and NaH (0.04 g, 1.0 mmol).  The flask was cooled down to 0°C then a 
solution of compound 20 in 5 mL dry THF was added and the mixture stirred from 0 – 25 
°C for 12 h (i.e. the ice-bath was allowed to melt and warm to  25 °C).  After this time, 10 
mL water was added slowly to stop the reaction, and the mixture was transferred to a 
separatory funnel and diluted with 10 mL EtOAc.  Additional 5 mL EtOAc was used to 
wash the flask.  The layers were separated and the aqueous layer extracted 3 times with 
10 mL EtOAc.  The combined organics were washed with 10 mL water (2x) and 10 mL 
brine (1x) dried over Na2SO4, concentrated in vacuum and purified via column 
chromatography using first 10 % Et2O/hexanes then 10 % EtOAc/hex as eluents.  The 
fraction corresponding to the product was collected, concentrated and dried in vacuum to 
give compound 16 as yellow solid (0.27 g, 52 %).  1H NMR (500 MHz, CDCl3): δ = 
11.46 (s, 1H), 8.62 (t, J = 5.9 Hz, 1H), 8.19-8.17 (m, 1H), 8.14-8.10 (m, 2H), 3.61-3.57 
(m, 2H), 3.23-3.20 (m, 2H), 2.48 (t, J = 7.0 Hz, 2H), 1.64-1.58 (m, 2H), 1.55 (s, 9H), 
1.53-1.49 (m, 2H), 1.47 (s, 9H), 0.94 (t, J = 7.3 Hz, 3H); 13H NMR (125 MHz, CDCl3): δ 
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= 163.4, 156.3, 153.1, 148.8, 144.4, 126.7, 124.5, 123.1, 122.2, 100.2, 83.5, 79.6, 76.4, 
39.6, 30.5, 29.2, 28.4, 28.0, 22.0, 19.3, 13.6. 
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 Synthesis of compound 17.  The procedure followed that for compound 16 
except that in place of compound 20, N-Boc-3-propanolamine was used.  The crude 
product was isolated via column chromatography using 10 % EtOAc/hexanes then 40% 
EtOAc/hexanes to give the product as light yellow solid (1.08 g, 76 %).  1H NMR (500 
MHz, CDCl3): δ = 8.21 (d, J = 2.8 Hz, 1H), 8.10 (dd, J = 9.4, 2.8 Hz, 1H), 6.86 (d, J = 
9.2 Hz, 1H), 4.87 (s, 1H), 4.14(t, J = 6.0 Hz, 2H), 3.36 (q, J = 6.2 Hz, 2H), 2.46 (t, J = 
7.1 Hz, 2H), 2.08-2.02 (m, 2H), 1.63-1.55 (m, 2H), 1.53-1.44 (m, 2H), 1.41 (s, 9H), 0.93 
(t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 163.8, 166.0, 141.0, 128.8, 124.7, 
114.6, 110.8, 97.3, 79.3, 74.6, 67.4, 37.8, 30.5, 29.2, 28.4, 21.9, 19.2, 13.6. 
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13C NMR of compound 17 
 
 Synthesis of compound 18.  In a dry 50 mL round bottom flask, rac-2-butanol 
(0.224 mL, 2.5 mmol) and 10 mL dry THF were added.  The solution was cooled to 0 °C 
and then KOtBu (0.280 g, 2.5 mmol) was added.  The mixture was stirred for 5 min then 
compound 21 (0.50 g, 2.23 mmol) was added (the color became dark brown after 
addition).  The mixture was stirred for 5 min in ice-bath after which it was removed and 
allowed to warm to 25 °C and stirring was continued for 5 h.  After this time, 5 mL water 
and 15 mL EtOAc were added.  The layers were separated and the water layer was 
extracted 3 times with 10 mL EtOAc.  The organic extracts were combined, dried over 
Na2SO4, concd and dried in vacuum to give 3-bromo-4-O-2-butylnitrobenzene as yellow 
brown oil (0.581 g, 95 %).1H NMR (300 MHz, CDCl3): δ = 8.42 (d, J = 2.8 Hz, 1H), 
8.14 (dd, J= 9.1, 2.7 Hz, 1H), 6.89 (d, J = 9.1 Hz, 1H), 4.52-4.42 (m, 1H), 1.89-1.64 (m, 
2H), 1.37 (d, J = 6.4 Hz, 3H), 1.00 (t, J = 7.4 Hz); 13C NMR (75 MHz, CDCl3): δ = 
159.9, 140.1, 129.3, 124.5, 112.8, 112.4, 77.7, 28.9, 18.9, 9.5. 
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1H NMR of compound 3-bromo-4-O-2-butylnitrobenzene 
 
 
 
13C NMR of compound 3-bromo-4-O-2-butylnitrobenzene 
 
 
 The above product (0.581 g, 2.12 mmol) was placed in a dry 50 mL round bottom 
flask and was dissolved in 15 mL dry Et3N.  Propargyl alcohol (0.123 mL, 2.12 mmol) 
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was added and the solution was deaerated by bubbling nitrogen through for 20 min.  The 
resulting solution was transferred to a two-neck 50 mL round bottom flask containing 
CuI (20 mg, 5 mol %) and Pd(PPh3)4 (0.122 g, 5 mol %).  After the transfer, the two-neck 
flask was quickly fitted with a reflux condenser and the mixture stirred and heated to 
reflux (ca 95 °C) for 10 h.  After this time, 10 mL saturated NH4Cl was added followed 
by 20 mL Et2O.  The layers were separated and the aqueous layer extracted further with 
10 mL Et2O (3x).  The organic extracts were combined, dried over MgSO4 concentrated 
and purified via column chromatography using 30% EtOAc/hexanes with 1 % HOAc.  
The fractions corresponding to the product were collected, concentrated and dried in 
vacuum to give the Sonogashira product (0.321 g, 61 %).1H NMR (500 MHz, CDCl3): δ 
= 8.23 (d, J = 2.8 Hz, 1H), 8.11 (dd, J = 9.1, 2.8 Hz, 1H), 6.87 (d, J = 9.3 Hz, 1H), 4.51 
(s, 2H), 4.47-4.41 (m, 1H), 2.06 (s, 1H), 1.84-1.75 (m, 2H), 1.73-1.65 (m, 2H), 1.35 (d, J 
= 6.1 Hz, 3H), 0.98 (t, J = 7.5 Hz, 3H); 13H NMR (125 MHz, CDCl3): δ = 163.7, 140.4, 
129.4, 125.6, 113.6, 112.1, 92.9, 80.0, 51.6, 29.0, 18.9, 9.5 (one carbon is missing). 
 
 
O
NO2
HO
4-O-2-butyl-3-propargyl-
alcohol-nitrobenzene
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13C NMR of compound 4-O-2-butyl-3-propargylalcohol-nitrobenzene 
 
 The above product ( 0.321 g, 1.3 mmol) was placed in a 50 mL dry round bottom 
flask and dissolved in 10 mL dry CH2Cl2.  Et3N was added and the solution was cooled to 
0 °C.  Mesyl chloride (0.118 mL, 1.52 mmol) was then added slowly and the solution 
was stirred for 45 min.  A TLC indicated consumption of the starting material.  The 
solution was washed with 10 mL cold water, 10 mL cold 5 % HCl, and saturated 
NaHCO3 and then dried over Na2SO4.  The solution was concentrated and dried in 
vacuum to give the mesylated product which was used in the next step without 
purification. 
 The crude mesylated product from the above procedure was placed in a 50 mL 
dry round bottom flask.  Dry THF (15 mL) was added to dissolve the compound after 
which Et3N (0.725 mL, 5.2 mmol) was added.  To this solution was added compound 20 
(0.415 g, 1.3 mmol) and the solution was stirred for 10 h.  After this time, the solution 
was evaporated and the residue dissolved in 20 mL Et2O and washed with 10 mL water 
(3x), 10 mL brine, and dried over Na2SO4.  The solution was concentrated and purified 
via column chromatography using 10% EtOAc/hexanes as solvent to give compound 18 
as a yellow solid (200 mg, 27 %).  1H NMR (500 MHz, CDCl3): δ = 11.44 (bs, 1H), 8.63 
(t, J = 5.7 Hz, 1H), 8.23 (d, J = 2.9 Hz, 1H), 8.11 (dd, J = 9.1, 2.9 Hz, 1H), 6.85 (d, J = 
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9.3 Hz, 1H), 4.46-4.40 (m, 1H), 3.74-3.68 (m, 2H), 3.55 (s, 2H), 2.96 (t, J = 6.5 Hz, 2H), 
1.84-1.74 (m, 1H), 1.72-1.62 (m, 1H), 1.46 (s, 9H), 1.45 (s, 9H), 1.34 (d, J = 6.1 Hz, 3H), 
0.98 (t, J = 7.6 Hz, 3H).  MS (ESI) = 551.3 (M + H)+. 
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 Synthesis of convertible isonitrile 32.  A dry 100 mL two-neck round bottom 
flask was charged with 4,4-dimethyloxazoline 31 ( 5.0 g, 50.4 mmol) and the flask was 
then purged with nitrogen for 5 min.  After this time, 15 mL dry THF was added and the 
solution was cooled to -78 °C.  After equilibration for 10 min, n-BuLi (as 2.5 M/hexane; 
22 mL, 55 mmol) was added dropwise via syringe pump for 15 min.  The solution turned 
from clear colorless to clear yellow after addition is completed.  The yellow solution was 
stirred for 1 h at -78 °C then ethyl chloroformate (5 mL, 50.4 mmol) was added dropwise 
via syringe pump for 5 min.  The temperature was kept at -78 °C for 15 min after which 
the flask was removed from the acetone/dry ice bath.  The reaction mixture was allowed 
to warm to room temperature with continued stirring.  This took about 25 min with a 
change in color from yellow to beige.  Then 20 mL Et2O was added followed by 20 mL 
water and an additional 20 mL Et2O.  The layers were separated and the Et2O layer was 
washed with 20 mL brine and dried over Na2SO4.  The solution was filtered, concentrated 
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and dried in vacuum to give isonitrile 32 as a colorless viscous liquid (6.63 g, 77 %).  1H 
NMR (500 MHz, CDCl3): δ = 4.22, (q, J = 7.2 Hz, 2H), 4.07 (m, 2H), 1.46-1.45 (m, 6H), 
1.31 (t, J = 7.2 Hz, 3H). 
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 Synthesis of Cbz-protected 4-piperidone 34.  A 250 mL round bottom flask was 
charged with 4-piperidone monohydrate (98%; 5.0 g, 32.5 mmol) and K2CO3 (6.7 g, 48.8 
mmol).  Water (25 mL) was added and the solution was cooled to 5 °C via ice-water bath.  
Benzyl chloroformate (7.33 mL, 48.8 mmol) was then added dropwise and the mixture 
was stirred for 1 h at 5 °C.  After this time, the flask was removed from the ice-water bath 
and stirring was continued for 1 h.  EtOAc (40 mL) and water (20 mL) were added and 
the layers were separated.  The water layer was extracted further with 20 mL EtOAc (4x).  
The EtOAc layers were combined and washed with 25 mL 1N HCl then with 25 mL 
brine and dried over Na2SO4.  The product was purified via column chromatography first 
by using 20 % EtOAc/hexanes as solvent then 50 % EtOAc/hexanes.  The fractions 
corresponding to the product were combined and the solvent evaporated in vacuum to 
give the product as clear colorless oil (7.45 g, 98 %).  1H NMR (500 MHz, CDCl3): δ = 
7.38-7.37 (m, 4H), 7.35-7.31 (m, 1H), 5.18 (s, 2H), 3.79 (t, J = 6.1 Hz, 4H), 2.45 (s, 4 
 190
H); 13C NMR (125 MHz, CDCl3): δ = 207.1, 155.0, 136.2, 128.5, 128.5, 127.9, 67.5, 
43.0, 40.9. 
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 Synthesis of Ugi product 35.  A 50 mL dry round bottom flask was charged with 
compound 34 (0.233 g, 1.0 mmol) and benzyl amine (0.109 mL, 1 mmol).  Dry MeOH 
(10 mL) was added and the solution was stirred for 2h.  After this time, isonitrile 32 
(0.171 g, 1.0 mmol) was added followed by BocVal-OH (0.217 g, 1.0 mmol).  The 
mixture was stirred for 24 h after which the solution was concentrated to <0.5 mL and the 
product was isolated via column chromatography first using 10 % EtOAc/hexanes then 
50 % EtOAc/hexanes as solvent systems (0.45 g, 64 %).  1H NMR (500 MHz, acetone-
d6): δ = 7.45-7.29 (m, 10H), 6.18 (bs, 1H), 5.97 (d, J = 8.9 Hz, 1H), 5.02, (s, 2H), 4.89-
4.80 (m, 2H), 4.40-4.32 (m, 2H), 4.21-4.19 (m, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.88-3.78 
(m, 2H), 3.39-3.09 (m, 2H), 2.53-2.50 (m, 1H), 2.42-2.39 (m, 1H), 2.18-2.14 (m, 1H), 
1.71 (bs, 2H), 1.41 (s, 9H), 1.30 (s, 3H), 1.28 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H), 0.92 (t, J 
= 6.7 Hz, 6H); 13C NMR (125 MHz, acetone-d6): δ = 174.3, 172.7, 156.6, 155.7, 155.5, 
139.8, 138.2, 138.0, 129.7, 129.2, 128.6, 127.8, 79.3, 71.8, 67.6, 67.1, 65.4, 64.4, 57.9, 
53.4, 48.0, 41.4, 32.8, 31.8, 24.1, 20.2, 17.7, 14.5.  MS (ESI): (M + Li)+ 717.4. 
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13C NMR of compound 35 
 
 
 Synthesis of spirocyclic hydantoin 39.  A solution of (NH4)2CO3 (6.15 g, 64 
mmol) in 25 mL deionized water was added into a150 mL pressure flask containing a 
solution of KCN (1.73 g, 26 mmol) dissolved in 7 mL deionized water.  Compound 34 
(4.0 g, 17.1 mmol) was added to the reaction flask as a solution in 6 mL DMF.  Solids 
appear to form as 34 is being added dropwise.  The flask was sealed and heated to 60 °C 
with vigorous stirring.  Chunks of white solid begin to appear as the mixture was stirred 
for 4 h.  After this time, the mixture was removed from the oil bath and was stirred at 
room temperature for 12 h.  The white precipitate was then filtered and washed with 
copious amount of cold water followed by 5 mL CH2Cl2.  The white solid was dried in 
vacuum overnight and then in a vacuum oven (80 °C) for 8 h (4.85 g, 93 %).  1H NMR 
(500 MHz, dmso-d6): δ = 10.73 (s, 1H), 8.55 (s, 1H), 7.39-7.30 (m, 5H), 5.09 (s, 2H), 
3.90-3.87 (m, 2H), 3.19 (bs, 2H), 1.75-1.69 (m, 2H), 1.57-1.54 (m, 2H); 13C NMR (125 
MHz, dmso-d6): δ = 177.4, 156.2, 154.4, 136.9, 128.4, 127.9, 127.6, 66.3, 60.0, 40.0, 
32.7, 32.4. 
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 Synthesis of BisBocspirocyclic hydantoin 40.  A250 mL three-neck flask was 
charged with compound 39 (3 g, 9.9 mmol) and DMAP (60 mg, 5 mol %).  Anhydrous 
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DMF (8 mL) and dry THF (35 mL) were then added.  To the resulting white mixture was 
added Boc2O (as a solution in 35 mL dry THF) dropwise via syringe pump for 13 min.  
Halfway through the addition, all solids dissolved.  The clear colorless solution was 
stirred at room temperature for 3 h.  After this time, the solution was evaporated in 
vacuum and to the light yellow residue, 80 mL CH2Cl2 was added.  The resulting solution 
was washed with 50 mL 1N HCl (2x), saturated 35 mL NaHCO3 (1x) and 25 mL brine 
(1x) then dried over Na2SO4.  The solution was filtered, concentrated and dried in 
vacuum to give the product as white solid (5.0 g, 100 %).  1H NMR (500 MHz, CDCl3): δ 
= 7.38-7.31 (m, 5H), 5.19-5.11 (m, 2H), 4.28-4.14 (m, 2H), 3.57-3.44 (m, 2H), 2.74-2.68 
(m, 2H), 1.81-1.74 (m, 2H), 1.59 (s, 9H), 1.53 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 
169.7, 155.1, 150.0, 147.2, 146.7, 145.1, 136.6, 128.5, 127.9, 87.0, 85.2, 67.3, 62.1, 39.8, 
29.7, 29.5, 27.9, 27.7, 27.4.  MS (ESI): 510.2 (M + Li)+. 
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13C NMR of compound 40 
 
 
 Synthesis of amino acid 41.  In a 250 mL round bottom flask, compound 40 (5.0 
g, 9.9 mmol) was dissolved in 80 mL THF.  Complete dissolution took 10 min.  After this 
time, KOH (5.53 g, 98.5 mmol) dissolved in 60 mL water was added slowly.  The 
mixture was stirred vigorously for 1.5 h.  Et2O (70 mL) and water (30 mL) were then 
added and the layers were separated.  The aqueous layer was extracted once with 50 mL 
Et2O and the combined ether layers extracted with 50 mL 1 % KCl solution.  The layers 
were separated and the KCl layer was combined with the original aqueous layer.  This 
layer was cooled to 0 °C via ice-bath and the pH was adjusted to 8 with 6 N HCl, then to 
6.5 with 2 N HCl.  White precipitate appeared as pH nears to 6.5.  Addition of a few 
drops of 2 N HCl was needed to stabilize the pH at 6.5.  The resulting white precipitated 
was filtered and washed with copious amount of cold water.  The filtrate was 
concentrated to give a second crop of solid which was combined with the first.  The 
combined solids were dried in vacuum at 80 °C for 10 h to give the product as white solid 
(2.2 g, 80 % based on compound 39).   1H NMR (500 MHz, dmso-d6): δ = 7.68 (bs, 2H), 
7.39-7.30 (m, 5H), 5.07 (s, 2H), 3.65 (bs, 2H), 3.46 (bs, 2H), 1.95-1.89 (m, 2H), 1.52-
1.47 (m, 2H).  MS (ESI): 277.1 (M – H)-. 
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 Synthesis of methyl ester 42.  A dry 25 mL round bottom flask was charged with 
amino acid 39 (0.10 g, 0.359 mmol).  The solid was dissolved in 5 mL dry MeOH and 5 
mL dry CH2Cl2 and the solution was cooled to 0 °C.  After 5 minutes at this temperature, 
TMSCHN2 (2M in hexane; 0.54 mL, 1.08 mmol) was added dropwise for 3 min.  The 
yellow green solution was stirred at 0 °C for 15 min. then the ice-bath was removed and 
stirring was continued for 1.5 h.  After this time, 15 mL CH2Cl2 and 10 mL saturated 
NaHCO3 were added to the reaction mixture.  The layers were separated and the organic 
layers was washed with 10 mL brine (2x) and dried over Na2SO4.  The solution was then 
filtered, concentrated and dried in vacuum to give the product (93 mg, 88 %).  1HNMR 
(500 MHz, CDCl3): δ = 7.35-7.34 (m, 5H), 5.12 (s, 2H), 3.71 (s, 3H), 3.51-3.45 (2H), 
1.99 (bs, 2H). 1.76 (bs, 2H), 1.50 (bs, 2H) NH2 is missing; 13C NMR (125 MHz, CDCl3): 
δ = 176.8, 155.0, 136.7 128.4, 127.9, 127.7, 66.9, 55.6, 52.3, 39.6, 34.1, 31.7, 28.9, 27.9.  
MS (ESI): 293.1 (M + H)+. 
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 General procedure for dipeptide synthesis using amino methyl ester 42.  
Synthesis of dipeptide 45.  A 10 mL dry round bottom flask was charged with BocVal-
OH (0.35 g, 1.6 mmol) and HOAt (98 %; 0.22 g, 1.60 mmol).  The solids were dissolved 
 198
in 1 mL anhydrous DMF and then a solution of compound 42 in 0.5 mL anhydrous DMF 
was added.  The reaction mixture was cooled to 0 °C via ice-bath and then EDCI (0.34 g, 
1.79 mmol) was added all at once.  The yellow solution was stirred at 0 °C for 1 h, then 
removed from ice-bath and stirred for 24 h at room temperature.  After this time, the 
solution was transferred to a separatory funnel and the reaction flask washed with 20 mL 
EtOAc.  The washings were also transferred to the separatory funnel.  Water (100 mL) 
was then added and the layers were separated.  The water layer was extracted with 15 mL 
CH2Cl2 (4x) and the combined organic extracts were washed with saturated 20 mL 
NaHCO3 (1x), 20 mL water (1x), 15 mL 1N HCl (1x) and 20 mL brine (1x) before being 
dried over Na2SO4.  The solution was then filtered, concentrated and dried in vacuum to 
give the product as white solid (0.74 g, 94 %).  1H NMR (500 MHz, CDCl3): δ = 7.36-
7.30 (m, 5H), 6.55 (bs, 1H), 5.12 (s, 2H), 4.98 (d, J = 8.3 Hz, 1H), 3.94-3.88 (m, 2H), 
3.82-3.76 (m, 1H), 3.69 (s, 3H), 3.23-3.15 (m, 2H), 2.21-2.11 (m, 1H), 2.10-1.95 (m, 
4H), 0.97-0.92 (m, 6H); 13C NMR (125 MHz, CDCl3): δ = 173.0, 171.6, 156.2, 155.1, 
136.6, 128.5, 128.1, 127.9, 67.2, 60.2, 57.1, 52.5, 39.5, 31.9, 31.6, 29.8, 28.3, 28.2, 19.3, 
17.9. 
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 Synthesis of dipeptide 46.  The procedure follows that for compound 45 except 
that for BocVal-OH, BocLys(Cbz)-OH was used. (0.42 g, 96 %).  1H NMR (500 MHz, 
CDCl3): δ = 7.37-7.32 (m, 9H), 2.31-2.28 (m, 2H), 7.07 (s, 1H). 5.25 (bs, 1H), 5.12 (s, 
2H), 5.08 (s, 2H), 4.04 (bs, 1H), 3.91 (bs, 2H), 3.67 (s, 3H), 3.19 (s, 2H), 3.10 (bs, 2H), 
2.02 (s, 4H), 1.87-1.79 (m, 1H), 1.67-1.57 (m, 1H), 1.56-1.50 (m, 2H), 1.41 (s, 11H); 13C 
NMR (125 MHz, CDCl3): δ = 173.2, 172.1, 162.6, 156.7, 156.1, 155.0, 136.5, 136.4, 
128.4, 128.2, 128.02, 127.97, 127.8, 80.2, 67.1, 66.6, 57.1, 54.0, 52.5, 40.0, 39.4, 36.5, 
31.5, 31.4, 30.5, 29.2, 28.2, 22.2. 
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 General procedure for the synthesis of spirocyclic diketopiperazines.  
Synthesis of DKP 47.  In a 10 mL round bottom flask, compound 45 (0.10 g, 0.203 
mmol) was dissolved in 1 mL CH2Cl2.  The solution was cooled to 0 °C and then TFA 
(0.5 mL, 6.5 mmol) was added.  The solution was stirred at the same temperature for 5 
min then at 25 °C for 3 h.  After this time, saturated NaHCO3 solution was added to make 
the solution basic (pH 8-9).  This was followed by 20 mL CH2Cl2 and 10 mL brine.  The 
layers were separated and the aqueous layer was further extracted with 10 mL CH2Cl2 
(3x).  The combined organic extracts were washed with 15 mL brine and dried over 
Na2SO4.  The solution was filtered and concentrated in vacuum to give the free amine 
which was used in the next step without purification. 
 The resulting oily residue from the above procedure was dissolved in 15 mL 
toluene containing HOAc (resulting concentration is 0.2 %) and was transferred in a 
Schlenk tube.  The solution was then refluxed for 15 h after which white precipitate 
began to appear.  At this time, the reaction was cooled to room temperature and the 
precipitate was filtered and washed with CH2Cl2.  The filtrate was recovered, 
concentrated to 5 mL and was refluxed a second time for 15 h.  A second crop of 
precipitate formed which was filtered, washed with CH2Cl2 and was combined with the 
original crop.  The DKP appear as a white solid and was dried in vacuum (46 mg, 63 %).  
1H NMR (500 MHz, dmso-d6): δ = 8.41 (s, 1H), 8.02 (s, 1H). 7.39-7.30 (m, 5H), 5.08 (s, 
2H), 3.77-3.68 (m, 3H), 3.46 (bs, 2H), 2.23-2.17 (m, 1H), 2.00-1.88 (m, 2H). 1.65-1.51 
(m, 2H), 0.96 (d, J = 7.1 Hz, 3H), 0.84d, J = 7.1 Hz, 3H); 13C NMR (125 MHz, dmso-
d6): δ = 170.1, 166.9, 154.4, 136.9, 128.4, 127.8, 127.5, 66.2, 58.9, 54.8, 38.8, 35.2, 34.7, 
30.9, 18.3, 16.9.  MS (ESI): 360.2 (M + H)+. 
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COSY of compound 47 
 
 
 Synthesis of DKP 48.  The procedure for this compound followed that for 
compound 47 except that the dipeptide used was compound 46 (96 mg, 31 %).  1H NMR 
(500 MHz, CDCl3): δ = 7.59 (bs, 1H), 7.37-7.28 (m, 10H), 7.27 (s, 1H), 5.13 (s, 2H), 
5.11 (s, 1H), 5.09 (s, 2H), 4.01 (s, 2H), 3.97-3.94 (m, 1H), 3.38 (bs, 2H), 3.22-3.13 (m, 
2H), 2.27-2.22 (m, 1H), 2.16-2.10 (m, 1H), 1.97-1.89 (m, 2H), 1.85-1.78 (m, 1H), 1.66-
1.62 (m, 1H), 1.55-1.50 (m, 2H), 1.46-1.42 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 
170.6, 168.8, 156.7, 155.1, 136.5, 136.4, 128.55, 128.51, 128.49, 128.1, 128.0, 127.9, 
67.4, 56.1, 54.3, 40.2, 38.84, 38.75, 34.8, 34.6, 32.3, 29.4, 21.4.  MS (ESI): 523.0 (M + 
H)+. 
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COSY of compound 48 
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